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Abstract 
 
 The neuronal serine/threonine kinase cyclin-dependent kinase 5 (Cdk5) is activated by its 
regulatory subunit, p35, to post-translationally modify substrates through phosphorylation. In 
this thesis, I provide several lines of evidence that Cdk5 plays a critical role in synaptic function 
and plasticity. First, we characterized the function of Cdk5 in learning and memory by region-
specific Cdk5 ablation. From multiple Cdk5 conditional knockout mouse models, we determined 
that Cdk5 is essential for memory formation and synaptic plasticity. Loss of Cdk5 in the 
hippocampus disrupts the cAMP pathway due to increased phosphodiesterase proteins. This 
dysregulation of cAMP signaling can be attenuated by a phosphodiesterase inhibitor to restore 
levels of protein phosphorylation, synaptic plasticity, and memory. Moreover, forebrain-specific 
deletion of Cdk5 affected multiple aspects of behavior that can partially be rescued by lithium 
treatment. We next identified the N-type calcium channels as a presynaptic substrate of Cdk5. 
We described how Cdk5-mediated phosphorylation of the N-type calcium channel increased 
calcium influx and channel open probability. This in turn enhanced the association of the N-type 
calcium channel with the active zone protein RIM1, which impacted vesicle docking and 
neurotransmission. Finally, we identified the postsynaptic density protein Shank3 as a Cdk5 
substrate and observed that Cdk5-mediated phosphorylation of Shank3 plays a critical role in 
maintaining dendritic spine morphology and synaptic plasticity. Our collective results 
demonstrate a central role for Cdk5 in regulating both presynaptic and postsynaptic functions 
and provide better insight into how specific targets of Cdk5 can impact a general mechanism 
underlying synaptic transmission, synaptic plasticity, and cognitive function. 
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Chapter 1 
 
 
Introduction1 
 
 
 
Summary 
 Cyclin-dependent kinase 5 (Cdk5) is a multifaceted serine/threonine kinase protein with 
important roles in the nervous system. Two related proteins, p35 and p39, activate Cdk5 upon 
direct binding. Over the past decade, Cdk5 activity has been demonstrated to regulate many 
events during brain development, including neuronal migration as well as axon and dendrite 
development. Recent evidence also suggests a pivotal role for Cdk5 in synaptic plasticity, 
behavior, and cognition. Dysfunction of Cdk5 has been implicated in a number of neurological 
disorders and neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral 
sclerosis, Neimann-Pick type C disease, and ischemia. Hyperactivation of Cdk5 due to the 
conversion of p35 to p25 by the calcium-dependent protease calpain during neurotoxicity also 
contributes to the pathological state. This introduction surveys recent literature surrounding Cdk5 
in synaptic plasticity and homeostasis, with particular emphasis on Cdk5 kinase activity under 
neurodegenerative conditions. 
 
 
 
 
 
 
 
 
______________________ 
1 This chapter was previously published as: Su, SC and Tsai, LH. (2011). Cyclin-dependent kinases in 
brain development and disease. Annual Review of Cell and Developmental Biology 27:465-491. 
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 As neurological disorders such as Alzheimer’s disease (AD) progressively impact an 
aging population, there is a heightened urgency to determine the cellular and molecular events 
underlying these devastating illnesses. Cyclin-dependent kinase 5 (Cdk5) has received 
substantial attention as a result of its unique properties in the central nervous system (Dhavan & 
Tsai 2001, Smith et al. 2001). This chapter highlights recent discoveries regarding Cdk5 in 
neural development, synaptic plasticity, and synaptic homeostasis with particular emphasis on 
how Cdk5 dysregulation contributes to neurodegeneration. 
 
Discovery and characterization of cyclin-dependent kinase 5 
 Cdk5 was initially discovered and cloned on the basis of its sequence homology to other 
cyclin-dependent kinases such as cdc2, cdk2, and cdk3 (Lew et al. 1992, Meyerson et al. 1992). 
Formally known as PSSALRE, Cdk5 shares 60% homology with cdc2. Unlike the other cyclin-
dependent kinases, however, Cdk5 is not directly involved in the cell cycle. Using histone H1 as 
a substrate, the preferred sequence of the proline-directed serine/threonine kinase Cdk5 is 
X(S/T)PX(H/K/R), where S/T represents serine/threonine, X is any amino acid, P is the required 
proline residue, and H/K/R are basic residues (Beaudette et al. 1993). Cdk5 is highly expressed 
in the brain and requires binding to a regulatory subunit protein, p35, for activation (Tsai et al. 
1994). Notably, p35 messenger RNA is expressed in postmitotic cells of the mouse embryo and 
overlaps with Cdk5 expression in the central nervous system (Tsai et al. 1993, 1994). The 
discovery and cloning of p25, a truncated form of p35, hinted at the possibility of Cdk5 as the 
kinase responsible for phosphorylating neurofilament (NF) proteins (Lew et al. 1994). Figure 1 
highlights several currently known Cdk5-mediated functions, while Table 1 provides a more 
comprehensive list of identified Cdk5 substrates. 
 
Early discoveries in neural cytoarchitecture 
 Cdk5 knockout (KO) mice produced using gene-targeting techniques display perinatal 
lethality owing to neuronal migration deficits and impaired axonal transport of NFs (Ohshima et 
al. 1996). In p35 KO mice, a dramatic inversion of cortical layering is evident in which the 
newly generated postmitotic neurons fail to migrate past older neurons on radial glia (Chae et al. 
1997). The animals suffer adult seizures and lethality, and they exhibit alterations in cell 
orientation as well as dendrite and axon trajectories (Chae et al. 1997, Wenzel et al. 2001). A p35 
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homolog termed p39 was isolated (Tang et al. 1995) and found to localize to the synapse 
(Humbert et al. 2000b). The p35 and p39 double-null deletion mouse model exhibits a phenotype 
most similar to the Cdk5 KOs including severe disruption of various central nervous system 
components, an absence of Cdk5 kinase activity, lamination defects, and perinatal lethality (Ko 
et al. 2001). Therefore, p35 and p39 are the sole activators of Cdk5. The collective studies 
highlight Cdk5 and p35 as necessary components for establishing proper neocortical lamination. 
 
Cyclin-Dependent Kinase 5 and p35 in Neurite Development and Neuronal Migration 
 During embryonic development, Cdk5 is highly expressed in the cell body and axons of 
neurons. Furthermore, Cdk5/p35 colocalize to axonal growth cones (Nikolic et al. 1996, Tsai et 
al. 1993). If dominant negative Cdk5 (Cdk5-DN) constructs interfering with endogenous p35 
binding or the ATP binding pocket are expressed (D144N or K33T), or if p35 expression is 
reduced, neurite outgrowth is inhibited. Conversely, Cdk5 and p35 overexpression leads to 
longer neurites. 
 Cdk5/p35 mediates neurite outgrowth through Pak 1 kinase (Nikolic et al. 1998) and 
interaction between phosphorylated Y15 Cdk5, tyrosine kinase c-Abl, and Cables (Zukerberg et 
al. 2000). Other studies link Cdk5 phosphorylation of receptor tyrosine kinases TrkB in brain-
derived neurotrophic factor-stimulated dendrite outgrowth (Cheung et al. 2007), phosphorylation 
of the collapsin-response-mediated protein for semaphorin 3A-induced growth-cone collapse 
(Brown et al. 2004, Harada et al. 2001), phosphorylation of ephexin and WAVE1 in dendritic 
spine development (Fu & Ip 2007). Moreover Cdk5/p35 activity downstream of the Erk 
signaling pathway has been implicated in nerve growth factor-dependent neurite outgrowth 
(Harada et al. 2001), and Cdk5/p35 also interacts with ubiquitin ligase mind bomb 1 (Mib1) 
during neurite morphogenesis (Choe et al. 2007). Recent work has uncovered a role for s-
nitrosylation, a post-translational modification, on Cdk5 activity in regulation of neurite growth 
and branching (Zhang et al. 2010). Thus, Cdk5/p35 is essential for neurite development and 
maintenance of proper cytoskeletal architecture. 
 Cytoskeletal substrates of Cdk5 include NF proteins and the microtubule (MT)-associated 
protein tau (Baumann et al. 1993, Lew et al. 1994, Paudel et al. 1993), which is heavily 
phosphorylated by multiple proline-directed kinases including Cdk5, glycogen synthase kinase 3 
β (GSK-3β), and MT-associated protein (MAP) (Mandelkow & Mandelkow 1998, Paglini et al. 
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1998). Tau phosphorylation is thought to allow it to regulate MT polymerization, a particularly 
important function discussed below in terms of Cdk5 and AD (De Vos et al. 2008). 
 Cdk5 phosphorylates multiple proteins to mediate neuronal migration, including 
NUDEL, a Lis-1-interacting protein that cooperates with dynein, an MT-interacting motor 
protein (Niethammer et al. 2000, Sasaki et al. 2000); the tyrosine kinase FAK, which is 
phosphorylated to allow regulation of an MT fork to direct proper neuronal migration through 
nuclear translocation (Xie et al. 2003); doublecortin (Dcx), which allows for increased 
cytoskeletal dynamics during neuronal migration (Tanaka et al. 2004); Dix-domain containing 1 
(Dixdc1), which interacts with psychiatric illness risk gene Disrupted in Schizophrenia-1 
(DISC1) and NUDEL during migration (Singh et al. 2010); and DISC1 which mediates neural 
progenitor migration (Ishizuka et al. 2011). 
 
Cdk5 is a critical regulation of synaptic transmission 
Presynaptic substrates and neurotransmission 
 At presynaptic terminals of chemical synapses, vesicles containing neurotransmitters 
undergo docking and fusion, or exocytosis, at the active zone to allow neurotransmitter release 
across the synaptic cleft (Murthy and De Camilli 2003, Sudhof 2004). Presynaptic calcium influx 
triggers vesicle fusion and exocytosis by the SNARE (soluble N-ethylmaleimide-sensitive fusion 
attachment receptor) complex proteins, consisting of v-SNARES (synaptobrevin or VAMP) and 
t-SNARES (SNAP-25, syntaxin). Recycling of synaptic vesicle proteins occurs through clathrin-
mediated synaptic vesicle endocytosis (SVE). Components of SVE machinery include the 
accessory protein AP-2, dynamin and amphiphysin proteins to pinch off the vesicle from the 
active zone using GTP hydrolysis, synaptojanin I to assist in synaptic vesicle uncoating, and 
other dephosphin proteins. The phosphatase calcineurin removes the phosphate groups from the 
dephosphins in response to calcium influx and allows for synaptic vesicle exocytosis, and 
rephosphorylation by protein kinases, including Cdk5, are critical for continued SVE (Nguyen & 
Bibb 2003). 
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Figure 1 Cyclin-dependent kinase 5 (Cdk5) impacts various cellular processes and is vital for proper 
neuronal function. Cdk5 requires p35 binding for activation and regulates many events including neuronal 
migration, cytoskeletal dynamics, and neurite outgrowth. Cdk5 plays a critical role in dopaminergic 
neuron signaling and regulates components of the synaptic vesicle cycle. Recent evidence suggests a 
pivotal role for Cdk5 in synaptic plasticity, behavior, and cognition. Additionally, Cdk5 has been 
implicated in a number of molecular pathways such pain signaling, adult neurogenesis, and 
neuromuscular development. Abbreviations: AChR, acetylcholine receptor; Cdk5, cyclin-dependent 
kinase 5; DARPP, dopamine cyclic-AMP regulated phosphoprotein; LTD, long-term depression; LTP, 
long-term potentiation.  
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Table 1. List of major identified Cdk5 substrates and their functional categories 
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Abbreviations: AChR, acetylcholine receptor; Ape1, apurinic /apyrimidinic endonuclease 1; APP, 
amyloid precursor protein; ATM, Ataxia telangiectasia mutated; Bcl-2, B-cell CLL/lymphoma 2; BDNF, 
brain-derived neurotrophic factor; Cables, Cdk5 and Abl enzyme substrate; CASK, calcium/calmodulin-
dependent serine protein kinase; CaV1.2, L-type voltage-gated calcium channel; CaV2.1, P/Q-type 
voltage-gated calcium channel; Cdh1, cadherin-1; CRMP2, Collapsin response mediator protein 2; c-Src, 
non-receptor tyrosine kinase; DARPP-32, Dopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa; 
DISC1, Disrupted in schizophrenia1; DRG, dorsal root ganglion; Dixdc1, Dix-domain containing 1; 
ErbB3, receptor tyrosine-protein kinase erbB3; FAK, focal adhesion kinase; GR, glucocorticoid receptor; 
HDAC, histone deacetylase; JNK3, c-Jun N-terminal kinase 3; LTP, long-term potentiation; MAP1B, 
microtubule-associated protein 1B; MEK1, MAP kinase kinase-1; MEF2D, myocyte enhancer factor 2D; 
Munc18, mammalian uncoordinated 18; NF, neurofilament; NMJ, neuromuscular junction; NR2A, N-
methyl D-aspartate receptor subunit 2A; NR2B, N-methyl D-aspartate receptor subunit 2B; Nrg, 
neuregulin; NSF, N-ethylmaleimide sensitive factor; p27(kip1), cyclin-dependent kinase inhibitor; p35, 
regulatory activator of cyclin-dependent kinase 5 Mr 35 kDa; p39, regulatory activator of cyclin-
dependent kinase 5; p53, tumor protein 53; PAK1, p21-Activated Kinase; paxillin, focal adhesion-
associated adaptor protein; pctaire1, cyclin-dependent kinase 16 (cdk16); PIPKI, phosphatidylinositol(4) 
phosphate 5 kinase type I gamma; PPARγ, Peroxisome proliferator-activated receptor gamma; Plk2, polo-
like kinase 2; PP-1, protein phosphatase-1; Prx2, peroxiredoxin 2; PSD-95, Postsynaptic density protein 
95; RasGRF, ras guanine nucleotide releasing factor 2; Rb, retinoblastoma protein; S6K1, S6 kinase 1; 
SPAR, spine-associated Rap guanosine triphosphatase activating protein; STAT3, signal transducer and 
activator of transcription 3; TH, tyrosine hydroxylase; TRPV-1, Transient Receptor Potential Vanilloid-1. 
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Role in synaptic vesicle exocytosis and endocytosis 
 The synaptic vesicle cycle requires Cdk5 phosphorylation of presynaptic proteins 
implicated in both endocytosis and exocytosis. Munc18, a protein that interacts with syntaxin1A 
and is thought to be an essential complex in vesicle fusion, is phosphorylated by Cdk5/p35 
(Fletcher et al. 1999, Shuang et al. 1998). In vitro, Cdk5/p35 forms a complex with Munc18 and 
syntaxin1A that is dissociated upon the addition of ATP, which suggests that Cdk5 
phosphorylation of Munc18 may allow for syntaxin1A to form a SNARE complex and promote 
neurotransmitter release. The interaction between another protein implicated in exocytosis, 
Sept5, and syntaxin1 is also regulated by Cdk5/p35 (Taniguchi et al. 2007). 
 Cdk5 also phosphorylates the presynaptic protein CASK to facilitate synapse 
development (Samuels et al. 2007) and the P/Q-type voltage-gated calcium channel (CaV2.1) to 
inhibit its interaction between SNAP-25 and synaptotagmin in vitro (Tomizawa et al. 2002). 
Application of roscovitine, a cyclin-dependent kinase inhibitor, increases the field excitatory 
postsynaptic potential (fEPSP) slope in acute hippocampal slice preparations and upregulates 
glutamate release from synaptosomes, suggesting that blocking the action of Cdk5 results in a 
long-term potentiation (LTP) of synaptic strength. However, in addition to its role in the 
cytoplasm, roscovitine acts on the extracellular domain of CaV2.1 to slow channel deactivation 
kinetics and allow calcium influx (Yan et al. 2002). Therefore, exactly how Cdk5/p35 regulates 
synaptic transmission remains unclear. 
 Several components of the SVE are Cdk5 targets; these include synapsin I (Matsubara et 
al. 1996), amphiphysin (Floyd et al. 2001), synaptojanin I (Lee et al. 2004), and dynamin I (Tan 
et al. 2003, Tomizawa et al. 2003). However, one report indicates that Cdk5 phosphorylation 
disrupts SVE (Tomizawa et al. 2003), while another supports the notion that Cdk5 is essential for 
SVE (Tan et al. 2003). To add further complexity, Cdk5 is involved in activating Pctaire1, a key 
component in the phosphorylation and regulation of N-ethylmaleimide sensitive fusion protein, 
which is necessary for disassembling the SNARE complex (Cheng et al. 2002). It has been 
suggested that Cdk5 is necessary for the activity-dependent slow component of SVE (Evans and 
Cousin 2007). Continued work will better elucidate the intricate dynamics between Cdk5 and 
calcineurin in mediating exocytosis and the multiple stages of SVE. 
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Cyclin-dependent kinase 5 and modulation of transmission 
Dopaminergic signaling in striatum 
 A prominent area of Cdk5 research centers on dopaminergic signaling pathways (Chergui 
et al. 2004). Cdk5 directly phosphorylates the N-terminal regulatory domain of tyrosine 
hydroxylase, the dopamine-synthesis catalytic enzyme in presynaptic terminals (Moy & Tsai 
2004). Postsynaptically, Cdk5 phosphorylation of DARPP-32 (dopamine cyclic-AMP regulated 
phosphoprotein) on the T75 residue allows DARPP-32 to become a protein kinase A (PKA) 
inhibitor and therefore a protein phosphatase 1 activator, thus allowing phosphatase activity 
(Bibb et al. 1999). Conversely, if DARPP-32 is phosphorylated solely at T34 by PKA through 
the dopamine D1 receptor signaling pathway, it inhibits protein phosphatase 1 and promotes net 
phosphorylation activity as a kinase. 
 Following chronic cocaine exposure, as well as in ΔFosB mice, mRNA and protein levels 
of Cdk5/p35 are upregulated in medium spiny striatal neurons (Bibb et al. 2001). During acute 
cocaine exposure, PKA is activated to downregulate T75 phosphorylation. However, following 
chronic cocaine exposure, Cdk5 is activated to dampen the locomotor response as a part of a 
novel homeostatic mechanism, and subsequent phosphorylation of T75 will decrease D1/PKA 
signaling. Additional work examining the homeostatic regulation by Cdk5 in dopaminergic 
neurons will be critical for a more complete understanding of the cellular and molecular 
mechanisms underlying drug abuse and addiction. 
 
Glutamatergic transmission in the hippocampus 
 The postsynaptic density (PSD) found on dendritic spines of excitatory synapses of the 
mammalian central nervous system is comprised of a vast and complex network of proteins that 
provide a dynamic, compartmentalized framework for receiving inputs from hundreds of 
presynaptic axonal contacts (Sheng & Hoogenraad 2007). Systematic biochemical and animal 
model studies have established how each PSD protein interacts with the others to establish the 
neural circuitry for proper synaptic transmission. Despite considerable advances, there is still an 
incomplete understanding of the PSD; therefore, identifying novel Cdk5 substrates will provide a 
more comprehensive outlook on how the PSD network is formed and maintained. 
 The PSD has a large abundance of PSD-95 and PSD-95 family-related proteins, which 
outnumber most of the other proteins at the electron-microscope level. PSD-95, along with PSD-
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93, SAP-102, and SAP-97, belong to the MAGUK (membrane-associated guanylyl kinase) 
family of proteins. At the postsynaptic terminal of an excitatory glutamatergic synapse in the 
mouse hippocampus, Cdk5 phosphorylates the N-terminal domain of PSD-95 to regulate the 
synaptic recruitment and clustering of ion channels, particularly the potassium K+ channels, and 
the NMDA (N-methyl D-aspartate) receptors (Morabito et al. 2004). 
 The NMDA receptors bind PSD-95 and are critical for the induction of synaptic 
transmission. Upon glutamate release and spillover into the synaptic cleft, the magnesium block 
is removed from the NMDA receptor pore to allow calcium influx. In one study, Cdk5 
phosphorylation of the NMDA receptor NR2A subunit facilitates receptor activity and LTP in 
area CA1 of the mouse hippocampus (Li et al. 2001). Cdk5 also phosphorylates NR2A during 
neurotoxic conditions such as ischemia, which enhances NMDA receptor-mediated currents 
during hippocampal CA1 cell death (Wang et al. 2003). The Cdk5-dependent phosphorylation of 
NR2B, another major subunit of the NMDA receptor, retains its cell-surface expression via 
reduced activity-dependent endocyosis (Zhang et al. 2008). 
 CaMKII is another highly abundant PSD molecule that forms a holoenzyme upon 
calcium-dependent activity and whose activation is well known to play a role in LTP (Lisman et 
al. 2002). Thus, CaMKII may form a core PSD complex critical for the induction of synaptic 
transmission. The N-terminal regions of both p35 and p39 interact with α-actinin protein, a 
protein implicated in the anchoring of receptors to the actin cytoskeleton, and their C-termini 
bind the α isoform of CaMKII (CaMKIIα) (Dhavan et al. 2002). Biochemical and 
immunohistochemical data reveal a ternary structure consisting of p35, p39, α-actinin, and 
CaMKIIα that is dependent on calcium influx primarily through the NMDA receptor, which 
leads to activation of CaMKIIα via autophosphorylation at T286. 
 Cdk5 interacts with another important signaling complex in the PSD known as the 
ephrins and ephrin receptors in ephrin-A1-mediated regulation of spine density (Fu et al. 2007). 
Cdk5 was recently demonstrated to phosphorylate the PSD protein kalirin-7 at T1590 (Xin et al. 
2008). Kalirin-7 mediates spine formation as well as synaptic plasticity and behavior, and 
kalirin-7 KOs display reduced hippocampal spine density, deficient LTP, and behavior 
abnormalities (Ma et al. 2008). The absence of kalirin-7 results in decreased Cdk5 levels at the 
PSD, suggesting that Cdk5 phosphorylation of kalirin-7 is a critical aspect for proper synaptic 
formation and function of the PSD. Cdk5 can also regulate dendritic spine formation by 
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phosphorylating WAVE1 to modulate its interaction with the Arp2/3 actin polymerization 
complex (Kim et al. 2006). The collecive findings indicate that Cdk5-mediated phosphorylation 
of PSD proteins does not occur as separate, static events but rather in a dynamic, activity-
dependent manner that has implications on the downstream signaling pathways and feedback 
loops.  
 
Cdk5, p35, and p25 in synaptic plasticity 
 Owing to the embryonic lethality of Cdk5-null animals, various mouse models have been 
developed to either diminish Cdk5 postnatally or hyperactivate Cdk5. Loss of Cdk5 activity can 
be achieved through p35 KO animals (Chae et al. 1997) or conditional knockout (cKO) of Cdk5 
(Hawasli et al. 2007, Hirasawa et al. 2004, Takahashi et al. 2010). However, a striking and 
unexpected finding that p25, a truncated form of p35, deregulates Cdk5 activity has opened a 
new field of study (Patrick et al. 1999). This Cdk5/p25 complex can be studied by generating a 
p25 transgenic mouse model in which p25 is expressed under a neural promoter (Ahlijanian et al. 
2000, Bian et al. 2002, Cruz et al. 2006). 
 Early studies involving Cdk5 and synaptic plasticity utilize pharmacological methods 
such as roscovitine or olomoucine to reduce Cdk5 activity. Protocols eliciting LTP and long-term 
depression (LTD) can vary widely, but the end result is the long-lasting enhancement or 
depression of fEPSPs compared with baseline, prestimulation levels, in synaptic transmission of 
the examined area (Bliss and Collingridge 1993). The first hint that loss of Cdk5 activity directly 
affects plasticity came from p35 KO mice in which LTP as induced by tetanic stimulation (100 
Hz) appears to be normal in area CA1 of the hippocampus, but low-frequency stimulation used 
to induce LTD (1 Hz, 15 min) reveals a marked deficit in LTD (Ohshima et al. 2005). Whereas 
LTP is thought to correlate with memory formation, LTD may play a role in weakening synapses 
and perhaps blocking memory formation (Malenka and Bear 2004). Intriguingly, LTP can be 
reversed or depotentiated in the p35 KO slices. 
 Cdk5 cKO animals were subsequently created using the Cre-loxP system, which crossed 
the mouse NF heavy-chain Cre promoter mouse line to Cdk5-floxed mice (Hirasawa et al. 2004). 
Despite the perinatal ablation of Cdk5, the mice exhibit neuronal migration defects, and synaptic 
plasticity was not examined here. Another Cdk5 cKO line was derived under a prion promoter 
and regulated temporally by the estrogen-receptor transgene (Hawasli et al. 2007). In this line, 
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Cdk5 cKO mice display an enhancement of hippocampal-dependent spatial memory as assayed 
by the Morris water-maze task and contextual fear memory, and LTP is greater compared with 
that of control mice. The evoked excitatory postsynaptic current showed that the NMDA, but not 
the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), receptor-mediated current 
is enhanced in the mutant mice, which is attributed to greater surface NR2B levels and a 
reduction in NMDAR degradation.  
 Conversely, p25, a truncated form of p35, binds and hyperactivates Cdk5. Therefore, to 
study how aberrant Cdk5 signaling may play a role in modulating synaptic plasticity, a p25 
transgenic mouse model was employed using an inducible system whereby spatial specificity is 
achieved through the αCaMKII promoter, which is highly expressed in excitatory neurons of the 
forebrain (Mayford et al. 1996), and temporal specificity is regulated using the tetracycline-
controlled transactivator system (Cruz et al. 2003). 
 Strikingly, short-term, two-week p25 expression in αCaMKII p25 Tg adult mice (CK-
p25 Tg) dramatically enhances learning and memory in contextual fear conditioning and the 
Morris water-maze task (Fischer et al. 2005). This behavioral effect corresponds with a 
facilitation of hippocampal area CA1 LTP and an increase in dendritic spine formation. 
Importantly, the mice do not display overt deficits in motor responses or neurodegeneration. 
Electrophysiology experiments reveal no significant differences in synaptic transmission or 
presynaptic alterations but instead hint at the possibility of enhanced NMDAR function. 
However, long-term, six-week induction of p25 results in severe neuronal loss, memory 
impairments, and LTP deficits. It has been proposed that elevated p25 levels is an early, perhaps 
compensatory, step in neurodegeneration. Together, results from various Cdk5/p35 KO and p25 
transgenic mouse models propose a mechanism of NMDAR-dependent LTP mediated by Cdk5 
that exerts influence on cognitive function. 
 
Cdk5 and synaptic homeostasis 
 An intriguing theme emerging from the study of synaptic plasticity using mouse models 
of Cdk5, p35, and p25 is the notion that specific molecules may dynamically shape 
compensatory mechanisms in the brain and, furthermore, maintain a steady-state level of 
signaling known as synaptic homeostasis. Recent work implicates Cdk5 in synaptic homeostasis, 
which raises the fundamental question of how Cdk5 functions in normal and disease states. 
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 The phenomenon of synaptic scaling has been studied in cultured hippocampal neurons 
where cells regulate their postsynaptic AMPA receptor-mediated response to activity (Rutherford 
et al. 1998, Turrigiano et al. 1998). This synaptic scaling, or homeostasis, can be important for 
network stabilization during periods of development, plasticity, and disease. Under conditions 
where neural activity is silenced using tetrodotoxin, which blocks action potentials, several 
molecules including brain-derived neurotrophic factor (Rutherford et al. 1998), Arc (Shepherd et 
al. 2006), and adenylyl cyclase 1 (Gong et al. 2007) are involved in the homeostatic response. 
Less is known about the molecular pathways underlying sustained, heightened activity. Cdk5 has 
recently been identified as a novel molecule involved in synaptic homeostasis. 
 During periods of elevated activity, Cdk5 phosphorylates SPAR, a postsynaptic RapGap 
scaffolding molecule, prior to phosphorylation and subsequent degradation of SPAR by polo-like 
kinase 2 (Plk2) (Seeburg et al. 2008). Plk2 is necessary to downregulate the synaptic response 
during chronically elevated activity, but it can bind SPAR only when SPAR is phosphorylated by 
Cdk5. Blocking Cdk5 will also inhibit synaptic weakening in response to heightened activity. 
Thus, Cdk5 is a key player in the regulation of downstream signaling cascades involved in 
synaptic homeostasis. 
 Another study directly establishes Cdk5 as an integral player in controlling synaptic 
transmission (Kim & Ryan 2010). Acutely silencing Cdk5 using roscovitine or short-hairpin 
RNA increases presynaptic neurotransmitter release. Furthermore, the interaction between Cdk5 
and calcineurin maintains the recycling vesicle pool to provide fine-tuning of synaptic vesicle 
release at the nerve terminal. Chronic silencing of neuronal activity using tetrodotoxin 
downregulates Cdk5 levels by a yet-undetermined mechanism. A comprehensive analysis 
investigating how activity regulates Cdk5 localization and function will further reveal its 
importance in modulation of synaptic homeostasis at pre- and postsynaptic terminals. 
 
Activity-dependent regulation of Cdk5 
 One long-standing question has been how Cdk5 is regulated, either by its upstream 
signaling pathways or by controlling kinase activity. Previous hints suggest that Cdk5 is 
phosphorylated on Y15 to increase its kinase activity (Zukerberg et al. 2000), yet 
phosphorylation at a neighboring site T14 on Cdk5 inactivates other Cdks in addition to Cdk5 
(Matsuura & Wang 1996). It has also been established that phosphorylation at T160, but not 
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S159, is required for activation (Poon et al. 1997, Qi et al. 1995). The X-ray crystal structure of 
the Cdk5/p25 complex provided further support of an unusual kinase-substrate binding 
relationship, the unphosphorylated S159 at the T loop of Cdk5 is necessary for formation of the 
Cdk5/p25 complex (Tarricone et al. 2001). In addition, p35 undergoes activity-dependent 
degradation via the ubiquitin-proteosome pathway (Patrick et al. 1998, Wei et al. 2005b). 
 Notably, the activation of calpain, a calcium-dependent protease, cleaves p35 to produce 
p25 during neurotoxicity (Lee et al. 2000, Patrick et al. 1999). Elevated activity leading to 
neurotoxic conditions in synapses of cultured neurons can be induced through several pathways, 
including amyloid β (Aβ) treatment, excitotoxicity from excessive intracellular calcium levels 
due to ischemia or excessive glutamate spillover across the synaptic cleft, or chemical 
compounds, such as hydrogen peroxide or ionomycin. Neurotoxic treatments activate calpain, 
which in turn cleaves the N-terminal fragment of p35 to liberate the p25 fragment. This 
Cdk5/p25 complex accumulates predominantly in the cytoplasm and nucleus due to loss of a 
myristolation tag and exhibits a longer half-life compared with that of Cdk5/p35 which is 
localized mainly in the cell periphery (Patrick et al. 1999). 
 The significance of Cdk5/p25 in disease is further supported by observations of p25 
accumulation in AD brains (Patrick et al. 1999, Tseng et al. 2002). Also present in the same 
neurons of AD brains are neurofibrillary tangles (NFTs). Interestingly, p25, but not p35, is found 
in neurons containing NFTs as demonstrated by AT8 antibody staining. Tau 
hyperphosphorylation is observed using another antibody, PHF-1 (paired helical fragment 1). 
Cdk5/p25 is responsible for the phosphorylation event (Hashiguchi et al. 2002), which renders 
tau less likely to associate with MTs. Furthermore, overexpressing Cdk5/p25 in primary neurons 
causes cytoskeleton disruptions and ultimately apoptotic cell death as shown by fragmented 
nuclei. These studies highlight the first associations between p25 and neurodegenerative diseases 
such as AD and suggest that the unique properties associated with Cdk5/p25 hyperactivation 
may play a critical role in the pathogenesis of NFTs and neuronal death. 
 
Alzheimer’s Disease 
Theories of Alzheimer’s Disease 
 AD is a devastating neurodegenerative disease primarily affecting the elderly, although in 
rare cases there are inherited, familial AD (FAD). The pathological hallmarks of AD include 
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neuronal and synaptic loss, NFTs, and the presence of Aβ (amyloid beta) plaques in the 
postmortem brain. While the exact cause of sporadic AD is unknown, several hypotheses have 
garnered attention as contributing factors (Hardy & Selkoe 2002, Small & Duff 2008). The 
amyloid hypothesis posits that Aβ peptides, derived from the proteolytic processing of the 
transmembrane β-amyloid precursor protein (APP), accumulate and cause impairments in AD 
patients. FAD patients possess mutations in the APP gene, leading to an extensive area of APP 
studies using multiple animal models. Yet other FAD patients have presenilin 1 and 2 (PS1, PS2) 
mutations, genes which encode the proteolytic enzyme γ-secretase involved in the cleavage of 
APP to generate Aβ. Two other key enzymes in Aβ generation are α-secretase and β-secretase. 
After initial cleavage of the extracellular region of APP by either α- or β-secretase, γ-secretase 
cleavage occurs in the transmembrane domain to release either the non-pathogenic form of Aβ 
(p3) mediated by α-secretase or the pathogenic (Aβ42) peptide mediated by β-secretase. Another 
hypothesis suggests that tau hyperphosphorylation, in which tau filaments aggregate into 
insoluble NFTs, dampen cellular activity and lead to cognitive impairment. NFTs are also found 
in patients with frontotemporal dementia. 
 
p25-mediated neurodegeneration 
 To examine how dysregulation of Cdk5 by p25 may play a role in synaptic plasticity, a 
p25 transgenic (p25-Tg) mouse model was created using a neuron-specific enolase promoter 
expressing human p25 cDNA (Ahlijanian et al. 2000). The mice exhibit increased locomoter 
activity and appear less anxious as tested by the elevated-plus maze. Moreover, dramatic axonal 
swelling and hyperphosphorylation of tau and NFs were detected. In a second p25 transgenic 
mouse model, p25 overexpression driven by the CaMKII promoter triggered neurodegeneration 
and activated microglia but not tau phosphorylation or Aβ formation (Mullyaert et al. 2008). 
 To examine further how Cdk5 may play a role in tau aggregation and tangle formation, a 
mouse model overexpressing human mutant tau (P301L) was crossed to the p25-Tg mice (Noble 
et al. 2003). Enhanced Cdk5 activity, axonopathy, and greater tau phosphorylation at known 
Cdk5 sites are observed in P301L/p25 double-transgenic mice. Furthermore, insoluble, 
aggregated tau and NFT are markedly increased in the brainstem. Around the same time, two 
other p25-Tg mouse models were generated using the CMV (cytomegalovirus) or the PGDF 
(platelet growth-derived factor) promoter, but neither produced noticeable increases in tau 
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phosphorylation or neuronal apoptosis (programmed cell death due to extrinsic or intrinsic 
pathways) (Bian et al. 2002, Takashima et al. 2001). Crossing Cdk5, p35, and tau in a triple 
transgenic mouse model did not generate NFTs (Van den Haute et al. 2001), suggesting tau 
phosphorylation may be due to elevated, potent Cdk5/p25 activity. 
 Although other p25 mouse models do not exhibit signs of neurodegeneration, in CK-p25 
Tg mice (Cruz et al. 2003) long-term overexpression of p25 produces characteristic hallmarks of 
frontotemporal dementia and AD: progressive neuronal loss resulting in a dramatic reduction in 
brain weight, astrogliosis, enhanced NF phosphorylation as assayed by SMI34, tau 
hyperphosphorylation using AT-8 and PHF-1 antibodies, a higher abundance of sarkosyl-
insoluble tau, and late-stage NFT-like pathology from Bodian silver staining and Thioflavin-S 
staining (Cruz et al. 2003). The pathological events in the CK-p25 Tg mice occur in the cortex 
and hippocampus, areas primarily affected in neurodegenerative diseases. Furthermore, p25 
induction markedly enhances Aβ production and accumulation preceding neuron death, 
providing evidence that p25 overexpression can generate Aβ pathology in vivo (Cruz et al. 
2006). The presence of increased β-secretase enzyme activity may act together with γ-secretase 
to generate the toxic Aβ42 fragment from APP. The phenotypes may be dose dependent, as a 
lower-expressing mouse model of p25 can partially ameliorate watermaze learning deficits and 
fear conditioning due to a proposed compensatory mechanism (Angelo et al. 2003).  
 APP is phosphorylated by Cdk5, which may affect its localization (Iijima et al. 2000, Lee 
et al. 2003) and Aβ induces Cdk5 hyperactivity, presumably due to Cdk5/p25, to phosphorylate 
tau in another AD model, Tg2576 (Otth et al. 2002). Intriguingly, double PS1/PS2 KO animals 
exhibit memory impairment, reduction in NMDARs and CREB-mediated gene expression, and 
accelerated, progressive neurodegeneration accompanied by an increase in p25 levels and 
hyperphosphorylated tau (Saura et al. 2004). A recent study utilized viral-mediated knockdown 
of Cdk5 to reduce NFTs in a 3X-Tg AD model, providing support for modulating p25 levels or 
overall Cdk5 activity as potential strategies in therapeutically targeting AD (Piedrahita et al. 
2010). Aberrant Cdk5/p25 activity is also found in other neurodegenerative diseases (discussed 
below, also refer to Figure 2). Yet another potential therapeutic strategy is to reduce Aβ 
pathology by targeting β-secretase enzyme to diminish the neurodegeneration observed in 
various AD mouse models, including the CK-p25 Tg mice.  
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Epigenetic regulation in learning and memory 
 Epigenetics refers to long-lasting changes based on the modification of DNA or protein 
structures, such as chromatin, without altering the DNA sequence itself (Borrelli et al. 2008). 
Modifications include phosphorylation, DNA methylation, chromatin acetylation by histone 
acetylases (HATs) on histone complexes, and chromatin deacetylation by histone deacetylases 
(HDACs). HATs are generally viewed as relaxing the chromatin to permit gene transcription, 
whereas HDACs are seen as mainly functional for transcriptional repression. Recent publications 
have addressed the contribution of epigenetics, particularly individual HDACs, to other forms of 
neurological diseases in animal models (Fischer et al. 2010). 
 In work uncovering a link between Cdk5 in epigenetics, CK-p25 Tg mice (Cruz et al. 
2003) exhibiting signs of neurodegeneration were placed into an enriched environment. Despite 
massive neuronal loss, CK-p25 Tg mice in an enriched environment have enhanced learning 
ability as a result of new synapse formation in the surviving neurons and can remarkably recover 
their older memories (Fischer et al. 2007). Chromatin remodeling results in altered acetylation 
levels of various residues on histones H3 (lysine 14 or K14) and H4 (K5). The CK-p25 Tg mice 
treated with the broad HDAC inhibitor (HDACi) sodium butyrate show increased acetylation 
levels of H3 and H4, improved learning, and, most dramatically, restored access to long-lost 
memories in a similar manner to that seen in an enriched environment. Thus, altered epigenetic 
regulation in disease states may potentially be abrogated by drugs that target particular 
chromatin-remodeling enzymes. 
 Molecular alterations occur in the neuronal landscape prior to neurodegeneration in CK-
p25 Tg mice. After two weeks of p25 induction, Cdk5/p25 inhibits HDAC1 and upregulates a 
number of genes involved in neuronal cell death, cell-cycle reactivation, and DNA double-strand 
breaks as measured by γH2AX staining and increased transcription of cyclins A, B, E, E2F1, Ki-
67, and PCNA genes (Kim et al. 2008). Restoring HDAC1 can prevent neurons from undergoing 
double-strand breaks and cell death in a rodent model of ischemia. Cdk5 also phosphorylates 
nuclear ATM, a key molecule in mediating DNA damage responses and cell death (Tian et al. 
2009), Ape1, a protein involved in DNA repair (Huang et al. 2010), and mSds3, a component of 
the HDAC transcriptional corepressor complex (Li et al. 2004). The results highlight the 
importance of epigenetic regulation in disease. Indeed, Cdk5/p25 appears to be involved in 
parallel processes ranging from DNA damage, epigenetic modifications, to neurodegeneration.
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Figure 2 Cdk5, p35, and p25 are critical components in maintaining synaptic homeostasis with 
implications on neurodegenerative diseases. An emerging hypothesis predicts that Cdk5 mediates a 
neuronal intrinsic property in regulating synaptic homeostasis. Maintaining appropriate levels of Cdk5 
signaling provides a compensatory mechanism by which the cell normally responds to environmental 
stressors until severe disruptions lead to irreversible damage. Aberrant, mistargeted Cdk5 activity due to 
neurotoxicity and calpain-mediated cleavage of p35 to p25 will cause an imbalance in synaptic 
excitability and the generation of the Cdk5/p25 complex. Elevated and sustained Cdk5/p25 activity 
consequently modulates downstream events leading to DNA damage, epigenetic changes, and 
neurodegeneration.  
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Cdk5 and neurodegenerative diseases 
 The etiology of many diseases such as AD, Parkinson’s, and amyotrophic lateral sclerosis 
(ALS) is unknown, and these sporadic (idiopathic) cases comprise the majority of 
neurodegenerative diseases. Signature pathological hallmarks characterize each disease with 
different brain regions initially, and preferentially, affected. Nonetheless, as each disease 
progresses, neuronal death is severe and cognitive impairments are profound. Cdk5/p35 may 
serve as the common mechanism of neurodegeneration given its early function in response to 
neurotoxic agents that give rise to Cdk5/p25 activation in a particular cellular compartment. As 
Cdk5/p25 has been implicated in many neurodegenerative diseases, it merits closer examination. 
 
Amyotrophic Lateral Sclerosis 
 ALS is a rapid, progressive disease in which spinal motor neurons degenerate, leading to 
muscle atrophy, loss of movement, and eventually death. The copper/zinc superoxide dismutase 
1 (SOD1) was identified in ALS patients as a gene that contained point mutations (Bowling et al. 
1993). SOD1 normally eliminates free radicals in the body, and although the exact role of SOD1 
in ALS remains unknown, it is thought that mutant SOD1 aggregate to provoke multiple intrinsic 
toxicities including mitochondrial dysfunction, neurite and axonal abnormalities, and axonal 
transport impairments. 
 In a mouse model of ALS (SOD1G37R), the p25/p35 ratio was enhanced (Nguyen et al. 
2001). The NF heavy chain, a Cdk5 substrate, was hyperphosphorylated in the spinal cord as 
examined by AT-8 and PHF-1, which causes an abnormal distribution that colocalizes with 
Cdk5/p25. It is suggested that the NF heavy chain in the perikarya (cell body) may serve as a 
phosphorylation sink for Cdk5/p25, which would confer a protective effect on the neuron by 
sequestering the complex and preventing further toxicity. 
 The relationship between p25, neurodegenerative diseases, and epigenetics was further 
examined in the CK-p25 Tg mouse model (Kim et al. 2007). In CK-p25 Tg as well as 
SOD1G37R mice, there is an increase in histone deacetylase sirtuin 1 (SIRT1) levels throughout 
neurodegeneration. SIRT1 confers a neuroprotective effect on multiple organisms, and it is 
activated by the compound resveratrol. In vivo, application of resveratrol, a SIRT1 activator, or 
SIRT1 injections into the mouse brain protect against neurodegeneration and cognitive decline in 
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the CK-p25 Tg mice. There is an increase in the tumor suppressor p53 in CK-p25 Tg mice, but 
activation of SIRT1 by resveratrol reduces acetylation and total p53 levels. 
 Recently, mutations were identified in FUS/TLS, a DNA/RNA binding protein, of 
familial ALS patients in which FUS/TLS accumulated abnormally in the cytoplasm 
(Kwiatkowski et al. 2009, Vance et al. 2009). Mutations in TAR DNA binding protein (TDP-43), 
a gene with a structure similar to FUS/TLS, is also implicated in ALS (Sreedharan et al. 2008). 
One study found that TDP-43 is phosphorylated at serine residues and ubiquitinated in both ALS 
and frontotemporal dementia (Neumann et al. 2006). It would be interesting to speculate whether 
Cdk5/p25 interacts with components of the DNA/RNA processing pathways in ALS and if 
Cdk5/p25 colocalizes to cytoplasmic aggregates of FUS/TLS and TDP-43. 
 
Niemann-Pick Type C 
 Niemann-Pick type C (NPC) is caused by mutations on the NPC gene and is an 
autosomal-recessive neurodegenerative disorder that occurs without the presence of Aβ, causing 
distorted lipid storage in neurons, dendritic and axonal abnormalities, demyelination, and 
neuronal death (Elleder et al. 1985). NFTs, comprised of PHFs and phosphorylated tau, are 
present in those with NPC disease (Auer et al. 1995). 
 Although one study did not find greater Cdk5/p25 activity as measured by tau 
phosphorylation using NPC KO mouse models (Sawamura et al. 2001), another group found an 
increase in hyperphosphorylated tau (Bu et al. 2002). Additionally, kinase assays reveal an 
increase in Cdk5 activity in the NPC KO mice corresponding to an increase in p25 levels in 
human and mouse NPC models, in which Cdk5/p25 colocalizes with hyperphosphorylated tau in 
brain tissue. Inhibitors of Cdk5 attenuate the effects of tau hyperphosphorylation and motor 
defects (Zhang et al. 2004). 
 The issue of whether Cdk5/p25 is required for the pathogenesis in ALS and NPC, or even 
AD, remains unresolved and is complicated by the lack of a reduction in tau pathology onset and 
progression using p35 KO mice in animal models of ALS and NPC (Hallows et al. 2006, 
Takahashi & Kulkarni 2004). However, it cannot be ruled out that another Cdk5 coactivator, p39 
may compensate for loss of p35 function in these diseases or whether deletion of p35 throughout 
development serves as a representative animal model for neurodegeneration. 
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Ischemia and Stroke 
 The use of a cerebral focal ischemia paradigm in rodent models can increase Cdk5 
activity (Green et al. 1997, Hayashi et al. 1999). Moreover, ischemia induces hippocampal CA1 
pyramidal cell death primarily by Cdk5 phosphorylation of NR2A receptors (Wang et al. 2003). 
In hippocampal CA1 neurons, p25 is induced following ischemia, and inhibiting Cdk5 using 
Cdk5-DN protects them from cell death. It is proposed that ischemia, a form of excitotoxicity, 
induces calpain activity to generate p25, which then allows Cdk5/p25 phosphorylation of the 
NR2A receptors. This, in turn, results in an increased channel conductance and potentiates its 
function, which ultimately causes cell death. The activation of NR2A receptors may require 
calcium influx through the AMPA receptors as well, which can account for multiple sources of 
calcium during excitotoxicity that stimulate calpain. Interestingly, Cdk5/p25 has been implicated 
in promotion of cell apoptosis in neurons that have been subjected to endoplasmic reticulum-
mediated stress, suggesting an interplay between ischemia and other cellular compartments in 
which Cdk5/p25 is activated (Saito et al. 2007). 
 Consistent with the known events underlying p25 generation, Cdk5 also appears to 
mediate the excitotoxic component of cell death by an NMDA receptor-dependent pathway 
(Rashidian et al. 2005), whereas inhibition of the cell-cycle regulator Cdk4 may be involved in 
the delayed component of cell death. This suggests that Cdk5/p25 may be present during the 
early phase of neurotoxicity and acts in concert with chromatin remodeling enzymes, such as 
HDAC1, in regulating the transcription of cell-cycle genes. The link between Cdk5, p25, and 
cell-cycle gene regulation provides a converging avenue for further research, especially 
regarding DNA damage and its relationship to neuronal loss. 
 Recent work utilizes in vivo models of ischemia to examine Cdk5 in neuronal death. 
Under ischemic conditions, Cdk5 activity mediates excitotoxic cell death by phosphorylating 
cytoplasmic peroxiredoxin 2 (Prx 2) (Qu et al. 2007, Rashidian et al. 2009). In contrast, under 
focal ischemia by endothelin-1 application in the striatum, Cdk5 activity is present in the nucleus 
and facilitates neuronal death by phosphorylating myocyte enhancer factor 2D (MEF2D) (Smith 
et al. 2006). MEF2D was previously identified as a Cdk5 substrate in which it is degraded 
following phosphorylation in neurotoxiciy-induced apoptosis (Gong et al. 2003). The regional 
and substrate specificities in different ischemia models point to different components of neuronal 
death that share a common pathway involving Cdk5/p25. Cdk5/p25 hyperactivity is linked to 
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NFTs after transient ischemia (Wen et al. 2007), perhaps sharing similar mechanisms with AD or 
frontotemporal dementia. 
 
Parkinson’s Disease 
 Parkinson’s disease (PD) is a neurodegenerative disorder characterized by α-synuclein-
containing Lewy body inclusions, loss of dopaminergic neurons in the substantia nigra pars 
compacta, and impaired motor skills and cognition (Olanow & Tatton 1999). Symptoms include 
tremors, muscle rigidity, and postural instability. Current treatments for PD include dopamine 
agonists or deep-brain stimulation. In animal models, application of the chemical compound 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is sufficient to induce the pathological 
consequences of PD. 
 Cdk5/p35 is elevated in the Lewy bodies of postmortem PD brains (Brion & Couck 1995, 
Nakamura et al. 1997, Takahashi et al. 2000) but not in others (Muntane et al. 2008). In MPTP-
administered mice, greater Cdk5/p25 levels and robust kinase activity were observed in 
dopaminergic neurons (Smith et al. 2003). MPTP treatment does not affect other Cdks including 
Cdk2 or Cdk4, and treatment with either a Cdk5 inhibitor or Cdk5-DN virus attenuates neuronal 
death in dopaminergic neurons. The findings parallel Cdk5 signaling in the striatum because 
MPTP treatment also increases levels of ΔFosB, a transcriptional regulator of Cdk5 that is 
upregulated during drug addiction. However, in this mouse model of PD, Cdk2 and Cdk4 do not 
appear to play a critical role in MPTP-induced neuron death, in contrast to ischemia models. 
 A recent study identified parkin, a gene most frequently implicated in familial PD, as a 
Cdk5 interaction partner and substrate (Avraham et al. 2007). Parkin may confer a 
neuroprotective effect by its function as a ubiquitin ligase enzyme with substrates including α-
synuclein, synphilin-1, and p38. Cdk5/p35 phosphorylation of parkin can diminish the auto-
ubiquitination activity of parkin, which then modulates synphilin-1/α-synuclein inclusion 
formation. 
 Further work on the modulation of dopaminergic signaling by Cdk5/p35 revealed that 
Cdk5/p35 interacts with and phosphorylates Prx2 to downregulate its activity (Qu et al. 2007). 
Prx2 is thought to play a neuroprotective role, and diminishing Prx2 in neurons mediates 
neuronal death through reactive oxygen species both in vitro and in a MPTP mouse model of PD 
specifically in dopaminergic neurons of the substantia nigra pars compacta. Interestingly, MPTP 
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mediates calpain cleavage to generate Cdk5/p25, consistent with Prx2 phosphorylation during 
ischemia, and deregulates phosphorylation of the transcription factor MEF2D (Smith et al. 
2006). Moreover, in human PD postmortem brain samples, an increase in phospho-Prx2 can be 
detected. These findings complement recent observations of Cdk5/p35 signaling in the nucleus in 
which the phosphorylated apurinic/apyrimidinic endonuclease 1 (Ape1) substrate exhibits 
decreased endonuclease activity, resulting accumulated DNA damage and MPTP-mediated 
neuronal death (Huang et al. 2010). Increased phospho-Ape1 is also observed in human PD and 
AD brains. An emerging notion suggests that Cdk5/p35 is active in different cellular 
compartments of dopaminergic neurons and that it can potentially trigger various factors in a 
cascade that is detrimental to neuronal integrity. 
 
Huntington’s Disease 
 Huntington’s disease (HD) is an autosomal-dominant disorder caused by an expansion in 
the number of CAG-repeats in the Huntington gene, leading to abnormally large polyglutamine 
(poly-Q) repeats in the huntington (htt) protein (Cattaneo et al. 2001). HD patients exhibit 
involuntary tremors called chorea, physical impairments, and irreversible cognitive decline. 
Cdk5 phosphorylates htt in cytoplasmic fractions, which results in reduced caspase cleavage of 
htt and, in turn, lessens its aggregate formation and toxicity (Luo et al. 2005). There is a 
reduction of Cdk5 in late-stage HD patients, and the stabilization of Cdk5/p35 interaction is 
impaired by mutant htt. Reduction of Cdk5 activity is in contrast to previous observations in PD 
patients or mouse models of ALS and ischemia, and it could reflect a late-stage compensatory 
mode. 
 A separate study identified additional htt Cdk5 phosphorylation sites that confer a 
neuroprotective effect (Anne et al. 2007). Generation of phosphomutants mimic toxic htt and is 
mediated in part by p53. Moreover, γH2AX staining shows Cdk5/p35 phosphorylation of htt 
during DNA damage, which is consistent with Cdk5/p25 and DNA damage in CK-p25 Tg mice 
(Kim et al. 2008). Phosphorylation of htt precedes neuronal death, providing yet another line of 
evidence in a different disease system that Cdk5/p35 is upstream of a complex signaling cascade 
involving cell-cycle genes and DNA damage in postmitotic neurons, all of which are early events 
preceding neuronal death. 
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 There was no examination of p25 levels in the previous mouse studies; nonetheless, 
Cdk5/p25 activity or p25/p35 ratio are predicted to be elevated during disease states. Whereas 
Cdk5 and p35 levels are decreased in postmortem HD brain samples, Cdk5 phosphorylation and 
p25 levels mediated by calpain activity are increased in dopaminergic neurons (Paoletti et al. 
2008). Because the striatum is affected in HD and mutant htt is present in dopaminergic neurons, 
Cdk5/p25 can be regulated by intracellular calcium levels and phosphorylation downstream of 
the dopamine D1 receptor as well as the NMDA receptor. Therefore, Cdk5/p25 may initially 
function in an activity-dependent manner similar to other diseases such as PD but diverge in the 
final outcomes through currently unknown mechanisms. 
 
Potential therapeutic approaches 
 In addition to its role in neurodegenerative disease, Cdk5 is involved in neurogenesis by 
regulating the progression of newly born granule cells in the adult hippocampus of mouse brain 
(Jessberger et al. 2008, Lagace et al. 2008). Recent studies have also focused on the non-
neuronal functions of Cdk5 (also see Table 1). Cdk5 is present in adipose tissue, as Cdk5/p25 
hyperphosphorylation of the diabetes target gene PPARγ inhibits the transcription of antiobesity 
genes (Choi et al. 2010). Other studies implicate Cdk5/p35 in neuregulin-induced acetylcholine 
receptor formation at the neuromuscular junction (Fu et al. 2001, 2005), pain signaling in the 
dorsal root ganglion (Pareek et al. 2006, 2007), cellular senescence (Mao and Hinds 2010), and 
pancreatic cancer cell signaling (Feldman et al. 2010). Furthermore, the importance of Cdk5 
activity has been demonstrated in other model organisms, including Drosophila for proper axon 
formation and guidance (Connell-Crowley et al. 2000, Connell-Crowley et al. 2007), and 
Caenorhabditis elegans for proper targeting of presynaptic components to axons (Ou et al. 
2010), synaptic vesicle organization in facilitating synapse formation of DD motoneurons (Park 
et al. 2011) or regulating glutamate receptor abundancy to their ventral nerve cords (Juo et al. 
2007). Thus, Cdk5 presents an attractive target for therapeutic intervention during both 
developmental and aging processes. 
 Given the ever-increasing discoveries expanding the functions of Cdk5, it would be 
beneficial to examine and develop novel Cdk5 inhibitors for the treatment of various disorders. 
Cdk5 inhibitors such as roscovitine, olomoucine, or butyrolactone-1 are widely used, but the 
main disadvantage is their inhibition of other Cdks (Glab et al. 1994, Glicksman et al. 2007, 
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Meijer et al. 1997). Taken together, developing therapies for neurodegeneration and other non-
neuronal disorders may include a combinatorial approach designed in order to activate HDAC1 
to maintain DNA integrity, target p35 to block p25 generation, and reduce Cdk5 activity with 
novel Cdk5-specific inhibitors.  
 
Conclusions 
 Research over the past two decades on Cdk5 has provided informative data on its diverse 
cellular functions. Not only is Cdk5 essential for proper neural development and migration, but 
Cdk5/p35 is also critically involved in neurite and axonal outgrowth, synaptic plasticity, 
cognition, and behavior. Work on Cdk5/p25 has yielded considerable insight into the 
pathogenesis of various neurological disorders. Nevertheless, it remains unresolved how Cdk5 
regulates synaptic plasticity during initial events of neurotoxicity and how excessive Cdk5/p25 
activity affects pathological events leading to neurodegeneration. Collectively, examining Cdk5 
in the greater context of homeostatic regulation may be beneficial in elucidating neurological 
disorders affecting cognition. 
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Chapter 2 
 
 
Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling 
 pathway2 
 
 
 
Summary 
 Memory formation is modulated by pre- and post-synaptic signaling events in neurons. 
The neuronal protein kinase Cyclin-Dependent Kinase 5 (Cdk5) phosphorylates a variety of 
synaptic substrates and is implicated in memory formation. It has also been shown to play a role 
in homeostatic regulation of synaptic plasticity in cultured neurons. Surprisingly, we found that 
Cdk5 loss of function in hippocampal circuits results in severe impairments in memory 
formation and retrieval. Moreover, Cdk5 loss of function in the hippocampus disrupts cAMP 
signaling due to an aberrant increase in phosphodiesterase (PDE) proteins. Dysregulation of 
cAMP is associated with defective CREB phosphorylation and disrupted composition of synaptic 
proteins in Cdk5-deficient mice. Rolipram, a PDE4 inhibitor that prevents cAMP depletion, 
restores synaptic plasticity and memory formation in Cdk5-deficient mice. Collectively, our 
results demonstrate a critical role for Cdk5 in the regulation of cAMP-mediated hippocampal 
functions essential for synaptic plasticity and memory formation.  
 
 
 
 
 
______________________ 
2 The findings presented in this chapter were previously published as: *Guan JS, *Su SC, Jun G, Joseph 
N, Xie Z, Zhou Y, Durak O, Zhang L, Zhu JJ, Clauser KR, Carr SA, Tsai LH. (2011). Cdk5 is required 
for memory function and hippocampal plasticity via the cAMP signaling pathway. PloS One 6(9):e25735. 
 
I generated the Cdk5f/f and Cdk5f/f/CW2 mouse lines, prepared the synaptosomal enrichment of Cdk5f/f 
and Cdk5f/f/CW2 samples for the total and phosphoproteomic screen, conducted biochemical analysis on 
Cdk5f/f/CW2 and Cdk5f/f/T29 with rolipram treatment, and conducted control behavioral experiments.
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Introduction 
 The hippocampus is considered to be a key region for long-term memory formation in 
humans and rodents (Morris et al., 1982; Squire, 1987), yet the molecular mechanisms 
underlying memory formation are still not fully understood. Transgenic mouse studies using 
hippocampal region-specific knockout of the NMDA receptor NR1 subunit strongly support the 
hypothesis that synaptic plasticity, especially NMDAR-mediated synaptic plasticity, is crucial 
for normal learning and memory (McHugh et al., 2007; Nakazawa et al., 2002). Numerous 
genetic and molecular studies have revealed that NMDAR activation, and its downstream 
cascade of events, are critical for synaptic plasticity. These events include calcium entry, 
autophosphorylation of CaMKII, activation of protein phosphatases, and the relocation and 
modification of AMPA receptors (Barria et al., 1997; Giese et al., 1998; Lee et al., 2000). 
Perturbations in the molecular cascade downstream of the NMDAR pathway result in defects in 
both long-term potentiation (LTP) and memory formation. Blocking the NMDAR pathway, in 
addition, impacts long-term depression (LTD). Interestingly, the PKC gamma mutant mouse, 
which displays normal LTD and impaired LTP, exhibits a relatively mild behavioral deficit 
(Abeliovich et al., 1993).  Thus, both forms of synaptic plasticity (LTD and LTP) are required 
for memory formation.  
  The cyclic AMP (cAMP) pathway is also critically involved in synaptic plasticity and 
learning and memory. The second messenger cAMP, as well as the cAMP-dependent protein 
kinase A (PKA), have been implicated in short- and long-lasting synaptic plasticity and intrinsic 
neuronal excitability in Aplysia by activating cAMP-responsive element binding protein 
(CREB)-dependent transcription (Mozzachiodi et al., 2008). Accumulating data regarding the 
molecular events underlying CREB-dependent learning and memory in Drosophila, mice, and 
rats all indicate that CREB activation by phosphorylation at the Serine 133 residue is required for 
the maintenance of LTP and formation of long-term memory (Silva et al., 1998). The 
maintenance of LTP and long-term memory are also both dependent on PKA activity and CREB-
mediated transcription (Frey et al., 1993). Cyclic nucleotide phophodiesterases (PDEs) catalyze 
the conversion of cAMP and cGMP into AMP and GMP, respectively, and are important for the 
homeostatic regulation of cyclic nucleotide-mediated signaling events. The PDEs are grouped 
into several families, two of which, PDEs 4 and 7, exclusively target cAMP.  Rolipram, a PDE4-
specific small molecule inhibitor, has antidepressant effects (Wachtel, 1983) and was recently 
	  49 
found to facilitate memory formation and synaptic plasticity in rodents (Vitolo et al., 2002).  
Rolipram was also shown to reverse synaptic plasticity and memory deficits in CBP+/- mice, a 
mouse model of Rubinstein-Taybi syndrome (Alarcon et al., 2004; Bourtchouladze et al., 2003). 
  Cyclin-dependent kinase 5 (Cdk5) was initially classified as a cyclin-dependent kinase 
based on sequence homology to other Cdks that operate in the cell cycle (Meyerson et al., 1992).  
Cdk5 has been implicated in almost every aspect of brain development and neural function 
including neuronal migration, neurite extension, synaptic transmission, and synaptic plasticity 
(Fischer et al., 2005; Niethammer et al., 2000; Ou et al., 2010; Tanaka et al., 2004; Zukerberg et 
al., 2000). Intriguingly, Cdk5 gain-of-function mutations result in an increased number of 
synapses in vivo and the facilitation of LTP in slices (Fischer et al., 2005), whereas the loss of 
Cdk5 activity in p35 knockout mice results in impaired hippocampal LTD (Ohshima et al., 
2005).  In contrast, an inducible Cdk5 conditional knockout mouse model exhibited facilitated 
LTP and enhanced memory formation via reduced degradation of the NR2B subunit of the 
NMDA receptor (Hawasli et al., 2007). Despite a greater understanding of how Cdk5 is critically 
important for synapse formation, the in vivo role for Cdk5 as a part of a signaling pathway 
crucial to hippocampal learning and memory remains unclear.  
 In the current report, we found that Cdk5 loss of function in distinct hippocampal circuits 
resulted in impairments in various memory functions and synaptic plasticity, observations 
distinct from previously reported findings using a different Cdk5 mouse model (Hawasli et al., 
2007). In addition, multiple PDE isoforms were markedly upregulated, which led to the 
dysregulation of cAMP pathway and impaired CREB phosphorylation. Remarkably, the 
observed deficiencies in Cdk5 conditional knockout mice can be rescued by rolipram treatment.  
Taken together, these results indicate a key function for Cdk5 in regulating cAMP signaling via 
modulation of PDE expression to facilitate synaptic plasticity and hippocampal-dependent 
memory formation.  
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Methods 
Animals 
Animals were derived from the C57BL/6J strain obtained from Jackson Labs (Bar Harbor, ME) 
due to their common use in genetic crossing and maintaining genetically modified mouse lines. 
The mice were group housed in the small animal facility at the Department of Brain and 
Cognitive Sciences of Massachusetts Institute of Technology (Cambridge, MA) with a 12-hr 
light dark cycle and ad libitum feeding. All experiments were conducted in compliance with the 
humane animal care standards outlined in the NIH Guide for the Care and Use of Experimental 
Animals and were reviewed and approved by the MIT Committee on Animal Care (CAC).  
 
Generation of region-specific Cdk5 mutant mice  
 We constructed a targeting vector in which two loxP sequences were inserted into the 
Cdk5 gene. The first loxP sequence was placed before exon 1 and the second loxP sequence was 
placed between exons 5 and 6 so that they flanked exons 1-5 of the twelve total exons in the 
Cdk5 genomic sequence. The mice homozygous for the loxP-Cdk5-loxP sequence (henceforth 
named "floxed Cdk5" or simply 'Cdk5f/f') were generated through standard homologous 
recombination procedures (Figure 1). The Cdk5-loxP construct was linearized by Pme1 
digestion and electroporated into embryonic stem cells. The homologous recombinant clones 
were identified by Southern blot (see next section).  The chimeric mice were crossed to Flp 
transgenic mice (Susan Dymecki) to remove the neomycin cassette. Floxed mice were genotyped 
using the PCR primer sequences: (forward) cagtttctagcacccaactgatgta and (reverse) 
gctgtcctggaactccatctataga cagtttctagcacccaactgatgta and reverse: gctgtcctggaactccatctataga. 
Floxed Cdk5 mice were maintained on a C57BL/6 background.  
 For region-specific ablation of Cdk5, we used mouse lines predominantly expressing Cre 
in excitatory neurons of hippocampal areas CA1 or  CA3 and forebrain. We crossed Cdk5f/f 
mice with Cre transgenic mice, T29-2, which mediate Cre/loxP recombination predominantly in 
CA1 pyramidal cells (Tsien et al., 1996a; Tsien et al., 1996b) to generate Cdk5f/f/T29 mice 
(CreT29-2;fCdk5/fCdk5). Cdk5f/f/CW2 mice were generated by crossing the CW-2 Cre mice to 
the Cdk5f/f mice (Zeng et al., 2001) in order to ablate Cdk5 in excitatory neurons of the 
forebrain. To create Cdk5f/f/KA1 mice, we crossed Cdk5f/f mice with Cre transgenic mice, G32-
4, which express Cre predominantly in CA3 pyramidal cells (Nakazawa et al., 2002). We 
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confirmed CA1, forebrain, and CA3 Cre expression pattern by crossing the Cre lines to the 
ROSA26-EYFP line (Srinivas et al., 2001). For the following experiments, we used Cdk5 
homozygous floxed littermates (Cdk5f/f) as controls. Cdk5f/f/T29, Cdk5f/f/CW2, and 
Cdk5f/f/KA1 mice are viable and do not exhibit any obvious developmental defects, in contrast 
to the embryonic lethality of Cdk5 KO mice produced by conventional gene knockout strategies 
(Ohshima et al., 1996). We confirmed the ablation of Cdk5 in areas CA1 or CA3 by 
immunohistochemistry. Cdk5 is expressed in most areas of the mouse brain. In the hippocampus, 
we found that Cdk5 expression level in area CA1 was decreased in Cdk5f/f/T29 mice compared 
to controls. Importantly, there were no differences in Cdk5 expression levels between the 
Cdk5f/f/T29 and control mice in area CA3 and dentate gyrus (DG).  Cdk5 immunoreactivity in 
CA3 was reduced in the Cdk5f/f/KA1 mice compared to controls. Cdk5 was absent in the cell 
bodies of pyramidal cells in area CA1 of the Cdk5f/f/T29 mice and in area CA3 of Cdk5f/f/KA1 
mice. Morphological and histochemical examinations did not reveal obvious abnormalities in 
brains from Cdk5f/f/T29, Cdk5f/f/CW2, or Cdk5f/f/KA1 mice. Tissues collected from micro-
dissected area CA1 of the Cdk5f/f/T29 versus control mice (Cdk5f/f) revealed that Cdk5 protein 
levels are largely reduced in the CA1 region of these mice. 
 
Southern blotting 
 The following modified protocol was used: tail lysis overnight, followed by DNA 
extraction. Ten µg of genomic DNA was digested with BamHI and EcoRI overnight, followed 
by electrophoresis on a 0.8% agarose gel. The gel was then incubated in 2 gel volumes of 0.25 M 
HCl for 20 min at room temperature, briefly rinsed with ddH2O, then incubated in 2 gel volumes 
of denaturation buffer (0.5 M NaOH, 1.5 M NaCl) two times, 15 min each. The gel was briefly 
rinsed with ddH2O and subsequently incubated in 2 gel volumes of renaturation buffer two times, 
30 min each. The transfer was set up overnight on a sandwich consisting of 3 cm high paper 
towel stack, the agarose gel,  a nitrocellulose membrane (Micron Separation, Inc.), and filter 
paper with a bridge. The membrane was then rinsed and baked in a 80 °C oven under a vacuum 
for 2 hr, rinsed 2 times in 2X SSC buffer (for 1 L 20X SSC: 3 M NaCl,  0.3 M Sodium Citrate, 
pH 7.0), and prehybridized in ULTRAHTb (Ambion) for 1 hr at 42 °C in the hybridization 
chamber. The probe was made using a DECAprime II kit (Ambion, Cat #1455). The reaction 
was incubated at 37 °C for 7 min, terminated by 1 µl 0.5M EDTA, and unincorporated 
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nucleotides were removed using spin columns (NuAway, Ambion). Radiolabel incorporation 
was measured using a scintillation counter. 107 cpm per ml of probe was transferred to the 
prehybridized blot and incubated overnight at 42 °C. The membrane was then washed 
sequentially: 2X SSC, 0.1% SDS for 20 min at 65 °C, 0.1X SSC, 0.1% SDS for 20 min three 
times at 65 °C. The blot was then dried and developed with film. 
 
Behavior 
 Adult (2.5-3.5 month old) mice were used for all behavior, biochemical, and 
immunohistochemistry studies. We observed that the Cre expression in the T29-2 line is no 
longer restricted to the CA1 region in 4-month-old mice. Interestingly, the spreading of Cre 
expression in these mice, and thus Cdk5 knockdown, occurs at a time when the Cdk5f/f/T29 
mice begin to suffer seizures, and these mice begin to die around 6-8 months of age. 
Cdk5f/f/KA1 mice appear to be normal even after 1 year of age.  
  
Contextual fear conditioning  
 Training consisted of a 3 min exposure of mice to the conditioning box (context) 
followed by a foot shock (2 sec, 0.5/0.8/1.0 mA, constant current).  The memory test was 
performed 24 hr later by re-exposing the mice to the conditioning context for 3 min. Freezing, 
defined as a lack of movement except for heartbeat and respiration associated with a crouching 
posture, was recorded every 10 sec by two trained observers (one was blind to the experimental 
conditions) during the 3 min trial for a total of 18 sampling intervals. The mean number of 
observations indicating freezing from both observers was expressed as a percentage of the total 
number of observations. 
  
Cued fear conditioning 
 Training consisted of a 3 min exposure of mice to the conditioning box, followed by a 
tone (30 sec, 20 kHz, 75 dB sound pressure level (SPL) and a foot shock (2 sec, 0.8 mA, constant 
current) (Radulovic et al., 1999). The memory test was performed 24 hr later by exposing the 
mice for 3 min to a novel context followed by an additional 3 min exposure to a tone (20 kHz, 75 
dB SPL). Freezing was recorded every 10 sec by two trained observers as described above. 
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Morris water maze  
 The water maze with hidden platform paradigm (Morris et al., 1982) was performed in a 
circular tank (diameter 1.8 m) filled with opaque water.  A platform (11 × 11 cm) was 
submerged below the water's surface in the center of the target quadrant. The swimming path of 
the mice was recorded by a video camera and analyzed by the Videomot 2 software (TSE). For 
each training trial, the mice were placed into the maze consecutively from one of four random 
points of the tank. Mice were allowed to search for the platform for 60 s. If the mice did not find 
the platform within 60 s, they were gently guided to it. Mice were allowed to remain on the 
platform for 15 s. Two consecutive training trials were given every day; the latency for each trial 
was recorded for analysis. During the memory test (probe test), the platform was removed from 
the tank, and the mice were allowed to swim in the maze for 60 s. 
 
Immunohistochemistry and immunoblotting  
 Immunohistochemistry was performed as described previously (Guan et al., 2009). 
Briefly, brains were fixed in 4% paraformaldehyde and stained with antibodies against Cdk5 and 
pCREB. Five random fields from each experiment were obtained and quantified with the 
observer blind to genotype. The antibodies and dilutions used were as follows. For 
immunohistochemistry: Cdk5 (MBS240590, MyBioSource, 1:800); pCREB(S133) (Millipore 
06-519, 1:200). Immunoblotting was performed on mouse forebrains or microdissected 
hippocampi.  Brain lysates were obtained by dounce homogenization of tissue in 
radioimmunoprecipitation (RIPA) buffer. The RIPA buffer composition is as follows: 50 mM 
Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS with protease and 
phosphatase inhibitor tablets (Roche). Lysates were incubated on ice and cleared with a 13,000 
rpm spin and protein content was quantified (BCA protein assay, Bio-Rad Technologies). Ten 
micrograms of protein was diluted with 2X sample buffer consisting of the following: 100 mM 
Tris pH 6.8, 4% SDS (w/v), 0.2% bromophenol blue (w/v), 20% glycerol (v/v), 200 mM DTT. 
Samples were boiled at 95 °C for 5 minutes and resolved on a 10% SDS-polyacrylamide gel with 
8% stacking gels using Laemmli buffer. Proteins were transferred by electrophoresis using tris-
glycine wet transfer onto PVDF membranes (Millipore) for 1 hr on ice. After blocking with 
blocking buffer (5% non-fat dry milk/0.1% Tween-20/TBS) for 1 hr, membranes were probed 
with various antibodies overnight at 4 °C. Membranes were washed three times using 0.1% 
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Tween-20/TBS, incubated with secondary antibodies (enhanced chemiluminescence mouse or 
rabbit IgG, HRP-Linked F(ab’)2 fragment from sheep, GE Healthcare, diluted at 1:15,000) for 1 
hr at room temperature. Membranes were washed again and developed using Western Lightning 
ECL substrate (Perkin Elmer). All antibodies were diluted in blocking buffer. Membrane 
stripping (before reprobing) was performed with stripping buffer: (2%SDS, 62.5 mM Tris-HCL 
pH 6.8, 100 mM 2-mecaptoethanol) and incubation for 30 minutes at 50 °C (with rocking), 
followed by two washing steps with excess TBST, and blocking as usual. Immunoblots were 
quantified using ImageJ (NIH). Statistical analysis was performed using Prism software. 
Antibodies used for immunoblots: Cdk5 (DC-17, Tsai laboratory, 1:500); pCaMKII(T286) (Cell 
Signaling Technology #3361, 1:2000); pCREB(S133) (Millipore 06-519, 1:2000); 
pGluR1(S845) (Chemicon Ab5849); pGluR1(S831) (Chemicon, Ab5847); GluR1 (Abcam); 
pPP1 (Cell Signal 2581); pp1a (Abcam); DARRP-32 T75 (Cell Signal #2301); DARRP-32 T34 
(Cell Signal #2304); actin (Sigma #5316).  
 
Phosphatase assay 
 Whole hippocampi were dissected and homogenized in 3.75 mM Tris-HCl, pH7.4, 15 
mM KCl, 3.75 mM NaCl, 250 µM EDTA, 50 µM EGTA, 30% (w/v) sucrose, 30% (v/v) 
glycerol, protease inhibitor cocktail (Sigma), 100 µM PMSF using a Dounce homogenizer, then 
centrifuged (1000 g, 10 min). For each sample, the supernatant (cytoplasmic fraction) and pellet 
(nuclear fraction) were separated. Each fraction was resuspended in the same buffer without 
sucrose, but including 15 mM PMSF, using a Dounce homogenizer then triturated with a 26 G 
syringe before purification on PiResin (Innova Biosciences). Phosphatase activity was 
determined by incubating 2 µL sample with 0.15 mM RII substrate (BIOMOL) and 5 nM 
tautomycin (to inhibit PP1) or 5 nM tautomycin + OA (to inhibit PP1 and PP2A activity) in 50 
mM Tris-HCl, pH 7.0, 100 µM Na2EDTA, 5 mM DTT, 0.01% Brij35 at 30 °C for 10 min. The 
reaction was terminated by adding TCA followed by centrifugation (13,000 g, 5 min). The 
amount of free phosphates released in the reaction was measured with BIOMOL Green reagent 
(BIOMOL) at 620 nm and background-subtracted. For total phosphatase activity, tautomycin and 
OA were removed from the reaction. PP1 and PP2A activity was calculated using the ratio of 
phosphatase activity with inhibitors and total phosphatase activity. 
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Electrophysiology 
 Three to four month old Cdk5f/f/T29 mice or their Cdk5f/f control littermates were 
sacrificed by cervical dislocation, and hippocampi were rapidly dissected in ice-cold oxygenated 
artificial CSF (ACSF). Transverse hippocampal slices (400 µm thick) were placed in a chamber 
and continuously perfused with oxygenated ACSF consisting of (in mM): 119 NaCl, 2.5 KCl, 2.5 
CaCl2, 1.3 MgSO4, 1 NaH2PO4, 26.2 NaHCO3, 11 D-glucose, pH 7.4. A bipolar stimulating 
electrode (0.002 in diameter nichrome wire; A-M Systems) placed in the stratum radiatum was 
used to elicit action potentials in CA3 Schaffer collateral axons. An ACSF-filled glass 
microelectrode with a resistance between 0.5 and 3 MΩ was placed in the stratum radiatum 
region of area CA1 and was used to record the field excitatory post-synaptic potentials (fEPSP). 
Data were acquired using HEKA EPC10 and analyzed by Patchmaster. Peak fEPSP amplitudes 
from stimulators were required to be at least 2 mV, and stimulus intensity was set to produce 
40% of the maximal response. Baseline responses were recorded for 20 min. fEPSPs were 
evoked at area CA1 synapses by stimulating Schaffer collaterals at a low frequency (2 per min) 
to establish a stable baseline. Immediately following LTP induction with 2 trains of high-
frequency stimulation (HFS, 100 Hz, 1s), with an interval of 20 s, slices from Cdk5f/f/T29 and 
control Cdk5f/f mice showed an increase in fEPSP slope and amplitude, suggesting that short-
term potentiation (STP) occurs in all groups. 
 
PSD preparation 
 Forebrains from Cdk5f/f and Cdk5f/f/CW2 mice were homogenized and postsynaptic 
densities (PSD) isolated in ice-cold buffers with protease and phosphatase inhibitor cocktails 
(Roche) as previously described with minor modifications (Peng et al., 2004). Briefly, mouse 
forebrains were isolated and homogenized in ice-cold Buffer A (0.32 M Sucrose, 6 mM Tris (pH 
8), 1 mM MgCl2, 0.5 mM CaCl2) with a Teflon homogenizer (15 strokes). Homogenized brain 
extracts were spun at 1400 × g for 10 min. The supernatant (S1) was saved and the subsequent 
pellet (P1) was homogenized again (5 strokes). After centrifugation at 700 × g, the supernatant 
(S1’) was saved and pooled with S1. Pooled S1 and S1’ was centrifuged at 13,800 × g for 10 min 
to collect the pellet (P2). P2 was resuspended in Buffer B (0.32 M Sucrose, 6 mM Tris pH 8; 5 
strokes). The P2 suspension was loaded onto a discontinuous sucrose gradient (0.85 M/1 M/1.15 
M sucrose solution in 6 mM Tris, pH 8.0), followed by centrifugation for 2 h at 82,500 × g in a 
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SW-41 rotor. The synaptosome fraction between 1 M and 1.15 M sucrose was collected with a 
syringe needle and adjusted to 4 ml with Buffer B. Equal volumes of Buffer C (12 mM Tris pH 
8; 1% Triton X-100) was added and mixed for 15 min and then spun at 32,800 × g in a Ti70.1 
rotor for 20 min. The PSD-enriched pellet was resuspended in 40 mM Tris (pH 8) and protein 
concentration was measured using a BCA assay. To prepare samples for mass spectrometry, 
solubilized PSD proteins were reduced with 10 mM DTT for 30 min at 60 °C. After cooling to 
room temperature, the sample was then alkylated with 25 mM iodoacetamide for 30 min at room 
temperature. After adding 2X sample buffer (100 mM Tris pH 6.8, 200 mM DTT, 4% SDS, 
0.2% Bromophenol blue, 20% glycerol), the PSD samples were then boiled at 95°C for 5 min 
and 30 µg of each sample was loaded for separation on an 4-12% SDS-PAGE gradient gel 
(Invitrogen). 
 
In-gel Digestion and Mass Spectrometry  
 Lanes from the gel were excised, cut into 13 fields as shown in Figure S4B and digested 
overnight at 37 °C with an excess of sequencing grade trypsin. Peptides were extracted from the 
gel with 50% acetonitrile/0.1% trifluoroacetic acid and concentrated in a Speed-Vac. Tryptic 
digests were analyzed with an automated nano LC-MS/MS system, consisting of an Agilent 1100 
nano-LC system (Agilent Technologies, Wilmington, DE) coupled to an LTQ-Orbitrap Fourier 
transform mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with a nanoflow 
ionization source (James A. Hill Instrument Services, Arlington, MA). Peptides were eluted from 
a 10 cm column (Picofrit 75 µm ID, New Objectives) packed in-house with ReproSil-Pur C18-
AQ 3 µm reversed phase resin (Dr. Maisch , Ammerbuch Germany) using a 90 min 
acetonitrile/0.1% formic acid gradient at a flow rate of 200 nl/min to yield ~15 s peak widths. 
The elution portion of LC gradient was 3-7% solvent B in 2 min, 7-37% in 58 min, 37-90% in 3 
min, and held at 90% solvent B for 5 min. Data-dependent LC-MS/MS spectra were acquired in 
~3 s cycles; each cycle was of the following form: one full Orbitrap MS scan at 60,000 
resolution followed by 8 MS/MS scans in the ion trap on the most abundant precursor ions using 
an isolation width of 3 m/z. Dynamic exclusion was enabled with a mass width of ± 25 ppm, a 
repeat count of 1, and an exclusion duration of 12 sec. Charge state screening was enabled along 
with monoisotopic precursor selection to prevent triggering of MS/MS on precursor ions with 
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unassigned charge or a charge state of 1. Normalized collision energy was set to 30 with an 
activation Q of 0.25 and activation time of 30 ms. 
 
Protein identification, quantification, and phosphosite determination 
 All MS data was interpreted using the using the Spectrum Mill software package v4.0 
beta (Agilent Technologies, Santa Clara, CA). Similar MS/MS spectra acquired on the same 
precursor m/z within ± 60 sec were merged, and poor quality MS/MS spectra which failed the 
quality filter of having a sequence tag length > 0 (i.e., minimum of two masses separated by the 
in-chain mass of an amino acid) were excluded from searching. MS/MS spectra were searched 
against the International Protein Index (IPI) mouse database version 3.48. Initial search 
parameters included: ESI linear ion trap scoring parameters, trypsin enzyme specificity with a 
maximum of two missed cleavages, 30% minimum matched peak intensity, ± 20 ppm precursor 
mass tolerance, ± 0.7 Da product mass tolerance, and carbamidomethylation of cysteines as a 
fixed modification. Allowed variable modifications were oxidized methionines, deamidation of 
asparagine, and pyro-glutamic acid modification at N-terminal glutamines with a precursor MH+ 
shift range of -18 to 65 Da. Identities interpreted for individual spectra were automatically 
designated as valid by applying the scoring threshold criteria provided below to all spectra in a 
two-step process. First, protein mode was used, which requires two or more matched peptides 
per protein while allowing a range of medium to excellent scores for each peptide. Second, 
peptide mode was applied to the remaining spectra, allowing for excellent scoring peptides that 
are detected as the sole evidence for particular proteins. Protein mode thresholds: protein score 
>20, peptide (score, Scored Percent Intensity, delta rank1 - rank2) peptide charge +2: (>8, >65%, 
> 2) peptide charge +3: (>9, >65%, > 2) peptide charge +4: (>9, >70%, > 2) peptide charge +2: 
(>6, >90%, > 1). Peptide mode thresholds: peptide charge +2 and +3 (>13, >70, > 2) peptide 
charge +4 (>15, >70, > 2) respectively. The above criteria yielded a false discovery rate of < 1% 
as estimated by target-decoy based searches using reversed sequences. MS/MS spectra of 
phosphopeptides were interpreted in a second round of searches against only the subset of 
proteins confidently identified from the unphosphorylated peptides observed during the initial 
round of searches. The allowed variable modifications were expanded to include phosphorylated 
serine, threonine, and tyrosine, with a precursor MH+ shift range of -18 to 177 Da (no more than 
2 phosphosites/peptide). The spectrum of each phosphopeptide was manually inspected by an 
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expert. For ~10% of phosphosites observed the MS/MS spectra lack sufficient information to 
assign the site of phosphorylation to a particular Ser, Thr, or Tyr residue. 
 The relative abundances of proteins were determined using extracted ion chromatograms 
(XICs) for each peptide precursor ion in the intervening high resolution FT-MS scans of the LC-
MS/MS runs. An individual protein’s abundance was calculated as the sum of the ion current 
measured for all quantifiable peptide precursor ions with MS/MS spectra confidently assigned to 
that protein. Peptides were considered not quantifiable if they were shared across multiple 
subgroups of a protein or the precursor ions had a poorly defined isotope cluster (i.e. the 
“subgroup specific” and “exclude poor isotope quality precursor” XIC filters in Spectrum Mill 
were enabled). Proteins were considered not quantifiable if there were fewer than two distinct 
peptides observed in either the control or cKO samples. Since equivalent amounts of total protein 
were loaded in each lane of the gel, and both samples were subsequently treated equivalently, no 
further normalization was done when calculating protein abundance ratios between the two 
samples. The peak area for the XIC of each precursor ion subjected to MS/MS was calculated 
automatically by the Spectrum Mill software in the intervening high-resolution MS1 scans of the 
LC-MS/MS runs using narrow windows around each individual member of the isotope cluster. 
Peak widths in both the time and m/z domains were dynamically determined based on MS scan 
resolution, precursor charge, and m/z subject to quality metrics on the relative distribution of the 
peaks in the isotope cluster vs. theoretical.  
 
Quantitative RT-PCR primers 
AC1: cagcaggaaccaaggctaag; tggccacattgactgtgttt; AC3: tgaggagagcatcaacaacg; 
tggtgtgactcctgaagctg; AC8: ggactgtccccagagaaaca; cttactcccgtgctgtccat; pde1A: 
catgattgggttccatgttg; cagccaactctttccacctc; pde1b: tgcccttctctccactctgt; tgggctgacttttaggcttg; 
PDE2A: gaccgatggagatgatggac; acttgtgggacaccttggtc; PDE4D1: tatgaaggagcagccctcatg; 
ccaggacatcttcctgctctg; PDE4D4:  tggccagtttctggtaggcctc; gagctacccgtggtcgctac; PDE4D6: 
ccaggacatcttcctgctctg; cacattttagaacttgctgtcac; PDE4D7: tggccagtttctggtaggcctc; 
actactcaaaaccgcaccatgg; PDE4B: ggaaaaatcccaggttggtt; cagtccctgctcctctcatc 
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Results 
Associative and spatial memories are impaired in Cdk5f/f/T29 mice 
 To evaluate the consequences of Cdk5 ablation in hippocampal neurons, Cdk5f/f/T29 
mice were generated using the Cre line T29-2 (Tsien et al., 1996a; Tsien et al., 1996b), in which 
Cre is highly expressed in CA1 pyramidal neurons of the hippocampus (Table 1, Figure 1A-D, 
Figure 2A, 2B), and subjected to various behavior tasks.  
Mouse strain Cre promoter Cdk5 knockout region 
Cdk5f/f/T29 CaMKIIα (T29-1) Restricted mainly to hippocampal area CA1 
Cdk5f/f/KA1 Kainate receptor-1 Restricted mainly to hippocampal area CA3 
Cdk5f/f/CW2 CaMKIIα (CW2) Restricted to forebrain excitatory neurons 
Table 1. Cdk5 mutant mouse strains generated for analysis. The mouse strains used for analysis 
include three genotypes: Cdk5f/f/T29, Cdk5f/f/KA1, and Cdk5 f/f/CW2. Three different Cre promoter 
lines were used to generate these genotypes by breeding the Cre line to the Cdk5 floxed lines to obtain the 
CA1, CA3, and forebrain-specific knockdown of Cdk5. In all experiments, 2.5-3.5 month old mice were 
used, and age-matched littermate Cdk5f/f mice were used as controls. 
 
 The ablation of Cdk5 using T29-Cre does not lead to significant changes in overall brain 
architecture or cell survival (Figure 1F). We noted in the T29-Cre line that Cre-mediated Cdk5 
knockout is relatively specific to area CA1 in young mice (2.5-3.5 months old), with the deletion 
of Cdk5 spreading to cortical and other brain regions in older (4 month-old) mice. Beginning at 5 
months of age, Cdk5f/f/T29 mice suffered mild to severe seizures and died by 8 months, which 
might be due to the spreading of T29-Cre expression (Fukaya et al., 2003; Rampon et al., 2000). 
Therefore, we used 2.5 to 3.5 month-old mice to perform all behavior tests. Cdk5f/f/T29 mice 
were trained using Pavlovian fear conditioning paradigm 24 hours prior to a memory test. 
Cdk5f/f/T29 mice exhibited significantly reduced freezing behavior compared to control 
littermates (Cdk5f/f) in the context-dependent memory test (Figure 2C). Consistent with the 
notion that the hippocampus is not required for cued fear conditioning, Cdk5f/f/T29 mice did not 
exhibit significantly different freezing behavior compared to controls in the tone-dependent 
memory test (Figure 2C). Moreover, the reduced freezing behavior in Cdk5f/f/T29 mice was not 
due to motor defects or impaired pain sensation, as their locomotor activity and response to 
electrical foot shock were similar to control mice (Figure 2D, 2E).  No significant differences in 
anxiety levels were detected using the open field test (Figure 1G). Notably, after repeated fear 
conditioning training, control Cdk5f/f mice exhibited increased freezing behavior after three days 
of training, while Cdk5f/f/T29 mice demonstrated no increase in freezing behavior (Figure 2F). 
These results suggest that memory consolidation is impaired in the Cdk5f/f/T29 mice. 
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Figure 1. Generation of mouse models with Cdk5 ablation in hippocampal areas CA1 and CA3. 
A.  Cre/loxP recombination system design Cdk5 conditional knockouts. Exons 1-5 of CDK5 are flanked 
with loxP sites. B. Southern blot indicating the correct insertion of loxP sites.   C. The Cre/loxP strategy 
designed for cell-type-restricted Cdk5 knockout in area CA1 (Cdk5f/f/T29) or forebrain (Cdk5f/f/CW2). 
The Cre expression is driven by the αCaMKII promoter which is found in excitatory neurons D. 
Immunostaining for GFP in the hippocampus of reporter CRET29-2 / R26Sor mice. The T29-2 Cre line 
(area CA1-specific CRE line) was crossed to the reporter line R26Sor. Scale bar = 1 mm. E. 
Immunostaining for GFP in the hippocampus of reporter CRECW2 / R26Sor. The CW2 Cre line (forebrain-
specific CRE line) was crossed to the reporter line R26Sor. F. Representative pictures showing NeuN 
labeling in the hippocampus of Cdk5f/f, Cdk5f/f/T29 and Cdk5f/f/KA1 mice (3 month old). No obvious 
neuronal loss was seen in the different groups. G. Open field test for Cdk5f/f and Cdk5f/f/T29 mice. No 
differences were observed during the first 5 min of activity in the open field. H. Swimming speeds for 
Cdk5f/f and Cdk5f/f/T29 mice during the Morris water maze task. No significant difference was 
observed. I. Western immunoblot showing the reduction of Cdk5 in the forebrain of Cdk5f/f/CW2 mice 
and quantification (n=3 mice per group). 
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Figure 2. Associative and spatial learning are impaired in Cdk5f/f/T29 mice. 
A. Immunostaining for Cdk5 in hippocampal areas CA1 and CA3 in Cdk5f/f, Cdk5f/f/T29 mice. Scale 
bars, 100 µm. B. Western blot showing the reduction of Cdk5 in micro-dissected area CA1 of 
Cdk5f/f/T29 mice. C. Context- and tone-dependent (cued) fear conditioning tests for Cdk5f/f/T29 and 
Cdk5f/f (control) mice. Cdk5f/f, n=16; Cdk5f/f/T29, n=16 for context; Cdk5f/f, n=8; Cdk5f/f/T29 n=8 for 
tone-dependent task. D. Distance traveled during the initial 3 min exposure to the training box. E. The 
velocity during the 3 min of training and electrical foot shock. F. In context-dependent fear conditioning 
test, Cdk5f/f and Cdk5f/f/T29 mice were trained for 3 continuous days. Cdk5f/f, n=8; Cdk5f/f/T29, n=8. 
G. Morris water maze test. Escape latencies of Cdk5f/f mice improved significantly faster than 
Cdk5f/f/T29 mice. N=8 for each group. H. On day 7, a probe trial was conducted in which the swimming 
time in each quadrant was quantified. T, target quadrant; L, left quadrant; O, opposite quadrant; R, right 
quadrant. *p<0.05; **p<0.005; ***p<0.001. 
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 We next utilized the Morris water maze hidden-platform paradigm to evaluate 
hippocampal-dependent spatial learning in the Cdk5f/f/T29 mice. Over the course of the training 
period, Cdk5f/f mice displayed a significant decrease in the latency to find the hidden platform 
(51.5± 4.1 s, day 1; 24.7±5.5 s, day 7). However, the Cdk5f/f/T29 mice consistently showed 
longer escape latencies during the training period that did not improve over time (50.1±4.3s, day 
1; 51.0 ±4.2 s, day 7; control vs. KO group, p<0.0001, one way ANOVA; Figure 2G). During 
the probe trial on day 7, when the platform was removed from the swimming pool, Cdk5f/f/T29 
mice spent a comparable duration in the four quadrants, while the Cdk5f/f mice spent 
significantly more time in the target quadrant (T), where the platform had previously been placed 
(Figure 2H). The decreased time spent by the Cdk5f/f/T29 mice in the target quadrant compared 
to Cdk5f/f was not due to motor defects, as the swimming speed of Cdk5f/f/T29 mice was 
similar to Cdk5f/f mice (Figure 1H). Thus, the ablation of Cdk5 in CA1 pyramidal neurons 
significantly impairs spatial learning. 
 To confirm these results in another mouse model, we used the forebrain-targeted Cre line 
(Zeng et al., 2001) (CW2 line; CaMKII promoter transgenic mice, Figure 1C, 1E) to generate 
forebrain-targeted Cdk5 deletion in excitatory neurons (Figure 1I). Consistent with the 
Cdk5f/f/T29 mice, the Cdk5f/f/CW2 mice displayed impaired spatial learning in the Morris 
water maze task and contextual fear conditioning (Chapter 5). Our data strongly suggest that 
ablation of Cdk5 in excitatory neurons impairs memory formation without apparent neuronal 
death (Figure 3A, 3B).  
 
Pattern completion-based memory retrieval is impaired in Cdk5f/f/KA1 mice 
 To evaluate Cdk5 function in other neuronal populations, we utilized a kainate receptor 
subunit KA1 promoter Cre line (G32-4) (Nakazawa et al., 2003), which expresses Cre mainly in 
CA3 pyramidal neurons, to generate conditional Cdk5 KO mice (Cdk5f/f/KA1) (Figure 4A-C, 
Figure 5A). In contrast with Cdk5f/f/T29 mice, no seizure activity was observed in these 
Cdk5f/f/KA1 mice (data not shown). Therefore, 2.5-3.5 month-old Cdk5f/f/KA1 mice were 
subsequently used for behavior tests. The Cdk5f/f/KA1 mice did not show significant differences 
in freezing behavior 24 hr after contextual fear conditioning training compared to littermate 
(Cdk5f/f) controls (52.2±3.9% in Cdk5f/fs vs. 39.2±6.9% in Cdk5f/f/KA1; Figure 5B). 
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Figure 3. Examination of neuronal morphology and cell death in Cdk5 mutant mice. 
A. Cdk5f/f (control) and Cdk5f/f/CW2 mice were stained with DAPI and imaged in area CA1 of the 
hippocampus, the cortex, and thalamus. No overall differences in neuronal morphology or cell death were 
observed. Scale bars, 100 µm. 
B. Immunoblots from Cdk5f/f and Cdk5f/f/T29 micro-dissections of area CA1 of the hippocampus do not 
reveal any activated cell death markers as assayed by cleaved caspase-3. 
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Figure 4. Region-specific recombination in the hippocampus. 
A.  Immunostaining for GFP in the hippocampus of reporter CREG32-4/ R26Sor. G32-4 Cre mice (CA3-
specific CRE line, denoted as Cdk5f/f/KA1) were crossed to the reporter line R26Sor. Scale bar = 1 mm. 
B. the generation of Cdk5f/f/KA1 mice in which Cdk5 is depleted in hippocampal area CA3. C. 
Immunostaining for Cdk5 in areas CA3 and DG of control mice Cdk5f/f and  Cdk5f/f/KA1. Scale bar = 
100 µm. D. Swimming speeds for Cdk5f/f and Cdk5f/f/KA1 mice. No significant differences were 
observed. 
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 However, upon being tested in the training chamber one month after the training, Cdk5f/f/KA1 
mice exhibited dramatically reduced freezing behavior compared to the Cdk5f/f mice 
(55.9±5.8% in Cdk5f/fs vs. 20.5±6.1% in Cdk5f/f/KA1). This result suggests that either long-
term memory consolidation or long-term memory retrieval is impaired in the Cdk5f/f/KA1 mice. 
This observation cannot be attributed to the loss of the ability to express freezing behavior, 
because further training of these mice in the contextual fear conditioning chamber led to equal 
freezing behavior of Cdk5f/f/KA1 and Cdk5f/f mice when tested 24 hr after an additional 
training (1 month re-train group, Figure 5B).  The behavioral phenotype is not due to alterations 
in moving ability (Figure 5C). 
 The Cdk5f/f/KA1 mice were then tested with the Morris water maze hidden-platform 
task. During training, the Cdk5f/f/KA1 mice exhibited similar spatial learning behavior to the 
Cdk5f/f littermates (Figure 5D). The average escape latencies did not differ between the two 
groups (Cdk5f/f/KA1, 58.3±1.1s (day 1) to 34.5±4.8s (day 15); Cdk5f/f 58.3±1.3s (day 1) to 
38.6±4.4s (day 15)). The probe trial revealed that the Cdk5f/f/KA1 mice display similar 
searching patterns as the control littermates, spending more time in the target quadrant when 
presented with full spatial cues (Figure 5E). However, when presented with partial spatial cues 
during the probe trial (day 16), the Cdk5f/f/KA1 mice did not spend significantly more time in 
the target quadrant (Figure 5F). When presented with partial cues in the hidden platform test, the 
Cdk5f/f/KA1 mice displayed significantly increased escape latencies (45.7±5.9s) compared to 
the control mice (25.7±5.2s) in reaching the target position (Figure 5G). The frequency of the 
Cdk5f/f/KA1 mice crossing the platform was also significantly lower than controls (Figure 5H). 
No differences in swimming speeds were observed between Cdk5f/f/KA1 and Cdk5f/f mice 
(Figure 4D). These results suggest that Cdk5 is essential for pattern completion-based memory 
formation, a form of memory previously described as involving hippocampal CA3 circuits 
(Nakazawa et al., 2003).   
 Collectively, ablation of Cdk5 in hippocampal area CA1 impairs memory formation 
while the loss of Cdk5 function in hippocampal area CA3 affects pattern completion, consistent 
with previously established memory functions in these particular hippocampal circuits 
(Nakazawa et al., 2003; Tsien et al., 1996b). No neuronal degeneration or dramatic 
morphological changes were observed in these mice (Figure 1F, 3). These results provide 
compelling evidence for an integral role of Cdk5 in regulating hippocampus-dependent memory  
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Figure 5. Memory retrieval is impaired in Cdk5f/f/KA1 mice. 
A. Immunostaining for Cdk5 in hippocampal areas CA1 and CA3 in Cdk5f/f and Cdk5f/f/KA1 mice. 
Scale bar, 100 µm. B. Contextual-dependent fear conditioning test for Cdk5f/f/KA1 mice. Cdk5f/f, n=10; 
Cdk5f/f/KA1, n=8. C. Distance traveled during the initial 3 min exposure to the training box. D. Morris 
water maze training paradigm (top). Mice were trained for 16 days. On day 15, they were tested in a 
probe trial with full visual cues around the tank, followed by an additional training trial. On day 16, mice 
were tested in another probe trial with most of the visual cues removed around the tank. (Bottom) 
Latencies for the mice to reach the platform during training did not show significant differences between 
Cdk5f/f/KA1 (n=10) and Cdk5f/f mice (n=10). (P), partial cues, (F), full cues. E. Cdk5f/f/KA1 mice 
showed similar preferences toward the target quadrant as the Cdk5f/f group in a full cue trial on day 15. 
F. Cdk5f/f/KA1 mice did not show preferences toward the target quadrant in the partial-cue-trial on day 
16. G. Cdk5f/f/KA1 mice take more time to reach the hidden platform position than Cdk5f/f mice in the 
partial cue, but not the full cue, trial. H. In the probe trial with partial cues, the average number of 
crossings over the platform position is much lower for the Cdk5f/f/KA1 group than that for the Cdk5f/f 
group. *p<0.05; **p<0.005. 
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functions. As synaptic plasticity and the signaling molecules involved in hippocampus-
dependent memory events are best understood in area CA1, we utilized three-month-old 
Cdk5f/f/T29 mice for subsequent studies to dissect the downstream molecular pathway by which 
Cdk5 regulates learning and memory in the hippocampus. 
 
Impaired synaptic plasticity in Cdk5 mutant mice 
 As synaptic plasticity has been implicated in memory formation, we therefore evaluated 
synaptic plasticity in the hippocampus of Cdk5f/f/T29 mice by examining long-term potentiation 
(LTP) in CA1 neurons. Acute transverse slices (400 µm) were obtained from Cdk5f/f/T29 or 
Cdk5f/f mice, and field excitatory postsynaptic potentials (fEPSPs) were evoked by placing an 
electrode on the Schaffer collateral pathway. After 15 min of baseline recording, LTP was 
induced using two trains of high-frequency stimulation (HFS; 100 Hz, 1 s). Forty-five minutes 
after HFS, field excitatory postsynaptic potentials (fEPSPs) remained elevated in the Cdk5f/f 
slices (121.88 ± 7.04%; Figure 6A). In contrast, fEPSPs decayed to baseline in the Cdk5f/f/T29 
slices (109.13 ± 6.79%; Figure 6A, *p<0.01 Cdk5f/f vs. Cdk5f/f/T29). Presynaptic transmission 
was unimpaired, as measured by the paired-pulse facilitation (PPF) ratio, which measures the 
probability of presynaptic neurotransmitter release (Figure  6B). The input-output curves 
generated by plotting the fEPSP slopes against the slopes of the fiber volley were also 
indistinguishable, suggesting normal basal synaptic transmission (Figure 6C).  However, 
Cdk5f/f/T29 slices exhibited defects in post-tetanic potentiation (PTP; Figure 6D). Although 
PTP is thought to be mainly affected by presynaptic mechanisms, postsynaptic injection of Ca2+ 
chelators, which affects postsynaptic cAMP activation, have also been found to block PTP (Bao 
et al., 1997). Thus, neuronal Cdk5 ablation is associated with both LTP and PTP deficits in 
hippocampal CA1 neurons. We then proceeded to evaluate long-term depression (LTD). Low-
frequency stimulation (LFS; 1Hz, 900 pulses, 15 min) of the Schaffer collateral pathway induced 
a long-lasting synaptic depression in the Cdk5f/f animals. In contrast, LTD could not be induced 
in Cdk5f/f/T29 mice (Figure 6E). These data indicate that both LTP and LTD measures of 
synaptic plasticity are largely impaired in the Cdk5 mutant mice, which is consistent with their 
memory deficits. 
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Figure 6. Synaptic plasticity is largely impaired in Cdk5f/f/T29 mice.   
A.  Acute hippocampal slices obtained from 2-month-old Cdk5f/f/T29 and Cdk5f/f mice were stimulated 
with two trains of HFS (100 Hz, 1 s) in area CA1. Field EPSPs (fEPSPs) were measured from area CA1 
in Cdk5f/f and Cdk5f/f/T29 mice (n=8 for each group). B. Paired-pulse facilitation (PPF) in Cdk5f/f mice 
and Cdk5f/f/T29 and (n=9 for each group). C. The input-output curve indicates normal basal synaptic 
transmission in the Cdk5f/f/T29 mice. D. Post-tetanic potentiation (PTP) from Cdk5f/f/T29 mice was 
lower than in Cdk5f/f mice 30s after two trains of HFS (100 Hz, 1 s).  E. LTD was measured in area CA1 
of acute hippocampal slices from Cdk5f/f and Cdk5f/f/T29 after low frequency stimulation (1 Hz, 900 
pulse; n=6 for each group).  
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Disruption of CREB activity in Cdk5f/f/T29 mice 
 To dissect the molecular pathways involved in Cdk5-mediated synaptic plasticity and 
memory formation, we evaluated well-established signaling molecules involved in memory 
formation in the Cdk5f/f/T29 mice. CREB is an important transcription factor essential for 
expression of genes important for synaptic plasticity. A decrease in phosphorylated CREB on 
Serine 133 pCREB(S133), a modification required for CREB-mediated transcriptional activity 
during memory formation (Deisseroth et al., 1998), was detected in Cdk5f/f/T29 mice using an 
anti-pCREB(S133) antibody. The reduction of pCREB(S133) was specific to area CA1 neurons 
(Figure 7A, 7B), as no reduction of pCREB(S133) was detected in either cortical or CA3 
neurons, where Cdk5 expression was unaffected. In hippocampal area CA1 lysates, pCREB(133) 
was markedly decreased in the Cdk5f/f/T29 compared to the Cdk5f/f mice (Figure 7C). 
 NMDA receptors are major mediators of synaptic plasticity, and in a different Cdk5 
conditional knockout mouse model, it was demonstrated that NR2B degradation is impaired, 
resulting in increased surface expression of NR2B and enhanced synaptic plasticity (Hawasli et 
al., 2007). The degradation of NR2B was reported to be regulated by phosphorylation of 
Tyrosine 1472 (Y1472) on NR2B via Cdk5 (Zhang et al., 2008). We found no differences in 
NR2A and NR2B protein levels in area CA1 between Cdk5f/f/T29 and Cdk5f/f mice (Figure 
7C). Moreover, pNR2B (Y1472) was not altered in CA1 hippocampal lysates from Cdk5f/f/T29 
mice compared to control littermates. Thus, the synaptic plasticity and learning behavior deficits 
observed in the Cdk5f/f/T29 mouse are associated with impaired CREB phosphorylation, but not 
with alterations in total NR2A/NR2B protein levels, or NR2B Y1472 phosphorylation. 
 The insertion of GluR1-containing AMPA receptors into the synapse constitutes a major 
mechanism underlying the plasticity produced by the activation of CaMKII and LTP induction 
(Hayashi et al., 2000). We found that the GluR1 phosphorylation on S831, a site phosphorylated 
by CaMKII (Roche et al., 1996), was increased in Cdk5f/f/T29 samples compared to controls at 
basal levels (Figure 7D). In addition, GluR1 phosphorylation on S845, a PKA site (Roche et al., 
1996), was also upregulated (Figure 7D). Conversely, the activity of protein phosphatases 1 and 
2 (PP1 and PP2) was reduced in the Cdk5f/f/T29 mice (Figure 7E). Thus, decreased phosphatase 
activity may contribute to increased GluR1 phosphorylation. These results indicate that 
perturbations in intracellular signaling pathways related to synaptic plasticity occur in the 
absence of Cdk5.   
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Figure 7. Impaired CREB phosphorylation and hyper-phorsphorylation of GluR1 in Cdk5f/f/T29 
mice.  
Immunostaining (A) and quantification (B) of pCREB in hippocampal CA1 and cortex. Scale bar = 100 
µm. C. Western blots of micro-dissected CA1 tissue show reduced pCREB levels. D. Western blots of 
micro-dissected CA1 tissue reveals hyper-phosphorylation of GluR1. E. Area CA1 phosphatase activity 
in Cdk5f/f and Cdk5f/f/T29 mice (n=3, each group). *p<0.05, **p<0.005, ***p<0.001. 
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Proteomic analysis reveals protein composition changes in Cdk5 mutant mice 
 To further decipher the mechanism by which Cdk5 influences synaptic plasticity, we 
applied a total, unbiased, proteomic approach to analyze changes in protein composition and 
phosphorylation in synaptosomal preparations of control and mutant mice.  To this end, brains 
from control and Cdk5f/f/CW2 mice were homogenized and subjected to standard synaptosomal, 
postsynaptic density (PSD) isolation. Solubilized PSD proteins were run on an SDS-PAGE gel 
that was sliced into thirteen fields, and sequenced by LC/MS/MS (Figure 8A, 8B, Figure 9A). 
Approximately 1595 distinct, differentially expressed peptide groups were detected from control 
(Cdk5f/f) and Cdk5f/f/CW2 PSD preparations; of these, 700 peptides, implicated in dendritic 
spine/synapse formation, synaptic vesicle exocytosis, small GTPase signaling pathways, and ion 
channel functions, contain consensus Cdk5 phosphorylation sites. Among these potential Cdk5 
substrates, the abundance of 296 proteins was increased, and the abundance of 51 proteins was 
decreased, in the Cdk5f/f/CW2 mice compared with controls (Figure 9B). These proteins 
comprised multiple different categories, including motor proteins and protein involved in 
membrane trafficking and kinase/phosphatase activity. Interestingly, consistent with the western 
immunoblotting results, NMDA receptor subunits did not show significant changes (<1.5 fold) in 
the PSD fractions (Figure 9C; Grin2a, 2b). In contrast, multiple GluRs showed dramatic 
increase in the PSD fractions (Figure 9C; Gria1-4), suggesting increased synaptic AMPA 
receptors protein levels in the mutant mice. Overall, the drastic changes of protein composition 
in the PSD of Cdk5f/f/CW2 vs. controls suggest a key role of Cdk5 in regulating synaptic protein 
expression and abundance. 
To further probe the mechanism underlying the phenotype of the Cdk5 conditional 
knock-out mice, we used our proteomic data to examine potential Cdk5 targets that could affect 
CREB activation. Among the known regulators of cAMP signaling pathway, cyclic nucleotide 
phosphodiesterase (PDE) proteins, enzymes that catalyze the conversion of cAMP and AMP into 
cGMP and GMP, respectively, were markedly increased in the Cdk5f/f/CW2 mice (Figure 9C). 
Conversely the adenylyl cyclase (AC) family proteins, which catalyze ATP to cAMP (Levin et 
al., 1992), were not detected in our proteomic data set, suggesting a low abundance of those 
proteins in the PSD preparation.  
 To further confirm the proteomic analysis, mRNA levels of AC family members were 
measured in control and mutant mice. Group 1 ACs are represented by AC1, AC3, and AC8, and 
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are stimulated by calmodulin in a Ca2+-dependent manner (Wong et al., 1999).  We examined the 
mRNA levels of AC1, 3, and 8, but did not observe differences in the Cdk5f/f/T29 mice 
compared to controls (Figure 9D). However, we detected increased mRNA expression of PDE 
family proteins in the Cdk5 mutant mice using quantitative PCR with hippocampal RNA 
extracts. After signal normalization, mRNAs for PDE1a, PDE4D1, PDE4D4, PDE2a, and 
PDE4b were significantly increased in the Cdk5f/f/T29 mouse hippocampus compared to 
Cdk5f/f (Figure 9E). PDE4 proteins exclusively target cAMP and is a specific target for 
rolipram, while PDE1 and 2 also target cGMP. While cAMP has been shown to regulate LTP 
(Blitzer et al., 1995; Frey et al., 1993), cGMP is involved in regulating LTD (Calabresi et al., 
1999), The increase in the PDE1 and 2 isoforms, which deplete cGMP, in Cdk5f/f/T29 mice 
might be a contributing factor to the loss of LTD. Thus, increased PDE expression in the 
Cdk5f/f/T29 mice may impair LTP and LTD induction via depletion of cAMP and cGMP.  
Cdk5 loss of function blocks activation of the cAMP activation pathway, which can be restored 
by rolipram  
 To further test the hypothesis that the dysregulated cAMP signaling, by virtue of 
increased PDE expression, underlies the observed plasticity and behavioral phenotypes exhibited 
by the Cdk5 mutant mice, we evaluated the consequences of the pharmacological inhibition of 
these enzymes in the Cdk5f/f/T29 mice.  Rolipram, a PDE4-specific small molecule inhibitor, 
was recently reported to facilitate memory formation and synaptic plasticity in rodents (Vitolo et 
al., 2002). In Cdk5f/f mice, rolipram treatment resulted in the increased phosphorylation of 
GluR1 at S845, consistent with a role for cAMP signaling and PKA phosphorylation of S845 
(Figure 10A). At basal levels, phosphorylation of GluR1 at both S831 and S845 in Cdk5f/f/T29 
mice is significantly higher compared to Cdk5f/f controls. However, rolipram treatment in 
Cdk5f/f/T29 mice selectively reduces phosphorylation of GluR1 at S831, indicating that the 
inhibition of PDE4 may affect GluR1 phosphorylation preferentially at the CaMKII 
phosphorylation site.  To further examine if PDE inhibition, and therefore persistent cAMP 
signaling, has influences on other biochemical changes in Cdk5f/f/T29 mice, we evaluated PP1 
activity. As PDEs are upregulated in the Cdk5 mutant mice, we explored the consequences of 
PDE inhibition by rolipram. Interestingly, blocking PDE4 activity by rolipram (0.1mg/kg, i.p.) in 
Cdk5f/f/T29 mice restores PP1 activity (Figure 10B). 
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Figure 8. Mass-spectrometry preparation of PSD samples. 
A. Western immunoblotting of PSD proteins after preparation. Cdk5 is significantly reduced in forebrain 
PSD preparations of Cdk5f/f/CW2 mice. B. Coomassie blue staining of PSD proteins on an SDS-PAGE 
gel. Thirteen gel slices were obtained from each lane in preparation for LC/MS/MS. 
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Figure 9. Proteomic analysis of post-synaptic densities reveals changes in PDE proteins in CDK5 
mutant mice.   
A.  Procedure sequence for mass-spectrometry analysis with PSDs from control (Cdk5f/f) and 
Cdk5f/f/CW2 (cKO) mice. B. Summary of detected protein abundance differences categorized by various 
protein functions. C. Representative molecules changes detected in Cdk5 cKO mice. Red number 
indicates reduction folds; black number indicates increase folds. D. RT-qPCR results of ACs in 
hippocampal CA1 in Cdk5f/f and Cdk5f/f/T29. qPCR signals were normalized to actin in each sample 
(n=3). E. RT-qPCR results of PDEs from hippocampal area CA1 in Cdk5f/f and Cdk5f/f/T29.   
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 We next evaluated the effect of rolipram pretreatment on the activity-induced 
phosphorylation of CREB(S133) in the Cdk5f/f/T29 mouse. Rolipram (0.1 mg/kg) was 
administered into Cdk5f/f or Cdk5f/f/T29 mice 20 min before contextual fear conditioning 
training. Animals were sacrificed 20 min after training and hippocampal area CA1 was dissected 
for biochemical processing. Training increased pCREB(S133) in area CA1 of Cdk5f/f mice 
(Figure 10C), whereas the saline-injected Cdk5f/f/T29 group did not show any increase in 
pCREB(S133) levels after training (Figure 10D). However, in rolipram-treated Cdk5f/f/T29 
mice, contextual fear training induced a significant increase in pCREB in hippocampal area 
CA1, suggesting that rolipram treatment rescued the training-induced activation of pCREB 
(Figure 10D). Thus, Cdk5 enabled the activation of pCREB via the regulation of cAMP levels. 
 
Rolipram treatment partially restores synaptic plasticity in Cdk5f/f/T29 mice 
 To determine if rolipram treatment influences synaptic plasticity, Cdk5f/f and 
Cdk5f/f/T29 mice were injected with rolipram (0.1 mg/kg) 20 min before the preparation of 
acute hippocampal slices for LTP and LTD recordings. Rolipram (0.7 µM) was present in the 
bath solution throughout the entire experiment. Cdk5f/f slices treated with rolipram alone did not 
demonstrate enhanced LTP induction compared to Cdk5f/f treated with saline (Figure 10E). 
Consistent with our previous observations, Cdk5f/f/T29 mice treated with saline exhibited 
deficits in LTP. Remarkably, following HFS stimulation, fEPSPs remained potentiated 
(123.2±5.7%) in the hippocampal slices prepared from the rolipram-treated Cdk5f/f/T29 slices, 
comparable to the level of LTP induced in Cdk5f/f slices.  Thus, inhibition of PDE4 by rolipram 
rescues LTP in the Cdk5f/f/T29 mice. In contrast, although fEPSPs were initially depressed in 
the rolipram-treated Cdk5f/f/T29 mice after LFS stimulation for LTD induction, synaptic 
depression was transient and rapidly decayed to baseline levels (Figure 10F). Thus, rolipram 
treatment is sufficient to restore LTP, but not LTD, in the Cdk5f/f/T29 mice. This is also 
consistent with a reduced phosphorylation of GluR1 on the CaMKII (S831) site, but not the PKA 
(S845) site (Lee et al., 2000), in the untrained mice.  
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Figure 10. Inhibition of PDE4 by rolipram can restore LTP deficits and rescue memory 
impairments in Cdk5f/f/T29 mice.  
A. Western blot from CA1 lysates after rolipram treatment. Samples were collected 20 min after rolipram 
or saline (control) injection. B. PP1 activity in area CA1 tissue was measured after rolipram treatment 
(0.1 mg/kg, i.p.). C. Western blots (left) for CA1 tissues from Cdk5f/f mice, with quantification (right). 
Mice were trained in a contextual fear conditioning paradigm followed by tissue harvest 20 min after 
training. n=5 for each group. D. Western blots (left) from micro-dissected CA1 tissues from Cdk5f/f/T29 
mice with quantification (right). Rolipram (0.1 mg/kg, i.p.) was injected 20 min before contextual fear 
conditioning training. Samples were collected 20 min after training (n=3 for each group).  E. Rolipram 
restored LTP deficits in the Cdk5f/f/T29 slices. Mice were injected with rolipram or vehicle (Veh) 20 min 
before sacrifice and slice preparation. Rolipram was also present in the bath solution at 0.7 µM. Slices 
were stimulated with two trains of HFS (100 Hz, 1 s; n=6 for each group; *p<0.05, between vehicle- and 
rolipram-treated groups in Cdk5f/f/T29 mice). F. Rolipram did not rescue the LTD impairment in 
Cdk5f/f/T29 slices (n=5 for each group). G. In a contextual fear conditioning task, the percent of time 
spent freezing in Cdk5f/f/T29 mice (n=16) is significantly lower than that of control Cdk5f/f mice (n=8). 
The percent freezing time for the Cdk5f/f/T29 mice injected with rolipram (0.1 mg/kg, i.p.) 20 min before 
training (n=8) or 3 hr after training (n=7) is similar to that of the control Cdk5 f/f mice.   
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Rolipram treatment rescues associative memory in Cdk5f/f/T29 mice 
 We next investigated whether rolipram could extend its ameliorative effects to the 
memory impairment caused by Cdk5 loss of function in hippocampal area CA1. Using the 
contextual fear conditioning paradigm, we found that rolipram administration (0.1 mg/kg) either 
20 min before, or 3 hr after, training rescued the memory impairments in the Cdk5f/f/T29 mice 
(Figure 10G). When tested 24 hr after training, the average freezing time of Cdk5f/f/T29 mice 
was 5.9±2.6%.  However, the average freezing time of Cdk5f/f/T29 mice receiving rolipram 
increased to 35.4±10.8% (the group treated 20 min before training) and 37.3±7.1% (the group 
treated 3 hr after training) respectively, which were comparable to the average freezing time of 
control mice (39.6±8.6%; Figure 10G). Rolipram treatment in control animals did not alter 
freezing behavior (30.6±11.0% vs. 39.6±8.6%) in the contextual fear conditioning tasks (Figure 
10G). The rescue of contextual fear memory consolidation with rolipram treatment is especially 
remarkable considering the severity of the Cdk5f/f/T29 behavioral phenotype, in which untreated 
mice fail to express contextual fear memory even after three consecutive days of training (Figure 
2F).  
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Figure 11. Cdk5 regulates homeostasis of the cAMP pathway. 
Model figure demonstrating the proposed role of Cdk5/p35 in regulating the cAMP pathway and synaptic 
plasticity. Under normal conditions, activity stimulates cAMP and PKA activity, leading to altered 
cAMP-dependent changes in gene transcription and memory formation. Loss of Cdk5 severely attenuates 
cAMP signaling and impairs memory formation due to increased PDE activity. Rolipram, a PDE4 
inhibitor,  prevents the breakdown of cAMP and restores the signaling pathway mediating synaptic 
plasticity and memory formation. 
 
	  79 
Discussion 
Cdk5 is essential for hippocampal-dependent learning and memory 
 Cdk5 is thought to be involved in the morphogenesis of synaptic connections, as well as 
in the regulation of synaptic transmission, through interactions at both presynaptic terminals and 
postsynaptic spines with proteins that include PSD-95 (Morabito et al., 2004), ErbB (Fu et al., 
2001), Stat3 (Fu et al., 2004), DARPP-32 (Bibb et al., 1999), CASK (Samuels et al., 2007), and 
Eph4/ephexin1 (Fu et al., 2007). In contrast to an earlier study by Hawasli et al in which 
enhanced hippocampal synaptic plasticity and spatial learning behaviors were observed due to 
upregulated NMDA receptor subunit NR2B levels (Hawasli et al., 2007), we find that the 
neuron-specific Cdk5 loss of function has a detrimental effect on hippocampal-dependent 
associative and spatial memory, and impairs synaptic plasticity, but leads to unaltered NR2B 
levels. The differences between the previously reported findings and our current observations 
can be attributed to the methods used to generate the different Cdk5 knockout mouse models. In 
the previous Cdk5 conditional knockout study (Hawasli et al., 2007), the use of the prion 
promoter extends Cdk5 knockdown to general regions of the brain including the forebrain, 
striatum, cerebellum, and hippocampus (Borchelt et al., 1996; Boy et al., 2006; Weber et al., 
2001). The prion promoter also drives expression in various neural cell types, including glial 
cells in which Cdk5 is also expressed (Boy et al., 2006; Lee et al., 2002). Thus, the regional loss 
of Cdk5 in different cell types may account for previous behavioral observations. Another 
distinction between these studies consists of acute versus chronic deletion of Cdk5, given the 
findings that chronic loss of Cdk5 in the inducible mouse model (8 weeks after ablation of Cdk5) 
resulted in significantly different behavior compared to the acute loss of Cdk5 function (2-4 
weeks) (Hawasli et al., 2009). Therefore, while data from the prion promoter mouse model 
suggest that the widespread acute loss of Cdk5 in both neurons and glia is beneficial for 
cognition, chronic ablation of Cdk5 in hippocampal circuits led to learning impairments in our 
Cdk5 models prior to the spread of the Cre promoter expression. This suggests that the targeted 
deletion of Cdk5 in excitatory neurons of hippocampal areas CA1 and CA3 or forebrain is 
associated with impaired cAMP signaling, synaptic plasticity, and memory formation. We 
noticed a slight reduction of Cdk5 in the dentate gyrus of Cdk5f/f/KA1 mice (Figure 4C). 
Therefore, it is possible that Cdk5 may play a role in the DG that affects the observed behavioral 
phenotypes. In future experiments, it would be of interest to examine how loss of Cdk5 in other 
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brain regions (such as the DG), or in specific cell-types, including dopaminergic neurons, 
cholinergic neurons, or a subset of interneurons, impacts the various neural circuits and signaling 
pathways by which Cdk5 regulates memory formation.  
 The same strategy used to generate Cdk5 conditional knockout mice in the current work 
was previously used in studies targeting the NR1 gene to study synaptic plasticity and evaluate 
the role of the NMDA receptor in areas CA1 and CA3 of the hippocampus (Nakazawa et al., 
2003; Tsien et al., 1996b). The similarities between our findings and those using CA1- and CA3-
targeted NR1 knockout mice support the notion that Cdk5 is involved in the CA1 spatial memory 
formation circuit, and in the CA3 pattern completion-based memory recall circuit. However, the 
memory deficit in the Cdk5f/f/T29 mice appears to be more severe than in mice lacking the NR1 
receptor subunit in the CA1 region, as reflected by their poor performance on contextual fear 
conditioning tasks, even following repeated training. During the Morris water maze hidden 
platform training, the Cdk5f/f/T29 mice did not exhibit any decrease in average escape latencies 
despite repeated trainings. Our findings indicate that the more severe phenotype evident in 
Cdk5f/f/T29 may result from the involvement of Cdk5 in the regulation of cAMP pathways and 
synaptic transmission via the regulation of phosphatases and PDEs. Thus, Cdk5-mediated 
regulation of the cAMP pathway is required and essential for memory formation. 
  
Cdk5 modulates PDE signaling pathways essential for synaptic plasticity 
 Mechanistically, the memory deficits caused by the ablation of Cdk5 are not due to 
developmental influences, as the postnatal nature of Cre expression with the T29-Cre line has 
been well-characterized (Tsien, 1998; Tsien et al., 1996a), and hippocampal morphology is not 
severely altered in any of our Cdk5 mutant mice.  The learning phenotype also cannot be 
attributed to neurodegeneration, as there are no significant differences in the number of 
pyramidal neurons between the Cdk5-deficient mice and controls (Figure 1F). Instead, we 
identified an abnormal increase in the expression of several PDEs in the brain, suggesting that 
the cAMP pathway is impacted in the Cdk5 mutant mice.  Furthermore, PDE inhibition by acute 
rolipram treatment restored LTP and CREB phosphorylation in Cdk5f/f/T29 mice. Importantly, 
rolipram treatment ameliorated the memory deficits observed in the Cdk5f/f/T29 mice. These 
data strongly support a novel role for Cdk5 in regulating memory via the cAMP pathway.  
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 Earlier mouse genetic studies have elegantly demonstrated that increases in CREB 
phosphorylation, and subsequent CREB-mediated gene transcription, occur following contextual 
fear conditioning. Conversely, disrupting CREB leads to deficiencies in transcription-dependent 
long-term memory in mice (Bourtchuladze et al., 1994; Impey et al., 1998). The impaired cAMP 
signaling observed in Cdk5-deficient mice in our study is accompanied by a reduction in 
pCREB(S133) in the hippocampus in both basal and post-training conditions. Interestingly, the 
Cdk5f/f/T29 mutant mice demonstrated an early LTP impairment, a phenomenon independent of 
CREB-mediated transcription modifications (Barco et al., 2002). It should be noted that CREB is 
not the only target and effecter of cAMP, and earlier studies have shown that postsynaptic cAMP 
pathways directly regulate early LTP in the hippocampal CA1 area (Blitzer et al., 1995). Our 
results support the essential role of the cAMP pathway in modulating synaptic functions as well 
as in learning and memory.    
 We propose that the alteration of the cAMP pathway, resulting from increased PDE 
expression, is a major factor in the aberrant signaling pathways and behavior deficits observed in 
Cdk5-deficient mice (Figure 11). However, the detailed mechanism by which Cdk5 regulates 
PDEs remains unclear. Cdk5 might act upon multiple targets to regulate the levels of 
intracellular cAMP. We found that both the mRNA and protein levels of PDE4 are increased in 
Cdk5 mutant mice, which could result from a lack of inhibition by Cdk5 on targeted transcription 
factors such as MEF2 (Gong et al., 2003). In the Cdk5 mutant mice, we also detected a lack of 
pDARRP-32(T75) (data not shown), which would inhibit PKA signaling (Bibb et al., 1999; 
Chergui et al., 2004) and could indirectly affect cAMP levels via feedback regulation through the 
AC-cAMP-PKA axis (Bauman et al., 2006). Other possibilities include a direct regulation on the 
activity of AC by Cdk5, which cannot be excluded as an alternative interpretation based on our 
experimental evidence.  
 
Other potential synaptic mechanisms regulated by Cdk5 
 Interestingly, in our PSD proteomic screen, many PSD molecules in pathways other than 
the cAMP pathway are altered in the absence of Cdk5, including receptor, channel, and 
trafficking molecules. For example, GluR4 and the L-type calcium channel, alpha 2, myo5a, 
Kif2a are increased, while ACCN1, GABA receptor type 2, and dynll2 are decreased, in the PSD 
of Cdk5 mutant mice (Figure 9C). The alterations in PSD protein composition resulting from the 
	  82 
loss of Cdk5 suggest that Cdk5 is an active participant at the synapse whose critical role in 
synaptic plasticity may be mediated via more than one distinct pathway. 
 Here we also identified altered AMPAR-dependent regulation, as measured by changes in 
GluR1 phosphorylation. In Cdk5f/f/T29 mice, we observed increased GluR1 phosphorylation at 
both S831 and S845 (Figure 7D). Partially increasing GluR1 phosphorylation at S831 might 
facilitate LTP (Barria et al., 1997; Lee et al., 2000), while the occlusion of GluR1 
phosphorylation by the long-term deletion of Cdk5 is predicted to lead to a failure in LTP 
induction. The mouse models used in this study may therefore represent a chronic loss of Cdk5 
in adult mice in which LTP occlusion is derived from persistent GluR1 phosphorylation. 
Intriguingly, rolipram treatment in the Cdk5f/f/T29 mice decreased the S831, but not S845, 
GluR1 phosphorylation and restored LTP, but not LTD, signaling. As PP1 phosphatase activity 
is also restored to control levels with rolipram application, one could speculate that PP1 regulates 
the bidirectional GluR1 signaling and LTP by the dephosphorylation of S831. However, as LTD 
is not restored in Cdk5f/f/T29 mice treated with rolipram, Cdk5 may act through a PDE4-
independent pathway, such as the PDE1 and PDE2 pathways that deplete cGMP, in regulating 
LTD maintenance. Alternatively, Cdk5 may play a role in generating LTD that is separate from 
PDE function altogether.  
 
Directions for future research 
 In the current work, we have elucidated a novel role for Cdk5 in the modulation of the 
cAMP pathway. We cannot exclude the possibility that other targets of Cdk5 may also be 
involved in the regulation of cAMP, such as the direct phosphorylation of PDE4 or AC by Cdk5. 
Future experiments include addressing the relationships between Cdk5 activity and intracellular 
signaling molecules such as cAMP or PP1 as key regulators of activity-dependent mechanisms 
of memory formation, along with work examining how GluR1 phosphorylation is regulated by 
Cdk5 and how this contributes to pathways by which Cdk5 maintains downstream signaling at 
the glutamatergic synapse. Recent evidence has highlighted Cdk5 as a critical molecule 
implicated in the downregulation of synaptic activity in hippocampal neurons (Seeburg et al., 
2008) and in the regulation of synaptic transmission (Kim and Ryan, 2010). Further work on the 
molecular targets of Cdk5, including cAMP, will reveal the mechanisms by which Cdk5 
maintains synaptic homeostasis.  
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 The modulation of the PDEs and cAMP pathways has already been utilized to treat 
mouse models of cognitive decline, as rolipram was previously shown to be able to rescue the 
memory deficits in mouse models of Rubinstein-Taybi Syndrome (Alarcon et al., 2004), 
ischemia (Imanishi et al., 1997), and Alzheimer’s disease (Gong et al., 2004; Vitolo et al., 2002). 
Our findings that rolipram ameliorates the memory deficits caused by ablation of Cdk5 in 
hippocampal CA1 neurons provides a compelling direction for future research in targeting PDEs 
and other cAMP pathway activators to restore memory deficits, particularly those associated 
with neurodegeneration and cognitive decline. 
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Chapter 3 
 
 
Regulation of N-type voltage-gated calcium channels and presynaptic function by cyclin-
 dependent kinase 53 
 
 
 
Summary 
 
 N-type voltage-gated calcium channels (CaV2.2) localize to presynaptic nerve terminals 
and mediate key events including synaptogenesis and neurotransmission. While several kinases 
have been implicated in the modulation of calcium channels, their impact on presynaptic 
functions remains unclear. Here we report that the N-type calcium channel is a substrate for 
cyclin-dependent kinase 5 (Cdk5). The pore-forming α1 subunit of the N-­‐type calcium channel is 
phosphorylated in the C-terminal domain, and phosphorylation results in enhanced calcium 
influx due to increased channel open probability. Phosphorylation of the N-type calcium channel 
by Cdk5 facilitates neurotransmitter release and alters presynaptic plasticity by increasing the 
number of docked vesicles at the synaptic cleft. These effects are mediated by an altered 
interaction between N-type calcium channels and RIM1, which tethers presynaptic calcium 
channels to the active zone. Collectively, our results highlight a molecular mechanism by which 
N-type calcium channels are regulated by Cdk5 to affect presynaptic functions. 
 
 
______________________ 
3 The findings presented in this chapter were previously published as: Su SC, Seo J, Pan JQ, Samuels BA, 
Rudenko A, Ericsson M, Neve RL, Yue DT, Tsai LH. 2012. Regulation of N-type voltage-gated calcium 
channels and presynaptic function by cyclin-dependent kinase 5. Neuron 75(4):675-87. 
 
I conducted the kinase assays, generated and purified and characterized the phospho-specific antibody, 
cloned the full-length 8X CaV2.2 phosphorylation mutant, cloned the constructs into viral vectors, 
maintained stable cell lines, cultured primary neurons, conducted the electrophysiology recordings in 
heterologous cells and primary neurons and analyzed the data, prepared samples for electron microscopy 
processing and acquired images for analysis, conducted surface biotinylation and protein binding 
biochemical experiments and analysis, and performed the stereotaxic injections. 
	   90 
Introduction  
 Calcium channels in the CaV2 voltage-gated calcium channel family are enriched in 
neurons and are composed of multiple subunits. The α1B subunit encodes the pore-forming 
subunit of N-type calcium channels (CaV2.2) (Westenbroek et al., 1992). In addition to their 
well-established roles in spinal nociception and neuropathic pain signaling mediated by Gβγ G-
protein subunits (Snutch, 2005), N-type calcium channels contribute to synaptic transmission in 
the hippocampus (Catterall and Few, 2008). Together with the P/Q-type calcium channels, these 
two major classes of presynaptic calcium channels are sufficient to account for synaptic 
transmission at the hippocampal CA3-CA1 synapse (Luebke et al., 1993; Wheeler et al., 1994).  
 N-type calcium channels play a prominent role in neurotransmitter release and directly 
bind several key synaptic transmission proteins. The intracellular domain between the II-III 
loops of the CaV2.2 pore-forming α1 subunit is known as the synaptic protein interaction 
(synprint) region (Sheng et al., 1994). The synprint region binds syntaxin and synaptotagmin, 
two important components of the SNARE complex (Sheng et al., 1998). Synaptic transmission at 
the presynaptic terminal involves calcium influx, which triggers vesicle fusion and exocytosis by 
the ‘zippering’ of SNARE proteins with the plasma membrane (Jahn et al., 2003). The synprint 
region of CaV2.2 is also a binding site for the active zone protein RIM1 (Coppola et al., 2001). 
RIM1 can interact with the β auxiliary subunit of P/Q-type calcium channels to suppress 
inactivation, allow calcium influx, and facilitate synaptic vesicle docking to the active zone 
(Kiyonaka et al., 2007). Furthermore, RIM1 directly binds the C-terminal regions of the α1 
subunit of both N- and P/Q-type calcium channels, and it tethers these channels to presynaptic 
terminals in order to facilitate synchronous transmitter release (Han et al., 2011; Kaeser et al., 
2011). The interaction between N-type calcium channels and SNARE complex proteins is 
significant because kinases, such as protein kinase C (PKC) and calcium calmodulin-dependent 
kinase II (CaMKII), phosphorylate the II-III loop of the calcium channel, which affects the N-
type calcium channel interaction with various components of the SNARE complex and impacts 
neurotransmitter release (Yokoyama et al., 1997). However, it remains unknown whether other 
kinases play a role in modulating N-type calcium channel function. Recently, the scaffolding 
molecule CASK, which contains a binding domain for N-type calcium channels, was identified 
as a cyclin-dependent kinase 5 (Cdk5) substrate (Samuels et al., 2007). Upon phosphorylation by 
Cdk5, CASK increases its interaction with N-type calcium channels to regulate synaptogenesis.  
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 Cdk5 is a proline-directed serine/threonine kinase that is highly expressed in postmitotic 
cells of the central nervous system and requires its binding partner, p35, for activity (Chae et al., 
1997; Tsai et al., 1994). Cdk5-mediated phosphorylations of a wide variety of substrates 
highlights its diverse roles in neuronal functions, including migration (Ohshima et al., 1996), 
cytoskeletal dynamics (Fu et al., 2007), synaptic vesicle cycle (Tan et al., 2003), and synaptic 
plasticity (Guan et al., 2011). Under excitotoxic conditions, calcium influx through the NMDA 
receptors activates the calcium-dependent protease calpain to cleave p35 to p25, which in turn 
hyperactivates Cdk5 (Lee et al., 2000; Patrick et al., 1999). The Cdk5/p25 complex has been 
implicated in neurodegenerative diseases, including Alzheimer’s disease (Su and Tsai, 2011).  
 Recent evidence suggests that Cdk5 plays a critical role in regulating synapse formation 
(Cheung et al., 2007) and in synaptic scaling (Seeburg et al., 2008). Additionally, Cdk5 is 
proposed to be a major regulator of neurotransmitter release by regulating the size of the synaptic 
vesicle pool (Kim and Ryan, 2010), and has also been implicated in the modification of synaptic 
connectivity and strength of hippocampal CA3 recurrent synapses (Mitra et al., 2011). However, 
the Cdk5 substrates directly responsible for neurotransmitter release are still poorly understood. 
Cdk5 was previously demonstrated to phosphorylate an intracellular domain of presynaptic P/Q-
type calcium channels (Tomizawa et al., 2002). As a consequence of this phosphorylation event, 
neurotransmitter release is decreased due to the dissociation of P/Q-type calcium channels from 
the SNAP-25 and synaptotagmin complex.  
 Although several kinases have been implicated in phosphorylating and thereby affecting 
the binding of voltage-gated calcium channels to various synaptic proteins, no specific 
mechanisms have been elucidated by which a particular kinase regulates calcium channels to 
ultimately impact neurotransmitter release and presynaptic plasticity. Here we demonstrate that 
the N-type voltage-gated calcium channel (CaV2.2), a major presynaptic calcium channel, is a 
Cdk5 substrate. Phosphorylation of the CaV2.2 pore-forming α1 subunit by Cdk5 increases 
calcium influx by enhancing channel open probability and also facilitates neurotransmitter 
release. These events are mediated by an interaction between CaV2.2 and RIM1, which impacts 
vesicle docking at the active zone. Our results outline a mechanism by which Cdk5 regulates N-
type calcium channels and affects presynaptic functions.  
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Methods	  
In vitro kinase assay 
 GST vector alone or various GST-CaV2.2 intracellular fusion protein fragments were 
purified and incubated with purified p25/Cdk5 kinase (Cell Signaling Technology) in kinase 
buffer (30 mM HEPES [pH 7.2], 10 mM MgCl2, 5 mM MnCl2, 100 mM ATP, 5 mCi [32P] 
γATP (Perkin-Elmer, MA, USA), 1 mM DTT), for 30 min at room temperature. The reaction 
was stopped with the addition of 2X sample buffer (100 mM Tris [pH 6.8], 4% SDS (w/v), 0.2% 
Bromophenol blue (w/v), 20% glycerol (v/v), 200 mM DTT), separated by 10% SDS-PAGE 
polyacrylamide gels (Bio-Rad), stained with Coomassie blue (SimplyBlue Safestain, Invitrogen) 
and then dried prior to analysis by autoradiography.  
 
Antibodies 
 To generate the phospho-specific antibody to S2013 in rat CaV2.2, a 13-amino acid 
phosphorylated and non-phosphorylated peptide NH2-QPAPNASPMKRSC-COOH was 
synthesized and purified using high performance liquid chromatography (Tufts Core Facility, 
Physiology Dept). The peptides were conjugated to KLH for polyclonal rabbit antibody 
production (Covance Research Products). Antisera were affinity purified and collected after 
passing through non-phospho peptide columns using a SulfoLink immobilization kit for peptides 
(Thermo Scientific). The following antibodies were used for immunoblotting: β-actin (Sigma); 
anti-GST (Santa Cruz Biotechnology); anti-CaV2.2 (Millipore and Alomone Labs); anti-Munc18-
1, anti-RIM1, anti-SNAP-25, anti-Syntaxin1A, anti-Synaptotagmin I (all from Synaptic 
Systems). Cdk5 (DC17) monoclonal and p35 polyclonal antibodies have previously been 
described (Tsai et al., 1994).  
 
Expression plasmids and constructs 
 The vector pGEX-4T0-2 (GE Healthcare) was used for cloning the rat isoform of CaV2.2 
into various GST-CaV2.2 fragments (Accession number AF055477). Mutagenesis of the GST-
CaV2.2 fragments or full-length human isoform of CaV2.2 (Accession number NM_000718) was 
carried out as described using the outlined protocol (QuickChange, Stratagene) and sequence 
verified (MIT Biopolymer Facility, Cambridge). 
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 To generate GST fusion proteins, BL21 competent cells were transformed with the 
desired construct. Protein expression was induced by adding 0.2 mM IPTG to the medium, and 
cells were harvested by centrifugation. Cells were resuspended in TNT buffer (100 mM Tris-HCl 
[pH 8], 150 mM NaCl, 5 mM EDTA, 0.05% Tween-20), sonicated, and bound to Glutathione 
Sepharose 4B beads (Amersham Biosciences). The bound protein was loaded onto a poly-prep 
chromatography column (Bio-Rad), washed with TNT buffer, and eluted in glutathione buffer 
(200 mM Tris [pH 8], 0.1% Triton-X 100, 15 mM glutathione). The eluate was de-salted and 
concentrated using high-speed centrifugation cellulose filter units (Centricon, Millipore), and the 
final protein concentration was assayed using the Bradford Protein Assay (Bio-Rad). Reagents 
were purchased from Sigma. 
 
Primary neurons  
 Plates were coated with poly-d-lysine (BD Biosciences) and laminin (Invitrogen) at 37°C 
overnight. Pre-coated coverslips were used for lower density cultures (BD Biosciences). The 
neocortex or hippocampus was dissected from E15-17 timed-pregnant Swiss Webster mice 
(Taconic) on ice using 1X Hank’s Balanced Salt Solution (Invitrogen) supplemented with 20 
mM HEPES (pH 7.3) and treated with trypsin and DNase (0.1%, Sigma) for 10 min in a 37°C 
water bath. After dissociation and trituration, cells were diluted in Neurobasal media 
supplemented with 10% horse serum and 0.5 mM L-glutamine (all from Invitrogen). Cells were 
plated at a density of 50,000 cells/cm2. Two to four hours after plating, the media was replaced 
with Neurobasal medium supplemented with B27 (Gibco), 0.5 mM L-glutamine and 
penicillin/streptomycin. 
 
Electrophysiology 
 Confluent tSA-201 cells were transfected using Lipofectamine 2000 at a 1:2:1 ratio of the 
α1B, β3, and α2bδ subunits with either GFP or Cdk5/p35-GFP according to the protocol 
(Invitrogen). For whole-cell patch clamp recordings, electrodes were pulled to a resistance of 3-6 
MΩ (Sutter Instruments) and fire-polished (Narishige Instruments). The external solution 
consisted of (in mM) 150 TEA-Cl, 5 BaCl2, 1 MgCl2, 10 glucose, 10 HEPES, pH 7.3 (TEAOH), 
osmolality 320±5. The internal solution contained (in mM) 135 CsCl, 4 MgCl2, 4 Mg-ATP, 10 
HEPES, 10 EGTA, and 1 EDTA, adjusted to pH 7.2 with TEAOH, osmolality 300±10. For 
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whole-cell patch clamp recordings obtained from cultured hippocampal neurons at DIV12-15, 
cells were transduced with HSV for 1-2 days prior to recordings (Neve et al., 2005). The external 
media was the same as above except for TEA-Cl  (140 mM) and BaCl2 (10 mM) and was 
supplemented with 1 µM tetrodotoxin (TTX), 10 µM Nifedipine (Tocris), 200 nM ω-agatoxin-
TK (Peptides International) to isolate CaV2.2 currents or 2µM ω-conotoxin GVIA to isolate 
CaV2.1 currents.  
 For miniature recordings, the external solution consisted of (in mM) 140 NaCl, 4 KCl, 2 
CaCl2, 2 MgCl2, 10 HEPES, 10 glucose, pH 7.3 with NaOH, 315 mOsm. The internal solution 
contained (in mM) 145 CsCl, 5 NaCl, 10 HEPES, 10 EGTA, 4 Mg-ATP, 0.3 Na2-GTP, pH 7.3 
with CsOH, 305 mOsm. The external solution also contained 1 µM TTX, 50 µM  picrotoxin 
(PTX) and 50 µM D-APV for mEPSCs, or 1 µM TTX, 10 µM CNQX or 50 µM D-APV for 
mIPSCs. Series resistance was compensated by 70-90% with a 10-µs lag and online leak 
correction was performed with a P/−4 protocol. Recordings were obtained at room temperatures 
using an inverted fluorescent microscope (Zeiss). Data was acquired using the Axopatch 200B 
amplifier and analyzed with the pClamp10 and Origin8 software (Molecular Devices). 
 For field excitatory postsynaptic potential (fEPSP) recordings, slices were prepared from 
mice transduced with GFP, WT CaV2.2 or 8X CaV2.2 HSV by rapidly removing the brain and 
transferring to ice-cold, oxygenated (95% O2 and 5% CO2) cutting solution containing (mM) 211 
sucrose, 3.3 KCl, 1.3 NaH2PO4, 0.5 CaCl2, 10 MgCl2, 26 NaHCO3 and 11 glucose. Hippocampal 
slices were cut with a VT1000S vibratome (Leica) and transferred for recovery to a holding 
chamber containing oxygenated artificial cerebrospinal fluid (ACSF) consisting of (mM) 124 
NaCl, 3.3 KCl, 1.3 NaH2PO4, 2.5 CaCl2, 1.5 MgCl2, 26 NaHCO3 and 11 glucose at 28-30°C for 
at least 1 hr prior to Schaffer collateral stimulation recording. CA1 field potentials in the stratum 
radiatum were measured after stimulation of the Schaffer collateral fibers using a concentric 
bipolar electrode. After recording stable responses for at least 20 min of baseline, LTP was 
induced by high frequency stimulation (HFS) at 100 Hz for 1 s. Recordings were performed 
using a MultiClamp 700B amplifier and a Digidata 1440A A-D converter (Axon Instruments). 
All data were digitized and analyzed with pClamp10 software (Axon Instruments). Experiments 
were performed blind to the group of subjects. Sample traces represent fEPSPs at 1 min before 
(gray trace) and 30 min after (black trace) HFS. Bar graphs represent average slopes of fEPSP 
during the first 5 min after HFS or the last 5 min of recording (percentage of baseline response).  
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Surface biotinylation assay 
 Surface biotinylation assay was conducted as essentially described according to the 
protocol (Thermo Scientific). Transfected tSA201 cells were washed with ice-cold PBS, 
followed by Sulfo-NHS-SS-Biotin labeing. After 30 min on ice, the reaction was quenched and 
the cells were harvested. After rinsing with TBS, cells were lysed in RIPA buffer, sonicated, and 
centrifuged at 10,000 × g for 2 minutes at 4°C for clarified supernatant. The NeutrAvidin 
Agarose slurry to isolate surface proteins. After washing three times, protein was eluted using 
SDS-PAGE sample buffer and analyzed by immunoblotting. 
 
Biochemistry 
 Cdk5 control or Cdk5 cKO mice were generated as previously described (Guan et al., 
2011).  Brain lysates or primary neurons were homogenized in radioimmunoprecipitation (RIPA) 
buffer (50 mM Tris [pH 8], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS 
with protease and phosphatase inhibitor tablets (Roche), incubated on ice for 30 min, cleared 
with a 13,000 rpm spin at 4°C, and protein content quantified using the BCA protein assay (Bio-
Rad). For immunoprecipitations, lysates were incubated overnight with primary antibody, 
immunoprecipitated with Protein A sepharose beads (GE Healthcare) for 1 hr at 4°C, and washed 
four times at 4°C with 3,000 rpm spin. Protein samples were diluted with 2X sample buffer (100 
mM Tris pH 6.8, 4% SDS (w/v), 0.2% bromophenol blue (w/v), 20% glycerol (v/v), 200 mM 
DTT), heated at 75°C for 5 minutes and resolved on a SDS-polyacrylamide gel with 8% stacking 
gels using Laemmli buffer. Proteins were transferred by electrophoresis using Tris-Glycine 
buffer onto PVDF membranes (Millipore). Blocking buffer (5% BSA/0.1% Tween-20/PBS, or 
PBS for infrared detection) was applied for 1 hr, and membranes were probed with various 
primary antibodies overnight at 4°C. Membranes were washed four times using PBST (PBS with 
0.1% Tween-20) for 10 min each, incubated with secondary antibodies (enhanced 
chemiluminescence mouse or rabbit IgG, HRP-Linked F(ab’)2 fragment from sheep, GE 
Healthcare, 1:10,000) for 1 hr at room temperature, washed again and developed using Western 
Lightning ECL substrate (Perkin Elmer) or infrared secondaries (Li-Cor). All antibodies were 
diluted in blocking buffer. Membrane stripping was performed with stripping buffer (Pierce) 
prior to reprobing. Immunoblots were quantified using ImageJ (NIH) or with Odyssey Image 
(Li-Cor). Statistical analysis was performed using Prism software (GraphPad). 
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Electron microscopy 
 For conventional layer electron microscopy, DIV14-17 primary neurons transduced with 
HSV containing either GFP, WT CaV2.2, or 8X CaV2.2 and fixed for 1 hr at room temperature 
using 2.5% glutaraldehyde, 1.25% paraformaldehyde, and 0.03% picric acid in 0.1 M sodium 
cacodylate buffer, pH 7.4 (Electron Microscopy Sciences). After washing in 0.1 M sodium 
cacodylate buffer, cells were postfixed for 30 min in 1% osmium tetroxide (OsO4)/1.5% 
potassiumferrocyanide (KFeCN6), washed in water 3x and incubated in 1% aqueous uranyl 
acetate for 30 min followed by 2 washes in water and subsequent dehydration in grades of 
alcohol (5 min each; 50%, 70%, 95%, 2x 100%). Cells were removed from the dish in 
propyleneoxide, pelleted at 3000 rpm for 3 min and infiltrated for 2 hr in a 1:1 mixture of 
propyleneoxide and TAAB Epon (Marivac Canada Inc). Samples were subsequently embedded 
in TAAB Epon and polymerized at 60°C for 48 hr. Ultrathin sections (60 nm) were cut on a 
Reichert Ultracut-S microtome, picked up on to copper grids stained with lead citrate and 
examined in a JEOL 1200EX Transmission electron microscope or a TecnaiG² Spirit BioTWIN 
and images were recorded with an AMT 2k CCD camera. Vesicles were quantified according to 
distance: docked vesicles were touching the synaptic face, readily releasable pool of vesicles 
were within 150 nm of the presynaptic terminal, and the rest were counted in the resting pool.  
 For immunogold labeling, neurons were fixed with 4% paraformaldehyde/0.1 M sodium 
phosphate buffer (pH 7.4), permeabilized in PBS/0.1% Triton X-100 for 2 min, blocked with 
PBS/1% BSA for 30 min, and incubated in primary antibody overnight in blocking solution at 
4°C. The next day, cells were washed with PBS 3x in 30 min each, incubated with protein A-
gold (5 nm) for 1 hr, and washed again with PBS 5x in 1 hr. Samples were then fixed in 2.5% 
glutaraldehyde/0.1M cacodylate buffer (pH 7.4) and ultrathin sections were prepared as above.  
 
Immunocytochemistry 
 Primary hippocampal neurons at DIV13-15 were fixed with 4% paraformaldehyde (PFA) 
for 10 min at RT. Fixation was stopped by substituting PFA with 10 mM glycine/PBS quench 
buffer. The quenching procedure was repeated 2 times. Neurons were rinsed with cold PBS, 
permeabilized/blocked in 0.1% Triton X-100/10% normal donkey serum/3% BSA/PBS for 1 hr 
and incubated overnight at 4°C in blocking solution with anti-N-type calcium channel (CaV2.2) 
rabbit polyclonal antibodies (Santa Cruz Biotechnology) and anti-Synaptophysin mouse 
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monoclonal antibody (Abcam). Neurons were then incubated in blocking buffer with Cy3 anti-
rabbit and Cy5 anti-mouse secondary antibodies (Jackson Labs) for 1 hr at RT. Cells were 
washed for 5 min with PBS, followed by 2 min incubation with Hoechst dye (Invitrogen) and 2 
additional washes with PBS. Samples were prepared for imaging using ProLong Gold anti-fade 
reagent (Invitrogen). Images were acquired using high-resolution multi-channel scanning 
confocal microscopy (Zeiss LSM 510). The whole-field views were obtained using 10X air 
objective (NA0.45). Individual neurons were imaged using 63X oil objective (NA1.4) with 3X 
zoom. Single optical sections were acquired with identical settings applied to all samples. 
Between 5 and 7 HSV-transduced neurons per culture in three independent experiments were 
used to quantify the relative synaptic localization of CaV2.2 by assessing its co-localization with 
presynaptic Synaptophysin. Quantitative immunolocalization analysis was conducted using 
ImageJ software (NIH). All the counts were performed blind to the treatment conditions. 
Synaptic levels of CaV2.2 under different conditions were compared by one-way ANOVA.    
 
Surgery and viruses 
 Animals were group housed in the small animal facility at the Department of Brain and 
Cognitive Sciences of Massachusetts Institute of Technology (Cambridge) and handled 
according to the protocols in accordance with the National Institute of Health Guide for the Care 
and Use of Laboratory Animals. Eight-week old C57Bl/6J male mice were used for bilateral 
stereotaxic injections into hippocampal area CA3 (Jackson Labs). Ketamine/xylazine (100/10 
mg/kg) was injected intraperitoneally prior to surgery, and sterilized instruments were applied 
using aseptic technique. Herpes-simplex virus (HSV) containing the cDNA of interest were 
generated as previously described (Neve et al., 2005; Samuels et al., 2007) and delivered into 
hippocampal area CA3 using a microinjector (Stoelting Company) according to the Bregma 
coordinates (Paxinos and Franklin, 2001): AP −2, ML ± 2.6, DV −2.3 (1.5µl, 1.5x108 infectious 
units/mL, at a rate of 0.15µl/min). The needle was left in the injection site for 3-5 min after 
injection to allow for diffusion. Animals were monitored during post-operative care with 
subcutaneous administration of buprenorphine (100 mg/kg). Experiments were conducted at days 
2–3 post-surgery, when HSV expression is highest (Han et al., 2007; Lobo et al., 2010). 
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Results 
The N-type calcium channel is a Cdk5 substrate  
  To investigate if the N-type (CaV2.2) calcium channel is a Cdk5 substrate, we cloned the 
intracellular domains of the CaV2.2 α1 subunit into GST fusion protein constructs for in vitro 
kinase assays (Figure 1A). Each purified GST-CaV2.2 protein fragment was incubated with an 
activated Cdk5/p25 protein complex along with radioactive [γ32-P]ATP to assay the level of 
Cdk5 kinase activity (Figure 1B). Two GST-CaV2.2 fusion protein fragments, the C-terminal 3 
(CT 3, amino acids 1981-2120) and C-terminal 4 fragments (CT 4, amino acids 2121-2240) were 
consistently phosphorylated by Cdk5 (Figure 1C). Mutagenesis of serine 2013 (S2013), a 
consensus Cdk5 site on the CT 3 fragment, to alanine abolished Cdk5 phosphorylation. 
However, several combinations of point mutations on the CT 4 fragment were insufficient to 
reduce Cdk5/p25 phosphorylation (Figure 2). Only mutagenesis of all seven putative Cdk5 
phosphorylation sites on the CT 4 fragment resulted in undetectable phosphorylation levels 
(Figure 1D). These kinase assays identify the N-type calcium channel as a Cdk5 substrate.  
 
The N-type calcium channel is phosphorylated by Cdk5 in vivo 
 To confirm phosphorylation of the N-type calcium channel, we generated and purified a 
phosphorylation state-specific antibody to S2013, a well-conserved residue (Figure 3A). The 
phospho-CaV2.2 antibody (pCaV2.2) signal was robust when the CT 3 fragment, but not the CT 3 
(S2013A) fragment, was co-incubated with Cdk5/p25, indicating that the antibody was specific 
to S2013-phosphorylated CaV2.2 in vitro (Figure 4). Furthermore, the pCaV2.2 antibody signal 
was observed only in the presence of Cdk5/p35 in a cell line stably expressing the rat isoform of 
CaV2.2 (Lin et al., 2004), and alkaline phosphatase (CIP) treatment abolished the signal (Figure 
3B). Since S2013 is also conserved in P/Q-type calcium channels, we tested the specificity of the 
Cdk5-dependent S2013 phosphorylation by immunoprecipitation of brain lysates with an anti-
CaV2.2 antibody, followed by immunoblotting for pCaV2.2 in lysates of control and Cdk5 
conditional knockout (cKO) mice (Guan et al., 2011). We noted that pCaV2.2 levels were 
significantly reduced in forebrain lysates of adult Cdk5 cKO mice, providing in vivo evidence 
that the N-type calcium channel is a Cdk5 substrate (Figure 3C). 
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Figure 1. Phosphorylation mapping of the N-type calcium channel in vitro. 
(A) Schematic of the N-type voltage-gated calcium channel α1 pore-forming subunit. The α1 subunit is 
the functional core of the voltage-gated calcium channel containing the gating mechanisms, toxin-binding 
domains and the ion conducting pore. Voltage-gated calcium channels form heteromeric subunit 
complexes consisting of the pore-forming α1 subunit and auxiliary β, α2δ, and γ subunits. 
(B) Diagram of the various GST fusion protein constructs. The intracellular domains spanning the entire 
CaV2.2 α1 subunit were cloned into GST fusion protein constructs (GST-CaV2.2).  
(C) GST-CaV2.2 fragments were subjected to an in vitro kinase assay with purified Cdk5/p25. The C-
terminal fragments 3 and 4 (CT 3 and CT 4) were phosphorylated by autoradiography (top). GST-CaV2.2 
proteins expression as revealed by Coomassie staining (bottom). 
(D) Mutagenesis of the single Cdk5 consensus site on the CT 3 fragment (S2013A) abolished Cdk5 
phosphorylation. A combination of serine/threonine to alanine point mutations at Cdk5 phosphorylation 
sites dramatically decreased Cdk5/p25 phosphorylation of the CT 4 fragment. Sequential mutations were 
generated from the C-terminus end (7X represents all the combination of 7 phosphorylation mutations 
spanning CT 4). GST: negative control, FAK: positive control. 
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Figure 2. Mapping CaV2.2 phosphorylation sites by Cdk5. 
Whereas mutagenesis of the single site on C-terminal 3 fragment (S2013A) consistently abolished 
Cdk5/p25 phosphorylation, various combinations of single, double, or triple point mutations in the C-
terminal 4 fragments failed to reduce Cdk5/p25 phosphorylation.  
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Figure 3. Phosphorylation of the N-type calcium channel in vivo at Serine 2013. 
(A) Serine 2013 (S2013) is a highly conserved residue on the C-terminal domain of the N-type calcium 
channel α1 subunit. 
(B) Verification of the specificity of the phospho-specific antibody pCaV2.2 in a stable cell line in the 
presence of Cdk5/p35. Upon phosphatase treatment, the pCaV2.2 signal was abolished. 
(C) After immunoprecipitation with anti-CaV2.2 antibody, the pCaV2.2 antibody was used to probe for 
phosphorylated N-type calcium channel signal. In the Cdk5 cKO brain lysates, phosphorylation was 
significantly decreased, indicating that the S2013 site of CaV2.2 is indeed an in vivo Cdk5 substrate. 
Right: Quantification of phosphorylation levels in Cdk5 cKO brain lysates. Normalized protein levels are 
shown, with n=3 per condition. Control, 1.00 ± 0.14; Cdk5 cKO, 0.35 ± 0.02; **p<0.01. Data shown are 
means ± SEM.	  Statistical significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 
0.001). 
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Figure 4. Phospho-specific antibody generation for CaV2.2.  
The purified pCaV2.2 antibody recognized the phosphorylated form of CaV2.2 at S2013 using in vitro 
kinase assays, as the pCaV2.2 signal is robustly observed only in the presence of activated Cdk5/p25 
kinase and GST-CaV2.2 C-terminal 3 (CT 3) protein fragment but is abolished in the CT 3 protein 
fragment harboring the point mutation S2013A.  
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Increased N-type calcium current density as a consequence of Cdk5-mediated 
phosphorylation  
 To examine the functional significance of Cdk5-mediated phosphorylation of CaV2.2 on 
the biophysical properties of the channel, we conducted whole-cell recordings in heterologous 
tSA-201 cells transfected with either the full-length wild-type human CaV2.2 α1 subunit (WT 
CaV2.2) or the phosphorylation mutant CaV2.2 α1 subunit, in which all eight Cdk5 
phosphorylation sites in the C-terminal region were abolished (8X CaV2.2), in addition to the 
obligatory β3 and α2δ auxiliary subunit cDNAs. Using 5 mM barium as the charge carrier, we 
found that the expression of WT CaV2.2 elicited canonical voltage-gated N-type currents. The 
phosphorylation mutant 8X CaV2.2 expressed a current-density profile similar to that of WT 
CaV2.2. Remarkably, following coexpression with Cdk5/p35, the WT CaV2.2 peak current 
amplitude and current density were significantly increased compared to those of WT CaV2.2 
alone (Figure 5A, 5B, Table 1). In contrast to WT CaV2.2 however, cells transfected with 8X 
CaV2.2 in the presence of Cdk5/p35 did not display an increase in N-type current density (Figure 
5A, 5B). In a cell line stably expressing the rat isoform of CaV2.2 (Lin et al., 2004), 
phosphorylation of CaV2.2 by Cdk5/p35 also dramatically increased N-type current density, 
providing independent support that the increase in N-type current density is mediated by Cdk5 
phosphorylation (Figure 6A, 6B, Table 2). There were no differences in activation kinetics or 
voltage dependence of activation between the WT CaV2.2 and 8X CaV2.2 channels in the 
presence or absence of Cdk5/p35 (Figure 5C, 5D, Figure 6C, 6D). In examining inactivation 
kinetics, co-transfection with Cdk5/p35 increased the WT CaV2.2 inactivation time constant at 
the first test potential; however, the presence of Cdk5/p35 did not affect the inactivation kinetics 
of the 8X CaV2.2 channel at three different test potentials (Figure 5E, Figure 6E). In steady-
state inactivation (SSI) profiles, WT CaV2.2 demonstrated a greater availability of channels for 
opening in the presence of Cdk5/p35, as denoted by the rightward shift of the SSI curve (Figure 
5F, Figure 6F). Taken together, these data indicate that phosphorylation of CaV2.2 by Cdk5 
increases the availability of calcium channels. Notably, there were no differences in SSIs at the 
holding potential at which N-type current density was measured (−100 mV), suggesting that 
differences in channel availability cannot account for the increased N-type current density 
mediated by Cdk5 phosphorylation.  
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Figure 5. Modulation of biophysical properties of N-type calcium channels by Cdk5/p35. 
(A) Cdk5 dramatically increased N-type current amplitude in cells expressing WT CaV2.2. Inward 
currents were evoked by 100 ms step depolarizations applied to test potentials between −55 mV to +55 
mV from a holding potential of −100 mV. Peak current amplitudes were plotted on a current-voltage (I/V) 
curve. While cells expressing 8X CaV2.2 passed inward current at similar levels to WT CaV2.2, the 
presence of Cdk5/p35 failed to increase N-type current in cells expressing 8X CaV2.2. Scale bars, 50 nA, 
20 ms.  (B) Current density measurements were obtained by normalizing peak CaV2.2 current amplitude 
to cell capacitance. The current density of cells expressing WT CaV2.2 was significantly enhanced with 
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co-expression of Cdk5/p35. Scale bars, 50 nA, 20 ms.  (C) A voltage-step protocol was applied and fitted 
an exponential curve to the timepoint spanning the maximal inward calcium current to obtain time 
constants for channel activation. Lines were plotted from best fit linear regression. Cdk5/p35 
phosphorylation of WT CaV2.2 did not affect activation kinetics at any of the membrane potentials tested 
(5 mV, 10 mV, 15 mV).  (D) Cdk5-mediated phosphorylation of CaV2.2 did not alter voltage dependence 
of activation. Cells were held at −100 mV, and tail currents from the test pulse were normalized to the 
largest tail current from each series. The normalized curves were fit by a single Boltzmann distribution 
I/Imax = A2+(A1-A2)/(1+exp((Vm−V1/2)/dx)), with V1/2 as the midpoint for half-maximal activation, A1 
and A2 being the normalized amplitudes and dx as the slope.  (E) A long voltage-step protocol was 
applied and fitted to an exponential curve to the timepoint at the peak inward current towards the end of 
the protocol to obtain inactivation time constants. Co-expression of Cdk5/p35 increased inactivation 
kinetics of WT CaV2.2 at the test potential of 5 mV.  (F) Cdk5-mediated phosphorylation of WT CaV2.2 
affected the voltage-dependence of steady state inactivation (SSI), a measure of the number of  available 
channels at a given potential. Cells were held at −100 mV, and SSI values from the test pulse were 
normalized to the largest tail current. SSI curves were fitted by a single Boltzmann equation to calculate 
the membrane potential in which half of the channels are inactivated (V1/2,inact).  The rightward-shift of the 
SSI curve indicated that co-expression of Cdk5/p35 augmented the number of WT CaV2.2 channels 
available for opening. Data shown are the values (mean ± SEM) in	  Table 1. Statistical significance was 
calculated by one-way ANOVA (Bonferroni multiple comparison test) (*p < 0.05; **p < 0.01; ***p < 
0.001).  
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Table 1. Values of electrophysiology experiments found in Figure 5 
Measure Condition 
Value  
(mean± 
SEM) 
n 
(cells/ 
cultures) 
p-value Statistics test Fig 
Peak current 
amplitude  
(pA) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
0.93±0.09 
2.46±0.22 
0.96±0.08 
0.93±0.09 
32/10 
28/12 
23/11 
25/14 
<0.001 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
<0.001 (2 vs. 3) 
<0.001 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5A 
Current 
density 
(pA/pF) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
90.51±9.85 
235.57±42.17 
104.88±10.25 
86.52±10.26 
32/10 
28/12 
23/11 
25/14 
<0.001 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
<0.001 (2 vs. 3) 
<0.001 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5B 
Activation 
kinetics 
τ (ms) 
(5 mV) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
4.10±0.29 
4.07±0.29 
4.00±0.35 
4.04±0.27 
18/9 
14/8 
9/6 
7/5 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5C 
Activation 
kinetics  
τ (ms) 
(10 mV) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
3.04±0.18 
2.97±0.15 
3.11±0.22 
3.04±0.18 
18/9 
14/8 
9/6 
7/5 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5C 
Activation 
kinetics  
τ (ms) 
(15 mV) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
2.25±0.11 
2.21±0.08 
2.28±0.12 
2.28±0.10 
18/9 
14/8 
9/6 
7/5 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5C 
Activation 
kinetics  
(intercept) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
4.88±0.21 
4.77±.026 
4.83±0.04 
4.80±0.18 
18/9 
14/8 
9/6 
7/5 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5C 
Activation 
kinetics  
(slope) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
-0.18±0.02 
-0.17±0.02 
-0.17±0.00 
-0.17±0.01 
18/9 
14/8 
9/6 
7/5 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5C 
Tail current 
(V1/2) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
5.86±0.62 
6.61±0.70 
6.91±0.61 
6.95±0.74 
13/8 
17/8 
10/6 
13/8 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5D 
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Tail current 
(A1) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
-0.013±0.01 
-0.017±0.01 
-0.014±0.01 
-0.017±0.01 
13/8 
17/8 
10/6 
13/8 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5D 
Tail current 
(A2) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
0.95±0.014 
0.95±0.016 
0.95±0.014 
0.96±0.017 
13/8 
17/8 
10/6 
13/8 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5D 
Tail current 
(dx) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
8.13±0.56 
8.60±0.64 
8.19±0.55 
8.84±0.67 
13/8 
17/8 
10/6 
13/8 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5D 
Inactivation 
kinetics  
τ (ms) 
(5 mV) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
37.80±3.13 
47.34±1.50 
37.63±3.50 
40.05±1.72 
9/3 
9/3 
6/2 
9/3 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
<0.05 (2 vs. 3) 
<0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5E 
Inactivation 
kinetics 
τ (ms)  
(10 mV) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
56.10±4.97 
61.90±2.94 
55.40±4.16 
56.92±2.49 
9/3 
9/3 
6/2 
9/3 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5E 
Inactivation 
kinetics  
τ (ms) 
(15 mV) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
82.19±7.45 
82.93±2.59 
81.89±6.92 
81.43±5.16 
9/3 
9/3 
6/2 
9/3 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5E 
Inactivation 
kinetics  
(intercept) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
16.22±3.59 
29.54±2.54 
15.88±4.81 
20.61±3.58 
9/3 
9/3 
6/2 
9/3 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
3E 
Inactivation 
(slope) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
4.22±0.44 
3.49±0.29 
4.19±0.54 
3.80±0.46 
9/3 
9/3 
6/2 
9/3 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5E 
Steady-state 
inactivation 
(V1/2) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
-62.95±1.08 
-53.12±2.07 
-62.72±0.76 
-60.53±1.44 
17/9 
19/11 
11/8 
21/13 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
<0.05 (2 vs. 3) 
<0.05 (2 vs. 4) 
One-way 
ANOVA 
Fig. 
5F 
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>0.05 (3 vs. 4) 
Steady-state 
inactivation 
(A1) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
0.97±0.01 
0.97±0.01 
0.97±0.01 
0.97±0.01 
17/9 
19/11 
11/8 
21/13 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5F 
Steady-state 
inactivation 
(A2) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
0.02±0.01 
-0.06±0.06 
0.02±0.01 
-0.01±0.04 
17/9 
19/11 
11/8 
21/13 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5F 
Steady-state 
inactivation 
(dx) 
WT CaV2.2 
WT 
CaV2.2+Cdk5/p35 
8X CaV2.2 
8X CaV2.2+Cdk5/p35 
8.66±0.78 
11.30±1.50 
9.25±0.55 
10.54±1.27 
17/9 
19/11 
11/8 
21/13 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
<0.05 (2 vs. 3) 
<0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
5F 
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Figure 6. Modulation of biophysical properties of CaV2.2 by Cdk5/p35 in heterologous cells. 
(A) In a cell line stably expressing the rat isoform of CaV2.2, co-expression of Cdk5/p35 resulted in a 
significant increase of peak N-type current. Scale bars, 100 nA, 20 ms.  (B) The current density 
calculation showed a dramatic effect when Cdk5/p35 was co-expressed with CaV2.2 in the heterologous 
system. Scale bars, 100 nA, 20 ms.  (C) Cdk5-mediated phosphorylation of the rat isoform of CaV2.2 in a 
stable cell line did not alter activation kinetics.  (D) The voltage dependence of activation, as measured by 
tail currents, was unaffected by co-expression of Cdk5/p35.  (E) The inactivation kinetics of CaV2.2 were 
increased following Cdk5/p35 co-expression only at the test potential of −10 mV.  (F) Cdk5/p35-
mediated phosphorylation of CaV2.2 caused a rightward shift in the voltage-dependence of steady state 
inactivation, resulting in greater channel availability. Data shown are means ± s.e.m. in Table 2. 
Statistical significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Table 2. Values of electrophysiology experiments found in Supplementary Figure 6 
 
Measure Condition Value  (mean±SEM) 
n 
(cells/ 
cultures) 
p-value Statistical test Figure 
Peak current 
amplitude  
(pA) 
CaV2.2 
CaV2.2 + Cdk5/p35 
1.09±0.16 
2.53±0.32 
16/5 
21/4 <0.001 
Student’s  
t-test 
Fig.  
6A 
Current 
density 
(pA/pF) 
CaV2.2 
CaV2.2 + Cdk5/p35 
102.13±20.63 
240.00±26.72 
16/5 
21/4 <0.001 
Student’s  
t-test 
Fig.  
6B 
Activation   
τ (ms) 
(-10 mV) 
CaV2.2 
CaV2.2 + Cdk5/p35 
2.48±0.19 
2.69±0.20 
 
12/4 
13/3 >0.05 
Student’s  
t-test 
Fig.  
6C 
Activation  
τ (ms) 
(0 mV) 
CaV2.2 
CaV2.2 + Cdk5/p35 
2.05±0.20 
2.02±0.14 
12/4 
13/3 >0.05 
Student’s  
t-test 
Fig.  
6C 
Activation  
τ (ms)  
(10 mV) 
CaV2.2 
CaV2.2 + Cdk5/p35 
1.15±0.10 
1.08±0.07 
12/4 
13/3 >0.05 
Student’s  
t-test 
Fig.  
6C 
Activation 
(intercept) 
CaV2.2 
CaV2.2 + Cdk5/p35 
1.93±0.04 
-0.08±0.00 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6C 
Activation 
(slope) 
CaV2.2 
CaV2.2 + Cdk5/p35 
1.87±0.03 
-0.08±0.00 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6C 
Tail current 
(Vh) 
CaV2.2 
CaV2.2 + Cdk5/p35 
1.00±0.96 
-0.77±0.89 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6D 
Tail current 
(A1) 
CaV2.2 
CaV2.2 + Cdk5/p35 
-0.04±0.02 
-0.03±0.02 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6D 
Tail current 
(A2) 
CaV2.2 
CaV2.2 + Cdk5/p35 
0.97±0.02 
0.96±0.02 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6D 
Tail current 
(dx) 
CaV2.2 
CaV2.2 + Cdk5/p35 
11.56±0.95 
10.17±0.84 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6D 
Inactivation 
τ (ms) 
(-10 mV) 
CaV2.2 
CaV2.2 + Cdk5/p35 
35.59±1.75 
47.81±3.66 
12/6 
13/6 <0.01 
Student’s  
t-test 
Fig.  
6E 
Inactivation 
τ (ms)  
(0 mV) 
CaV2.2 
CaV2.2 + Cdk5/p35 
54.79±5.25 
59.68±5.41 
12/6 
13/6 >0.05 
Student’s  
t-test 
Fig.  
6E 
Inactivation 
τ (ms)  
(10 mV) 
CaV2.2 
CaV2.2 + Cdk5/p35 
79.33±8.83 
81.37±6.39 
12/6 
13/6 >0.05 
Student’s  
t-test 
Fig.  
6E 
Inactivation 
(intercept) 
CaV2.2 
CaV2.2 + Cdk5/p35 
57.10±2.08 
63.04±2.28 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6E 
Inactivation 
(slope) 
CaV2.2 
CaV2.2 + Cdk5/p35 
1.90±0.24 
1.60±0.26 
12/5 
11/6 >0.05 
Student’s  
t-test 
Fig.  
6E 
Steady-state 
inactivation 
(V1/2) 
CaV2.2 
CaV2.2 + Cdk5/p35 
-71.64±0.76 
-63.79±0.95 
13/7 
13/7 <0.05 
Student’s  
t-test 
Fig.  
6F 
Steady-state CaV2.2 0.95±0.01 13/7 >0.05 Student’s Fig.  
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inactivation 
(A1) 
CaV2.2 + Cdk5/p35 0.96±0.01 13/7 t-test 6F 
Steady-state 
inactivation 
(A2) 
CaV2.2 
CaV2.2 + Cdk5/p35 
-0.01±0.01 
-0.02±0.02 
13/7 
13/7 >0.05 
Student’s 
t-test 
Fig.  
6F 
Steady-state 
inactivation 
(slope) 
CaV2.2 
CaV2.2 + Cdk5/p35 
7.54±0.51 
10.42±0.76 
13/7 
13/7 <0.05 
Student’s 
t-test 
Fig.  
6F 
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Cdk5 plays a critical role in regulating channel open probability of CaV2.2 
 In addition to effects on steady-state inactivation, we reasoned that a distinct mechanism 
must underlie the dramatic increase in CaV2.2 current density following Cdk5/p35-mediated 
phosphorylation. Previous reports have indicated a role for scaffolding proteins in the 
modulation of calcium channels and enhanced calcium influx due to increased channel surface 
expression (Brittain et al., 2009; Lai et al., 2005; Leenders et al., 2008). Accordingly, we 
conducted cell surface biotinylation assays to examine whether Cdk5/p35 increases CaV2.2 
surface expression in our heterologous system. However, CaV2.2 surface expression was not 
upregulated by Cdk5/p35 in stable cell lines or after co-expression with WT CaV2.2 or 8X 
CaV2.2, indicating that altered channel surface expression was not responsible for the 
enhancement of the CaV2.2 current density by Cdk5/p35-mediated phosphorylation (Figure 7A, 
7B, Table 3). We next assessed channel open probability (Po) of CaV2.2 in the presence of 
Cdk5/p35 as previously described (Agler et al., 2005). To obtain maximal channel open 
probability, Po, for each cell, the maximal ionic current conductance Gmax (Figure 7C) was 
plotted as a function of the integral of the channel gating current at the reversal potential Qmax 
(Figure 7D). Interestingly, Cdk5/p35-mediated phosphorylation of CaV2.2 increased the channel 
open probability Po (Figure 7E, 7F). Importantly, the Cdk5/p35-mediated increase in the WT 
CaV2.2 channel open probability was not observed in 8X CaV2.2.  
 To further determine whether the dramatic increase in CaV2.2 current density impacts 
CaV2.2 surface expression in primary neurons, we cloned the full-length WT CaV2.2 α1 subunit 
or the 8X CaV2.2 α1 subunit cDNA into a bi-cistronic HSV (herpes simplex virus) backbone that 
co-expresses GFP (Neve et al., 2005). In primary neurons, transduction with HSV yields about 
90% GFP-positive cells after 24 hours (Figure 8A). Upon transduction of primary neurons with 
WT CaV2.2 or 8X CaV2.2 HSV, however, there were no alterations in CaV2.2 surface levels 
compared to neurons transduced with control GFP HSV (Figure 8B). Collectively, these data 
suggest that in addition to increased channel availability, Cdk5-mediated phosphorylation of 
CaV2.2 results in increased calcium influx due to enhanced channel open probability. 
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Figure 7. Analysis of surface expression levels and channel open probability after Cdk5-mediated 
phosphorylation of CaV2.2. 
(A) CaV2.2 surface expression levels were not altered by Cdk5-mediated phosphorylation. Left: In the 
stable cell line expressing CaV2.2, CaV2.2 was co-expressed with Cdk5 alone, Cdk5/p35, or Cdk5/p35 and 
a competing C-terminal peptide. Right: Compared to expression of WT CaV2.2 alone, surface levels of 
CaV2.2 protein were unaltered after WT CaV2.2 coexpression with Cdk5/p35, 8X CaV2.2 expression, or 
8X CaV2.2 coexpression with Cdk5/p35.  (B) Quantification was performed across independent 
experiments. Normalized protein levels are shown, with n=3 experiments per condition.  (C) 
Representative traces shown for peak current as a function of test-pulse potential. The Ipeak was calculated 
by dividing the peak current by the cell capacitance to obtain maximal current.  (D) Transient currents 
occur when the cell is brought from its resting potential to the reversal potential (approximately +55 mV). 
The area under the transient current was calculated as Qmax. Scale bars, 0.1 nA, 2 ms.  (E) Gmax (slope of 
the maximal current) was plotted against Qmax, with the ratio established as a measurement of the channel 
open probability.  (F) Quantification of Gmax/Qmax. Cdk5-mediated phosphorylation of WT CaV2.2 
increased channel open probability (Po). Data shown are the values (mean ± SEM) in	  Table 3. Statistical 
significance was calculated using one-way ANOVA (Tukey’s multiple comparison test) (*p < 0.05; **p < 
0.01; ***p < 0.001). 
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Table 3. Values of electrophysiology experiments and protein quantitation found in Figure 7 
 
Measure Condition 
Value  
(mean± 
SEM) 
n 
(cultures) p-value 
Statistical 
test Figure 
Surface 
CaV2.2 
 
CaV2.2 
CaV2.2+Cdk5 
CaV2.2+Cdk5/p35 
CaV2.2+Cdk5/p35/  
      CTpep 
1.00±0.10 
1.01±0.07 
0.97±0.05 
1.01±0.07 
4 (1) 
4 (2) 
4 (3) 
4 (4) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4)  
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA Fig. 7B 
Surface 
CaV2.2 
 
WT CaV2.2 
WT CaV2.2+Cdk5 
8X CaV2.2  
8X CaV2.2+Cdk5/p35 
1.00±0.04 
0.87±0.13 
0.97±0.21 
0.86±0.26 
4 (1) 
4 (2) 
4 (3) 
4 (4) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4)  
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA Fig. 7B 
Slope of 
Gmax/Qmax 
WT CaV2.2 
WT CaV2.2+Cdk5 
8X CaV2.2  
8X CaV2.2+Cdk5/p35 
0.29±0.03 
0.72±0.11 
0.36±0.05 
0.32±0.03 
13 (1) 
17 (2) 
8 (3) 
10 (4) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4)  
<0.05 (2 vs. 3) 
<0.01 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA Fig. 7F 
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Figure 8. HSV-mediated transduction of primary neurons and CaV2.2 surface expression. 
(A) A representative image highlighting the transduction efficiency of HSV in primary hippocampal 
cultures. Almost all neurons (90%) were successfully transduced with the GFP HSV. Scale bar, 100 µm.  
(B) Surface biotinylation assays of primary neurons transduced with GFP, WT CaV2.2, or 8X CaV2.2 
HSV. Expression of WT CaV2.2 or 8X CaV2.2 HSV had no significant effects on CaV2.2 surface levels 
when compared to neurons expressing control GFP HSV. Normalized protein levels are shown, with n=4 
experiments per condition. GFP, 1.00±0.07; WT CaV2.2, 1.01±0.06; 8X CaV2.2, 0.99±0.08; p>0.05. Data 
shown are means ± s.e.m. Statistical significance was calculated using one-way ANOVA (Tukey’s 
multiple comparison test) (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Altered synaptic properties in neurons expressing CaV2.2 
 We predicted that Cdk5-mediated phosphorylation of CaV2.2 might play an important 
physiological role in CaV2.2-mediated neurotransmission. To test this hypothesis, whole-cell 
CaV2.2 currents were isolated in neurons transduced with HSV expressing control GFP, WT 
CaV2.2, or 8X CaV2.2. Consistent with our heterologous cell data, Cdk5-mediated 
phosphorylation of WT CaV2.2, but not 8X CaV2.2, increased neuronal CaV2.2 current density 
when compared to neurons expressing control GFP HSV (Figure 9A, Table 4). Furthermore, 
inhibition of Cdk5 activity using a dominant-negative Cdk5 (DNK5) HSV further reduced 
CaV2.2 current density (Figure 9A), suggesting that Cdk5 is the major kinase responsible for 
CaV2.2 phosphorylation and increased CaV2.2 current density. We also examined if the P/Q-type 
calcium channel (CaV2.1), the other major presynaptic calcium channel in neurons, was affected 
by expression of WT CaV2.2 or 8X CaV2.2 HSV but found no differences in CaV2.1 current 
densities compared to neurons expressing GFP HSV (Figure 10, Table 5). CaV2.1 current 
density was also unaffected by the expression of DNK5 HSV (Figure 10).  
 We next measured miniature postsynaptic currents to determine whether Cdk5-mediated 
phosphorylation of CaV2.2 impacts neurotransmitter release. To obtain miniature excitatory and 
inhibitory postsynaptic currents (mEPSCs and mIPSCs), primary neurons at DIV13-15 were 
transduced with GFP, WT CaV2.2, or 8X CaV2.2 HSV, and recordings were conducted 24-48 hrs 
later. In neurons expressing WT CaV2.2 HSV, compared to those expressing GFP HSV, we 
observed increased frequencies of both mEPSCs and mIPSCs, with no changes in current 
amplitude	   (Figure 9B, 9C). However, neither the miniature frequency nor the amplitude of 
neurons expressing 8X CaV2.2 HSV differed significantly from those of neurons expressing GFP 
HSV	  (Figure 9B, 9C). The increased frequency of the miniature currents strongly suggests that 
Cdk5-mediated phosphorylation of WT CaV2.2 modulates presynaptic function by enhancing 
vesicle release. 
 To explore the effects of expressing CaV2.2 in presynaptic terminals at a higher 
resolution, cultured neurons were transduced with HSV expressing GFP, WT CaV2.2 or 8X 
CaV2.2 and fixed for monolayer electron microscopy. Consistent with the notion that increased 
release probability is related to the size of the readily releasable vesicle pool (Dobrunz and 
Stevens, 1997; Murthy et al., 1997), we found that the number of docked vesicles in the readily 
releasable pool was greater in the presynaptic terminals of neurons transduced with WT CaV2.2, 
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but not 8X CaV2.2, HSV when compared to neurons transduced with GFP HSV (Figure 9D). 
These observations indicate that expression of WT CaV2.2 HSV in primary neurons facilitates 
neurotransmitter release due to an increased number of docked vesicles at the synaptic terminal. 
 In order to examine whether CaV2.2 localization itself might be affected by HSV 
expression, we performed immunocytochemistry and immunogold electron microscopy studies. 
Similar to previous reports (Maximov and Bezprozvanny, 2002), and consistent with the 
increased frequency of mEPSCs and mIPSCs, expression of WT CaV2.2 HSV facilitated the 
synaptic localization of CaV2.2 (Figure 9E).While immunogold-labeled CaV2.2 was associated 
with the presynaptic terminal in neurons expressing GFP HSV, neurons transduced with WT 
CaV2.2 HSV displayed higher co-localization of CaV2.2 to the presynaptic area (Figure 9F). The 
localization effects were not observed in neurons transduced with 8X CaV2.2 HSV, which 
displayed a similar profile to neurons expressing GFP HSV. Therefore, Cdk5-mediated 
phosphorylation of WT CaV2.2 HSV facilitates neurotransmitter release by affecting the number 
of docked vesicles and also by increasing CaV2.2 localization at the synapse.  
 
Interactions between CaV2.2 and active zone proteins are affected by Cdk5 
 To gain additional insight into the molecular mechanisms underlying the effects of Cdk5-
mediated N-type calcium channel phosphorylation on neurotransmitter release, we transduced 
primary hippocampal neurons at DIV13-15 with GFP, WT CaV2.2, or 8X CaV2.2 HSV. The 
associations between CaV2.2 and various presynaptic proteins involved in synaptic vesicle 
scaffolding or fusion were then examined using co-immunoprecipitation and immunoblotting 
after 24-48 hrs in vitro. While the overall protein levels of multiple presynaptic components were 
unaltered, the binding of CaV2.2 to the active zone protein RIM1 was significantly increased in 
neurons transduced with WT CaV2.2 HSV when compared to neurons transduced with GFP HSV 
(Figure 11A, Table 6). Since RIM1 directly binds and tethers both CaV2.1 (P/Q-type) and 
CaV2.2 (N-type) channels to the synaptic cleft to facilitate synchronous neurotransmitter release 
(Kaeser et al., 2011), these results indicate that Cdk5-mediated phosphorylation of CaV2.2 may 
play a role in modulating CaV2.2 and RIM1 binding, thereby affecting vesicle docking and 
neurotransmitter release. We found that acute inhibition of Cdk5 by DNK5 HSV in primary 
neurons reduced the association between CaV2.2 and RIM1, providing further support that Cdk5-
mediated phosphorylation of CaV2.2 regulates its association with RIM1 (Figure 12A, Table 7).  
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Figure 9. Neurotransmitter release impacted by Cdk5-mediated phosphorylation of CaV2.2. 
(A) Current-voltage relationship of neurons expressing GFP, WT CaV2.2, 8X CaV2.2 or DNK5 HSV. 
Compared to CaV2.2-mediated current density in neurons expressing GFP, Cdk5-mediated 
phosphorylation of WT CaV2.2, but not 8X CaV2.2, enhanced CaV2.2 current density. However, 
expression of DNK5 HSV further reduced CaV2.2 current.  (B) Sample traces (left) and quantification 
(right) of the frequency and amplitude of the miniature excitatory postsynaptic currents (mEPSCs). 
Compared to neurons expressing GFP HSV, the frequency of mEPSCs was increased in hippocampal 
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neurons expressing WT CaV2.2 HSV. There were no significant differences in mEPSC amplitudes. Scale 
bars, 10 pA, 2 s.  (C) Sample traces (left) and quantification (right) of the frequency and amplitude of the 
miniature inhibitory postsynaptic currents (mIPSCs). Compared to neurons expressing GFP HSV, the 
frequency of mIPSCs was increased in hippocampal neurons expressing WT CaV2.2 HSV. There were no 
significant differences in mIPSC amplitudes. Scale bars, 10 pA, 2 s.  (D) Electron microscopy images 
from neurons transduced with GFP, WT CaV2.2 or 8X CaV2.2 HSV. Scale bar, 100 nm. Compared to 
neurons expressing GFP HSV, there was an increase in the number of docked vesicles in the presynaptic 
terminal of neurons expressing WT CaV2.2 HSV. There were no significant differences in vesicle 
properties of neurons expressing 8X Cav2.2 HSV when compared to neurons expressing GFP HSV.  (E) 
Approximately 5–7 HSV-transduced neurons (GFP-positive cells from HSV transduction; blue) per 
culture in three independent experiments were used to quantify the relative synaptic localization of 
CaV2.2 (red) by assessing its co-localization with presynaptic marker Synaptophysin (green). Compared 
to neurons expressing GFP HSV, expression of WT CaV2.2 HSV increased the synaptic co-localization of 
CaV2.2 and Synaptophysin. Right: quantification of synaptic levels. Scale bar, 5 µm.  (F) Immunogold 
labeling for primary hippocampal neurons at DIV16 transduced with GFP, WT CaV2.2, or 8X CaV2.2 
HSV. There was increased CaV2.2 localization to the presynaptic terminal in neurons expressing WT 
CaV2.2 HSV when compared to neurons expressing GFP HSV. Scale bar, 100 nm. Right: quantification 
of the immunogold labeling. Data shown are the values (mean ± SEM) in	  Table 4. Statistical significance 
was calculated using one-way ANOVA (Tukey’s multiple comparison test). (*p < 0.05; **p < 0.01; ***p 
< 0.001). 
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Table 4. Values of electrophysiology experiments and electron microscopy found in  
Figure 9 
 
Measure Condition 
Value  
(mean± 
SEM) 
n 
(cells/ 
cultures) 
p-value Statistical test Figure 
CaV2.2 peak 
current density 
(pA/pF) 
GFP 
WT CaV2.2 
8X CaV2.2 
DNK5 
7.70±1.49 
35.41±11.87 
10.91±3.52 
4.55±0.47 
12/4 (1) 
10/3 (2) 
8/3 (3) 
13/4 (4) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
<0.05 (2 vs. 3) 
<0.01 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA Fig. 9A 
mEPSC 
frequency 
(Hz) 
GFP 
WT CaV2.2 
8X CaV2.2 
2.55±0.23 
4.32±0.33 
2.73±0.20 
13/4 (1) 
12/4 (2) 
13/4 (3) 
<0.001 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.001 (2 vs. 3) 
One-way 
ANOVA Fig. 9B 
mEPSC 
amplitude 
(pA) 
GFP 
WT CaV2.2 
8X CaV2.2 
11.23±1.20 
12.21±0.95 
11.26±0.67 
13/4 (1) 
12/4 (2) 
13/4 (3) 
>0.05(1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA Fig. 9B 
mIPSC 
frequency 
(Hz) 
GFP 
WT CaV2.2 
8X CaV2.2 
2.43±0.34 
5.92±082 
2.55±0.26 
12/3 (1) 
14/3 (2) 
13/3 (3) 
<0.001 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.001 (2 vs. 3) 
One-way 
ANOVA Fig. 9C 
mIPSC 
amplitude 
(pA) 
GFP 
WT CaV2.2 
8X CaV2.2 
19.10±1.31 
18.85±1.72 
19.88±1.77 
12/3 (1) 
14/3 (2) 
13/3 (3) 
>0.05(1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA Fig. 9C 
EM  
docked 
vesicles 
GFP 
WT CaV2.2 
8X CaV2.2 
1.90±0.13 
2.72±0.20 
1.94±0.15 
38 (1) 
32 (2) 
37 (3) 
<0.01(1 vs. 2) 
>0.05 (1 vs. 3) 
<0.01 (2 vs. 3) 
One-way 
ANOVA Fig. 9D 
EM recycling 
pool 
GFP 
WT CaV2.2 
8X CaV2.2 
19.50±1.25 
18.34±1.67 
19.26±1.39 
38 (1) 
32 (2) 
37 (3) 
>0.05(1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA Fig. 9D 
EM  
reserve pool 
GFP 
WT CaV2.2 
8X CaV2.2 
58.63±5.67 
54.69±5.48 
56.91±5.94 
38 (1) 
32 (2) 
37 (3) 
>0.05(1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA Fig. 9D 
Relative 
synaptic co-
localization 
GFP 
WT CaV2.2 
8X CaV2.2 
0.54±0.05 
0.89±0.10 
0.49±0.06 
17/3 (1) 
15/3 (2) 
17/3 (3) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.001 (2 vs. 3) 
One-way 
ANOVA Fig. 9E 
Gold particles 
(immunogold 
EM) 
GFP 
WT CaV2.2 
8X CaV2.2 
5.91±0.67 
16.12±1.63 
5.58±0.67 
23 (1) 
42 (2) 
24 (3) 
<0.001 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.001 (2 vs. 3) 
One-way 
ANOVA Fig. 9F 	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Figure 10. Measurement of CaV2.1 current density after CaV2.2 expression in primary neurons. 
Measurement of CaV2.1 (P/Q-type calcium channel) current density in primary neurons transduced with 
GFP, WT CaV2.2, 8X CaV2.2 or DNK5 HSV. There were no significant differences in P/Q-type calcium 
current density. Data shown are means ± s.e.m. in Table 5. Statistical significance was calculated using 
one-way ANOVA (Tukey’s multiple comparison test) (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
 
 
Table 5. Values of electrophysiology experiments found in Figure 10 
 
Measure Condition Value  (mean±SEM) 
n 
(cells/ 
cultures) 
p-value Statistical test Figure 
CaV2.1 peak 
current density 
(pA/pF) 
GFP 
WT CaV2.2 
8X CaV2.2 
DNK5 
10.87±3.25 
8.48±1.42 
10.23±2.30 
8.42±1.27 
15/5 (1) 
13/4 (2) 
12/3 (3) 
19/5 (4) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA Fig. 10 
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Figure 11. Interactions between CaV2.2 and active zone proteins are affected by Cdk5. 
(A) Presynaptic proteins were probed in neurons transduced with GFP, WT CaV2.2 or 8X CaV2.2 HSV. 
Immunoprecipitation with CaV2.2 revealed an increase in the association between CaV2.2 and RIM1 in 
neurons expressing WT CaV2.2 HSV relative to neurons expressing GFP HSV.  (B) Chronic Cdk5 
depletion reduced the association between CaV2.2 and RIM1. The interaction between CaV2.2 and 
Syntaxin1A was also reduced. Normalized protein levels are shown, with n=3 mice per condition.  Data 
shown are the values (mean ± SEM) in Table 6. Statistical significance was calculated using one-way 
ANOVA (Tukey’s multiple comparison test, Bonferroni multiple comparison test) or Student’s t-test (*p 
< 0.05; **p < 0.01; ***p < 0.001). 
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Table 6. Values of protein quantitation found in Figure 11 
 
Measure Condition 
Value  
(mean± 
SEM 
n 
(mice) p-value 
Statistical 
test Figure 
RIM1  
(input) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.20 
1.15±0.01 
1.27±0.09 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
CaV2.2  
(input) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.12 
0.97±0.18 
1.16±0.40 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
Synapto-
tagmin1 
(input) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.14 
1.07±0.12 
1.27±0.36 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
Syntaxin1A 
(input) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.10 
0.99±0.14 
1.01±0.08 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
SNAP25 
(input) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.58 
1.15±0.52 
0.99±0.30 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
Cdk5  
(input) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.11 
1.00±0.03 
1.08±0.16 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
RIM1  
(IP) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.27 
2.17±0.31 
1.03±0.26 
3 (1) 
3 (2) 
3 (3) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
CaV2.2  
(IP) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.33 
1.36±0.54 
1.39±0.14 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
Synapto-
tagmin1  
(IP) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.32 
0.93±0.16 
0.93±0.29 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
Syntaxin1A 
(IP) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.17 
0.94±0.18 
1.17±0.26 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
SNAP25  
(IP) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.00±0.17 
0.90±0.45 
0.96±0.09 
3 (1) 
3 (2) 
3 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
11A 
RIM1  
input 
Control 
Cdk5 cKO 
1.00±0.44 
0.93±0.40 
3  
3  >0.05 
Student’s 
t-test Fig. 11B 
CaV2.2  
(input) 
Control 
Cdk5 cKO 
1.00±0.08 
1.19±0.15 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
Munc-18 
(input) 
Control 
Cdk5 cKO 
1.00±0.07 
1.03±0.14 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
Synapto-
tagmin1 
(input) 
Control 
Cdk5 cKO 
1.00±0.29 
0.98±0.28 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
Syntaxin1A 
(input) 
Control 
Cdk5 cKO 
1.00±0.37 
1.07±0.53 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
Cdk5  Control 1.00±0.15 3 <0.05 One-way Fig. 11B 
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(input) Cdk5 cKO 0.33±0.09 3 ANOVA 
CaV2.2  
(IP) 
Control 
Cdk5 cKO 
1.00±0.48 
1.10±0.49 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
RIM1  
(IP) 
Control 
Cdk5 cKO 
1.00±0.06 
0.47±0.10 
3 
3 <0.05 
Student’s 
t-test Fig. 11B 
Munc18  
(IP) 
Control 
Cdk5 cKO 
1.00±0.23 
0.84±0.22 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
Synapto-
tagmin 1  
(IP) 
Control 
Cdk5 cKO 
1.00±0.27 
1.21±0.60 
3 
3 >0.05 
Student’s 
t-test Fig. 11B 
Syntaxin1A 
(IP) 
Control 
Cdk5 cKO 
1.00±0.12 
0.40±0.12 
3 
3 <0.05 
Student’s 
t-test Fig. 11B 
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Figure 12. CaV2.2 association with RIM1 affected by Cdk5-mediated phosphorylation. 
(A) Compared to neurons transduced with GFP, acute inhibition of Cdk5 using DNK5 HSV in primary 
neurons decreased the association between CaV2.2 and RIM1. Right: quantification of the biochemistry 
experiments.  (B) Diagram highlighting HSV delivery into hippocampal area CA3. Mice were injected 
bilaterally with GFP, WT CaV2.2, or 8X CaV2.2 HSV (or co-injected with WT CaV2.2 and DNK5 HSV or 
8X CaV2.2 and DNK5 HSV) and allowed to recover for 2–3 days. Right: magnification of the injection 
site demonstrating successful transduction of HSV into hippocampal area CA3. Data shown are means ± 
s.e.m. in Table 7. Statistical significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; 
***p < 0.001). 
 
 
 
Table 7. Values of protein quantitation found in Figure 12 
 
Measure Condition 
Value  
(mean± 
SEM) 
n 
(cultures) p-value 
Statistical 
test Figure 
CaV2.2 
(input) 
GFP 
DNK5 
1.00±0.04 
1.05±0.04 
3 
3 >0.05 
Student’s  
t-test Fig. 12A 
RIM1 (input) GFP DNK5 
1.00±0.12 
1.05±0.12 
3 
3 >0.05 
Student’s  
t-test Fig. 12A 
CaV2.2  
(IP) 
GFP 
DNK5 
1.00±0.16 
1.06±0.19 
3 
3 >0.05 
Student’s  
t-test Fig. 12A 
RIM1  
(IP) 
GFP 
DNK5 
1.00±0.03 
0.65±0.04 
3 
3 <0.05 
Student’s  
t-test Fig. 12A 
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Furthermore, in brain lysates from control and Cdk5 cKO mice, chronic Cdk5 depletion reduced 
the binding of CaV2.2 to RIM1, indicating that Cdk5 is necessary for maintaining the association 
between CaV2.2 and RIM1 (Figure 11B). We observed that CaV2.2 binding to Syntaxin1A in 
Cdk5 cKO lysates was also reduced. These data demonstrate that Cdk5-mediated 
phosphorylation of CaV2.2 is required for its interaction with RIM1 and other SNARE proteins.  
 
CaV2.2 phosphorylation by Cdk5 affects basal synaptic transmission and alters paired-
pulse facilitation 
 Because Cdk5-mediated phosphorylation of CaV2.2 enhances miniature excitatory and 
inhibitory postsynaptic currents by modulating presynaptic release probability, we reasoned that 
synaptic plasticity is also affected. To address this hypothesis, we performed stereotaxic delivery 
of GFP, WT CaV2.2, or 8X CaV2.2 HSV into hippocampal area CA3 (Figure 12B). In an 
separate set of experiments, WT CaV2.2 or 8X CaV2.2 HSV was coinjected with DNK5 HSV, 
and the results were compared to those from injection of WT CaV2.2 or 8X CaV2.2 HSV alone. 
Acute transverse hippocampal slices were prepared to assess various forms of synaptic plasticity. 
We stimulated the Schaffer collateral/commissural pathway fibers, and field recordings were 
obtained from the dendritic region of hippocampal area CA1.  
 In contrast to slices expressing control GFP HSV, we discovered a significant 
enhancement of basal synaptic transmission in slices transduced with WT CaV2.2 HSV. This 
enhancement of basal synaptic transmission was not present in slices expressing 8X CaV2.2 HSV 
(Figure 13A, Table 8). Furthermore, the enhanced basal synaptic transmission observed in slices 
expressing WT CaV2.2 HSV alone was abolished in the presence of DNK5 HSV (Figure 14A, 
Table 9). We next examined paired-pulse facilitation (PPF), a form of short-term synaptic 
plasticity that predicts release probability (Zucker and Regehr, 2002). Strikingly, the PPF ratios 
calculated at multiple intervals were significantly lower in slices expressing WT CaV2.2 HSV 
than in those expressing GFP HSV. The PPF ratios were not significantly different between 
slices expressing GFP HSV and 8X CaV2.2 HSV (Figure 13B). However, the reduction in PPF 
ratio observed in slices expressing WT CaV2.2 HSV alone was absent in slices co-expressing WT 
CaV2.2 and DNK5 HSV (Figure 14B). The results are consistent with the hypothesis that 
neurons transduced with WT CaV2.2 HSV have a higher release probability and indicate that the 
enhancement of synaptic transmission relies on the activity of Cdk5. 
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Figure 13. Synaptic plasticity measurements after expression of Cav2.2 HSV in hippocampus.  
(A) Representative traces and quantification of the input/output curve in acute hippocampal slices 
transduced in area CA3 with GFP, WT Cav2.2, or 8X Cav2.2 HSV. Compared to slices expressing control 
GFP HSV, slices expressing WT Cav2.2 HSV exhibited enhanced basal synaptic transmission in the 
Schaffer collateral pathway. Scale bars, 0.5 mV, 10 ms. Right: quantification of the input/output curve.  
(B) Representative traces and quantification of the paired-pulse facilitation (PPF) response in acute 
hippocampal slices transduced in area CA3 with GFP, WT Cav2.2, or 8X Cav2.2 HSV. Scale bars, 0.5 
mV, 25 ms. Compared to slices expressing GFP HSV, slices expressing WT CaV2.2 exhibited 
significantly lower paired-pulse facilitation (PPF) ratios. Scale bars, 0.5 mV, 25 ms. Right: quantification 
of the PPF ratio at various stimuli.  (C) Representative traces and quantification of short-term facilitation 
during the 100 Hz stimulus at 0.5 mM [Ca2+]o. Slices expressing WT CaV2.2 HSV exhibited an overall 
reduction in synaptic facilitation during the 100 Hz stimulus train when compared to slices expressing 
GFP HSV. Scale bars, 0.5 mV, 10 ms. Right: quantification of the short-term plasticity at various stimuli.  
(D) Representative traces and quantification before and after HFS induction. Compared to hippocampal 
slices expressing GFP HSV, the fEPSP slope was markedly decreased in slices expressing WT CaV2.2 
HSV. In all plasticity measurements, there were no significant differences in synaptic properties between 
slices expressing GFP HSV alone and 8X Cav2.2 HSV. Scale bars, 0.5 mV, 10 ms. Right: quantification 
of the fEPSP slope immediately after HFS (5 min) and at the end of the 30 min period. Data shown are 
the values (mean ± SEM) in	  Table 8. Statistical significance was calculated using one-way ANOVA (t-
test) (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Table 8. Values of electrophysiology experiments found in Figure 13 
 
Measure Condition 
Value  
(mean±  
SEM) 
n 
(slices/ 
mice) 
p-value Statistical test Figure 
Input/output 
(0.1 mA) 
GFP 
WT CaV2.2 
8X CaV2.2 
42.93±11.71 
61.56±17.47 
37.96±11.38 
11/6 (1) 
11/6 (2) 
11/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13A 
Input/output 
(0.2 mA) 
GFP 
WT CaV2.2 
8X CaV2.2 
103.39±19.59 
175.82±37.18 
100.49±16.30 
11/6 (1) 
11/6 (2) 
11/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13A 
Input/output 
(0.3 mA) 
GFP 
WT CaV2.2 
8X CaV2.2 
150.61±19.18 
252.59±27.04 
187.61±29.79 
11/6 (1) 
11/6 (2) 
11/5 (3) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13A 
Input/output 
(0.5 mA) 
GFP 
WT CaV2.2 
8X CaV2.2 
270.11±32.86 
371.41±42.29 
293.26±51.52 
11/6 (1) 
11/6 (2) 
11/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13A 
Input/output 
(0.7 mA) 
GFP 
WT CaV2.2 
8X CaV2.2 
367.67±34.38 
497.00±37.93 
370.02±60.47 
11/6 (1) 
11/6 (2) 
11/5 (3) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13A 
Input/output 
(1 mA) 
GFP 
WT CaV2.2 
8X CaV2.2 
447.33±33.88 
586.82±51.40 
424.77±70.20 
11/6 (1) 
11/6 (2) 
11/5 (3) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13A 
PPF ratio 
(20 ms) 
GFP 
WT CaV2.2 
8X CaV2.2 
2.40±0.20 
1.44±0.13 
2.65±0.40 
11/6 (1) 
11/6 (2) 
11/5 (3) 
<0.001 (1 vs. 
2) 
>0.05 (1 vs. 3) 
<0.01 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13B 
PPF ratio 
(40 ms) 
GFP 
WT CaV2.2 
8X CaV2.2 
2.03±0.20 
1.25±0.07 
2.22±0.27 
11/6 (1) 
11/6 (2) 
11/5 (3) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.01 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13B 
PPF ratio 
(80 ms) 
GFP 
WT CaV2.2 
8X CaV2.2 
1.56±0.14 
1.14±0.04 
1.65±0.14 
11/6 (1) 
11/6 (2) 
11/5 (3) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.01 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13B 
STP 
100 Hz 
Stim. 2 
GFP 
WT CaV2.2 
8X CaV2.2 
5.04±0.88 
4.64±0.84 
5.19±1.21 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
Stim. 3 
GFP 
WT CaV2.2 
8X CaV2.2 
7.85±1.52 
5.37±0.74 
7.01±1.15 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
Stim. 4 
GFP 
WT CaV2.2 
8X CaV2.2 
5.26±1.00 
3.03±0.40 
5.45±0.96 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
Stim. 5 
GFP 
WT CaV2.2 
8X CaV2.2 
3.85±0.73 
2.15±0.27 
4.37±0.79 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
Stim. 6 
GFP 
WT CaV2.2 
8X CaV2.2 
3.11±0.58 
1.92±0.19 
4.03±0.68 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
GFP 
WT CaV2.2 
2.70±0.54 
1.59±0.15 
9/5 (1) 
13/5 (2) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
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Stim. 7 8X CaV2.2 3.43±0.56 9/5 (3) <0.05 (2 vs. 3) 
STP 
100 Hz 
Stim. 8 
GFP 
WT CaV2.2 
8X CaV2.2 
2.44±0.44 
1.37±0.13 
3.15±0.50 
9/5 (1) 
13/5 (2) 
9/5 (3) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.01 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
Stim. 9 
GFP 
WT CaV2.2 
8X CaV2.2 
2.17±0.40 
1.26±0.12 
2.85±0.49 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
STP 
100 Hz 
Stim. 10 
GFP 
WT CaV2.2 
8X CaV2.2 
2.01±0.50 
1.08±0.14 
2.67±0.47 
9/5 (1) 
13/5 (2) 
9/5 (3) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.01 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13C 
fEPSP slope 
(first 5 min) 
GFP 
WT CaV2.2 
8X CaV2.2 
256.98±26.13 
166.80±13.42 
300.52±49.54 
8/5 (1) 
10/5 (2) 
9/4 (3) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13D 
fEPSP slope 
(last 5 min) 
GFP 
WT CaV2.2 
8X CaV2.2 
123.38±3.39 
104.10±4.03 
126.31±8.11 
8/5 (1) 
10/5 (2) 
9/4 (3) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (2 vs. 3) 
One-way 
ANOVA 
Fig. 
13D 	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Figure 14. Synaptic plasticity measurements after co-expression of Cav2.2 and DNK5 HSV in 
hippocampus.  
(A) Representative traces of the input/output curves in hippocampal slices transduced with WT Cav2.2, 
WT Cav2.2 and DNK5, 8X Cav2.2, or 8X Cav2.2 and DNK5 HSV. The enhanced basal synaptic 
transmission in slices expressing WT Cav2.2 HSV alone is abolished in the presence of DNK5 HSV. 
Scale bars, 0.5 mV, 10 ms. Right: quantification of the input/output curve.  (B) Representative traces of 
the paired-pulse facilitation (PPF) response in hippocampal slices expressing WT Cav2.2, WT Cav2.2 and 
DNK5, 8X Cav2.2 or 8X Cav2.2 and DNK5 HSV. The decreased paired-pulse facilitation (PPF) ratio 
observed with the expression of WT Cav2.2 HSV alone is absent in slices co-expressing WT Cav2.2 and 
DNK5 HSV. Scale bars, 0.5 mV, 25 ms. Right: quantification of the PPF ratios at various stimulus 
intensities.  (C) Representative traces and quantification of short-term facilitation during the 100 Hz 
stimulus at 0.5 mM [Ca2+]o. While hippocampal slices transduced with WT CaV2.2 HSV alone exhibited a 
significant reduction in synaptic facilitation during the 100 Hz stimulus train, the reduction in synaptic 
facilitation was not present in slices co-expressing WT CaV2.2 and DNK5 HSV. Scale bars, 0.5 mV, 10 
ms. Right: quantification of the short-term plasticity at various stimuli.  (D) Representative traces and 
quantification before and after HFS induction. In contrast to the markedly decreased fEPSP slope after 
expression of WT CaV2.2 HSV alone in hippocampal area CA3, there were no alterations in synaptic 
plasticity after co-injection of WT CaV2.2 and DNK5 HSV into hippocampal area CA3. In all 
experiments, there were no significant differences in plasticity measurements between slices expressing 
8X CaV2.2 HSV alone and slices co-expressing 8X CaV2.2 and DNK5 HSV. Scale bars, 0.5 mV, 5 ms. 
Right: quantification of the fEPSP slope immediately following HFS (5 min) and at the end of the 30 min 
period. Data shown are means ± s.e.m. in Table 9. Statistical significance was calculated using one-way 
ANOVA (t-test) (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Table 9. Values of electrophysiology experiments found in Figure 14 
 
Measure Condition 
Value  
(mean±  
SEM) 
n 
(slices/ 
mice) 
p-value Statistical test Figure 
Input/ 
output 
(0.1 mA) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
27.93±10.32 
53.72±17.12 
30.87±6.04 
44.88±7.00 
7/4 (1) 
7/4 (2) 
6/3 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14A 
Input/ 
output 
(0.2 mA) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
219.89±18.03 
175.70±19.80 
127.80±21.09 
181.76±21.35 
7/4 (1) 
7/4 (2) 
6/3 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
<0.01 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14A 
Input/ 
output 
(0.3 mA) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
345.47±39.68 
236.37±31.47 
214.69±22.51 
262.56±23.63 
7/4 (1) 
7/4 (2) 
6/3 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14A 
Input/ 
output 
(0.5 mA) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
547.59±62.87 
392.30±63.23 
323.20±46.24 
417.45±39.84 
7/4 (1) 
7/4 (2) 
6/3 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14A 
Input/ 
output 
(0.7 mA) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
681.72±62.38 
459.37±74.44 
432.72±57.82 
477.11±55.85 
7/4 (1) 
7/4 (2) 
6/3 (3) 
9/4 (4) 
<0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14A 
Input/ 
output 
(1 mA) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
839.40±102.2
0 
550.57±71.87 
559.80±82.26 
556.93±67.74 
7/4 (1) 
7/4 (2) 
6/3 (3) 
9/4 (4) 
<0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14A 
PPF ratio 
(20 ms) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.57±0.09 
1.97±0.11 
2.37±0.22 
2.24±0.14 
7/4 (1) 
7/4 (2) 
8/4 (3) 
10/4 
(4) 
<0.05 (1 vs. 2) 
<0.01 (1 vs. 3) 
<0.001 (1 vs. 
4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14B 
PPF ratio WT CaV2.2 1.46±0.07 7/4 (1) <0.05 (1 vs. 2) One-way Fig.  
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(40 ms) WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.90±0.15 
2.07±0.17 
1.88±0.09 
7/4 (2) 
8/4 (3) 
10/4 
(4) 
<0.01 (1 vs. 3) 
<0.01 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
ANOVA 14B 
PPF ratio 
(80 ms) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.34±0.07 
1.57±0.07 
1.69±0.05 
1.55±0.05 
7/4 (1) 
7/4 (2) 
8/4 (3) 
10/4 
(4) 
<0.05 (1 vs. 2) 
<0.01 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14B 
STP 
100 Hz 
Stim. 2 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
3.99±0.52 
5.53±0.38 
5.97±0.64 
4.68±0.34 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 3 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
4.72±0.77 
6.62±0.79 
6.94±0.96 
5.42±0.26 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 4 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
3.26±0.54 
4.29±0.65 
5.23±0.74 
4.27±0.29 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
>0.05 (1 vs. 2) 
>0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 5 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
2.22±0.34 
3.23±0.30 
3.79±0.47 
3.17±0.23 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
<0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
>0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 6 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.60±0.30 
2.64±0.21 
3.06±0.46 
2.55±.013 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
<0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 7 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.37±0.18 
2.42±0.18 
2.38±0.36 
2.02±0.18 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
<0.01 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 8 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
1.11±0.11 
2.19±0.20 
2.40±0.53 
7/4 (1) 
5/3 (2) 
8/4 (3) 
<0.01 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.01 (1 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
	   133 
8X CaV2.2+DNK5 2.00±0.19 9/4 (4) >0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
STP 
100 Hz 
Stim. 9 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.04±0.14 
1.71±0.19 
2.37±0.51 
1.69±0.14 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
<0.05 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.01 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
STP 
100 Hz 
Stim. 10 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
1.02±0.08 
1.57±0.12 
1.88±0.42 
1.59±0.17 
7/4 (1) 
5/3 (2) 
8/4 (3) 
9/4 (4) 
<0.01 (1 vs. 2) 
>0.05 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig.  
14C 
fEPSP 
slope  
(first  
5 min) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
210.60±19.40 
301.66±32.89 
360.04±34.49 
315.30±33.27 
10/5 
(1) 
8/5 (2) 
10/5 
(3) 
12/5 
(4) 
<0.05 (1 vs. 2) 
<0.01 (1 vs. 3) 
<0.05 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14D  
fEPSP 
slope  
(last  
5 min) 
WT CaV2.2 
WT CaV2.2+DNK5 
8X CaV2.2 
8X CaV2.2+DNK5 
104.80±6.93 
131.91±5.07 
141.85±11.38 
132.62±6.87 
10/5 
(1) 
8/5 (2) 
10/5 
(3) 
12/5 
(4) 
<0.01 (1 vs. 2) 
<0.05 (1 vs. 3) 
<0.01 (1 vs. 4) 
>0.05 (2 vs. 3) 
>0.05 (2 vs. 4) 
>0.05 (3 vs. 4) 
One-way 
ANOVA 
Fig. 
14D  
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Cdk5-mediated phosphorylation of N-type calcium channels impacts presynaptic plasticity 
 To explore whether Cdk5-mediated phosphorylation of CaV2.2 affects synaptic 
facilitation, another form of presynaptic plasticity, we applied different stimulus trains to the 
Schaffer collateral pathway. Synaptic facilitation did not differ between slices expressing GFP 
and 8X CaV2.2 HSV. As predicted for neurons with lower PPF, and therefore a higher release 
probability, slices expressing WT CaV2.2 HSV exhibited a reduction in transient facilitation 
elicited during the stimulation (100 Hz at 0.5 mM [Ca2+]o) (Figure 13C). Moreover, the 
facilitation in slices expressing WT CaV2.2 HSV alone was absent when DNK5 HSV was co-
expressed with WT CaV2.2 HSV, demonstrating the requirement of Cdk5 activity for CaV2.2-
mediated synaptic facilitation (Figure 14C). 
 We next examined short-term synaptic plasticity elicited by high-frequency stimuli 
(HFS). Compared to slices transduced with GFP HSV, there was a strong reduction in the initial 
fEPSP slope following HFS in slices transduced with WT CaV2.2 HSV (Figure 13D). There 
were no differences in initial fEPSP slope between slices expressing GFP and 8X CaV2.2 HSV. 
Early-phase long-term potentiation (LTP), measured at 30 min post-stimulation, was also 
considerably reduced in slices expressing WT CaV2.2 HSV when compared to slices expressing 
GFP HSV (Figure 13D). However, the altered plasticity in slices expressing WT CaV2.2 HSV 
alone was not observed with co-expression of DNK5 HSV (Figure 14D). In all experiments, 
there were no significant differences in plasticity measurements between slices expressing 8X 
CaV2.2 HSV alone and slices co-expressing 8X CaV2.2 and DNK5 HSV (Figure 14A-D). 
Collectively, these results demonstrate that Cdk5-mediated phosphorylation of WT CaV2.2 
increases basal synaptic transmission and enhances presynaptic release probability, which in turn 
decreases synaptic facilitation and early-phase LTP. 
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Discussion 
 Here we demonstrated that the N-type calcium channel (CaV2.2) is a Cdk5 substrate. 
Phosphorylation of CaV2.2 by Cdk5 significantly increased calcium current density and channel 
open probability. We further showed that the interaction between CaV2.2 and RIM1 was 
modulated by Cdk5, which provided a molecular mechanism for the increased number of docked 
vesicles at the presynaptic terminal in neurons expressing CaV2.2. We also found presynaptic 
alterations in plasticity associated with Cdk5-mediated phosphorylation of CaV2.2 that included 
enhanced basal synaptic transmission, enhanced presynaptic release probability, and an overall 
reduction in short-term facilitation. Importantly, these effects were not observed with the Cdk5 
phosphorylation mutant 8X CaV2.2, either alone or in the presence of Cdk5. Taken together, 
these studies demonstrate a pivotal role for Cdk5-mediated post-translational modifications of 
the N-type calcium channel in regulating presynaptic function, and highlight the close interaction 
between kinases and calcium channels in neurons. 
 
Protein kinases that impact calcium channel function 
 While this study is the first to show that CaV2.2 is a Cdk5 substrate, previous work has 
implicated several kinases in the modulation of voltage-gated calcium channels (Bannister et al., 
2005). The calcium-calmodulin kinase II (CaMKII) interacts with the P/Q-type calcium channel 
to facilitate transmitter release (Jiang et al., 2008), and the glycogen synthase kinase (GSK3β) 
phosphorylates the P/Q-type calcium channel in the intracellular II-III loop (Zhu et al., 2010) to 
inhibit vesicle exocytosis by disrupting SNARE complex formation. Other kinases that target 
CaV2.2 include protein kinases A and C (PKA and PKC), and both PKA- and PKC-mediated 
phosphorylation of CaV2.2 inhibit CaV2.2 interaction with SNARE complexes (Yokoyama et al., 
1997). PKC-mediated phosphorylation of CaV2.2 also enhances N-type calcium current by 
reducing the G-protein inhibition of CaV2.2 (Swartz et al., 1993). Furthermore, PKC 
phosphorylation of CaV2.2 in the I-II linker region reduces the inhibitory effect of the Gβγ 
subunits on CaV2.2 (Zamponi et al., 1997). Notably, the CaV2.2 N-terminus, together with the I-
II region, plays a fundamental role in	   modulating	   Gβγ	   inhibition	   (Agler et al., 2005). 
Altogether, these results provide a complex representation of signaling pathways involving 
kinases, second messengers such as Gβγ subunits, and synaptic release machinery such as 
SNARE proteins leading up to neurotransmitter release.  
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 Pharmacological inhibition of Cdk5 using roscovitine was previously used to examine 
calcium channel function (Tomizawa et al., 2002). However, in addition to inhibiting Cdk5, 
roscovitine is an inhibitor of cyclin-dependent kinases 1, 2, 5, and 7 (Bach et al., 2005) and also 
acts directly on calcium channels by binding to the extracellular domain of L-type calcium 
channels (Yarotskyy and Elmslie, 2007). Furthermore, extracellular roscovitine application 
potentiates (P/Q-type) CaV2.1-mediated neurotransmitter release to slow deactivation kinetics 
(Yan et al., 2002) and increase the inactivation of CaV2.2 (Buraei et al., 2005). This may account 
for the differences observed between our study and a previous study demonstrating fEPSP 
enhancement following roscovitine application on hippocampal slices, which preferentially 
affected P/Q-type calcium channels (Tomizawa et al., 2002). Therefore, in our efforts to 
understand how CaV2.2 is regulated at the presynaptic terminal, we examined the regulation of 
CaV2.2 in the context of endogenous Cdk5 activity in neurons and inhibited Cdk5 with a 
dominant-negative Cdk5 virus rather than using roscovitine. 
 
Regulation of protein-protein interactions and presynaptic plasticity by Cdk5 
  Our findings also revealed a role for Cdk5-mediated phosphorylation of CaV2.2 in 
modulating the interactions of CaV2.2 with various active zone proteins, including RIM1, to 
regulate neurotransmission and presynaptic plasticity. It was previously reported that RIM1 
binds the auxiliary β subunit of both N-type and P/Q-type calcium channels to facilitate calcium 
influx and tether vesicles to the presynaptic terminal (Kiyonaka et al., 2007). Intriguingly, RIM1 
also further reduces the G-protein-mediated inhibition of CaV2.2, which subsequently contributes 
to a prolonged increase in calcium influx (Weiss et al., 2011). As RIM1 is required for calcium 
channel density and vesicle docking at the active zone of calyx of Held synapses and central 
synapses (Han et al., 2011; Kaeser et al., 2011), our results are consistent with the notion that the 
CaV2.2 interaction with RIM1 allows for coordinated transmitter release, and we propose that 
this interaction is regulated in part by Cdk5-mediated phosphorylation of CaV2.2.  
 CaV2.2 and RIM1 are both closely associated with other active zone proteins and SNARE 
complexes. In this study, we examined the binding of CaV2.2 to a number of presynaptic 
proteins, and showed that RIM binding increased in neurons expressing WT CaV2.2 HSV. 
Several groups previously reported a direct interaction between RIM1, or the RIM1 binding 
protein (RIMBP), and CaV2.2 (Coppola et al., 2001; Hibino et al., 2002; Kaeser et al., 2011). 
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However, our results differ from other reports that RIM1 does not bind CaV2.2, even though both 
localize to the presynaptic terminal (Khanna et al., 2006; Khanna et al., 2007b). A possible 
explanation might be the previous use of an antibody targeting the synprint region of chicken 
CaV2.2 (Li et al., 2004), even though one study was conducted on rat brain preparations (Khanna 
et al., 2007a). The chicken synprint region shares only about 59% homology to the mouse and rat 
synprint regions, which share 88% homology with each other. Therefore, the different antibodies 
that were used might explain the discrepancies between our findings and those published 
previously. 
 Although we did not observe a decrease in CaV2.2 binding to Syntaxin1A in primary 
neurons, in contrast to our Cdk5 cKO samples, we hypothesize that acute manipulations differ 
from chronic Cdk5 knockdown in vivo, which may in turn directly or indirectly affect the 
interaction of CaV2.2 with various SNARE proteins to alter neurotransmission. We also cannot 
exclude the possibility that other kinases, such as PKA, may phosphorylate CaV2.2 at similar 
residues and promote similar functions. It is also possible that the β or the α2δ auxiliary 
subunits, which also modulate calcium channel function and have previously been shown to be 
regulated by phosphorylation (Viard et al., 2004), are additional Cdk5 substrates that can modify 
CaV2.2 and SNARE protein interactions. 
 We demonstrated that Cdk5 impacts CaV2.2 channel availability and channel open 
probability. It will be intriguing to further elucidate how Cdk5-mediated phosphorylation of 
CaV2.2 may result in conformational alterations between the α1 subunit and other channel 
subunits, or potentially with the pore-forming domain, to influence channel gating properties. In 
line with previous reports, overexpression of CaV2.2 did not affect the CaV2.1 (P/Q-type calcium 
channel) current (Cao and Tsien, 2010). However, in our study, acute slices expressing WT 
CaV2.2 HSV exhibited decreased PPF, which is in agreement with some previous findings 
(Ahmed and Siegelbaum, 2009), but in contrast to others where no alterations in PPF were 
observed (Cao and Tsien, 2010). This may be due to differences in Schaffer collateral field 
recordings versus single-cell recordings of dissociated hippocampal neurons. Thus, in future 
studies it will be important to further probe how Cdk5-mediated phosphorylation of CaV2.2 
affects its contribution to excitatory postsynaptic currents. As Cdk5 and CaV2.2 are present in 
GABAergic interneurons (Poncer et al., 1997; Rakic et al., 2009), it would also be interesting to 
determine whether Cdk5 differentially affects excitatory and inhibitory neurotransmission. 
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The role of Cdk5 in homeostatic mechanisms 
 Combined with previous studies, our data suggest that both CaV2.2 and Cdk5 mediate 
presynaptic plasticity by regulating neurotransmitter release. Recent literature suggests that Cdk5 
is a central regulator of synaptic homeostasis. Cdk5 activity is required for the downregulation of 
heightened synaptic activity via phosphorylation of the postsynaptic protein SPAR. This priming 
effect allows polo-like kinase 2 to promote the degradation of SPAR during homeostatic scaling 
(Seeburg et al., 2008). Cdk5 also serves as a control point for neurotransmission, as inhibition of 
Cdk5 activity by roscovitine results in access to the resting synaptic vesicle pool (Kim and Ryan, 
2010). Furthermore, Cdk5 activity is critical for the presynaptic adaptation of hippocampal CA3 
recurrent circuitry under chronic inactivity, as it mediates reduced connectivity after silencing 
synapses but enhances synaptic strength of the remaining connections	   (Mitra et al., 2011). 
Precisely how Cdk5 levels, and Cdk5/p35 activity, are regulated under physiological or 
excitotoxic conditions to impart its action on CaV2.2 in specific cell populations remains an 
exciting topic for future work, which may also reveal additional CaV2.2 binding partners as well 
as Cdk5 substrates that play a vital role in synaptic homeostasis.  
 In summary, our data demonstrate a previously uncharacterized interaction between 
CaV2.2 and Cdk5 that results in a Cdk5-mediated increase in CaV2.2 current density, channel 
open probability, and altered CaV2.2 interaction with the active zone protein RIM1 to ultimately 
affect neurotransmission and plasticity by promoting vesicle docking and release. These findings 
provide a framework to examine how CaV2.2 is regulated in the context of endogenous Cdk5 
activity. Given the significant implications of Cdk5 in synaptic homeostasis, a compelling 
question is how post-translational modifications of CaV2.2 impact its interactions with other key 
presynaptic proteins involved in vesicle docking, neurotransmission, and plasticity. 
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Chapter 4 
 
 
Cdk5-mediated phosphorylation of Shank3 impacts dendritic spine morphology and 
 synaptic plasticity 
 
 
 
Summary 
 The postsynaptic scaffolding protein Shank3 is involved in excitatory transmission and 
has been implicated in autism spectrum disorders. Shank3 is present in postsynaptic densities of 
dendritic spines, where it promotes synapse formation and anchors various glutamate receptors 
to the synaptic cleft. Although Shank3 mutations are associated with autism spectrum disorders, 
how Shank3 is regulated by post-translational modifications remains unclear. Here we 
demonstrate Shank3 is a cyclin-dependent kinase (Cdk5) substrate and identified the key 
phosphorylation site as Serine 985. Using a molecular replacement strategy in primary neurons, 
we examined dendritic spine formation and synaptic plasticity after knockdown of endogenous 
Shank3 levels while simultaneously overexpressing a Shank3 S985A phosphorylation mutant. 
Our results suggest that Cdk5-mediated phosphorylation of Shank3 is important for maintenance 
of mature dendritic spines and is integral to facilitating synaptic plasticity, and provide insight to 
the regulation of the Shank3 protein by Cdk5. 
 
 
 
 
 
 
______________________ 
I prepared samples for the phosphoproteomic screen, cloned Shank3 fragments into GST constructs, 
conducted the kinase assays, generated full-length Shank3 phosphorylation mutants, screened the 
shRNAs in heterologous cells, cloned Shank3 shRNA-resistant constructs, cloned the Shank3 constructs 
into viral vectors, cultured primary neurons, analyzed data after transducing neurons with virus, 
conducted biochemical experiments, and performed the stereotaxic injections. 
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Introduction 
 Autism spectrum disorders are thought to arise from a combination of genetic and 
environmental factors, which in turn contribute to the proper development and maturation of 
synaptic connections in the developing brain (Geschwind and Levitt, 2007). Moreover, an 
imbalance between excitatory and inhibitory transmission has been implicated in social 
interaction deficits in animal models (Han et al., 2012). Excitatory synapses are identified by 
their presynaptic terminals opposite a prominent, postsynaptic dendritic spine. The postsynaptic 
density of the dendritic spine is comprised of an abundant set of proteins that form tight 
multimeric complexes to mediate synaptic transmission (Kim and Sheng, 2004). Scaffolding 
molecules such as PSD-95, GRIP, and Homer anchor NMDA, AMPA, and metabotropic 
glutamate receptors to the surface of the dendritic spine to mediate synapse maturation and 
transmission (Brakeman et al., 1997; Dong et al., 1997; Kim et al., 1995).  
 Shank3 is part of a family of large, multi-domain scaffolding proteins that include 
Shank1 and Shank2, and they are highly homologous to each other and similar in structure 
(Naisbitt et al., 1999; Tu et al., 1999). Enriched in the synapse, Shank3 is regulated by multiple 
pathways, including dimerization and ubiquitination (Bangash et al., 2011; Hayashi et al., 2009) 
and participates in dendritic spine formation (Roussignol et al., 2005). However, other forms of 
post-translational modifications on Shank3 are not well-studied. Recent studies have linked de 
novo mutations in the SHANK3 and SHANK2 genes to autism spectrum disorders (Berkel et al., 
2010; Durand et al., 2007). Intriguingly, Shank3 has also been associated with other psychiatric 
disorders including childhood schizophrenia (Gauthier et al., 2010). Different Shank3 knockout 
mouse models display a range of alterations including a reduction in the synaptic glutamate 
receptors (Wang et al., 2011), deficits in hippocampal long-term potentiation (Bozdagi et al., 
2010) or striatal transmission (Peca et al., 2011), alterations in ultrasonic vocalization (Bozdagi 
et al., 2010), anxiety phenotypes (Peca et al., 2011), cognitive deficits (Wang et al., 2011), and 
deficits in social interaction (Peca et al., 2011). Additionally, Shank2 knockout mice exhibit 
hyperactivity, reduced dendritic spines, and deficits in LTP and cognition (Schmeisser et al., 
2012; Won et al., 2012). Interestingly, however, Shank1 knockout mice exhibit smaller dendritic 
spines and reduced postsynaptic protein composition, but have enhanced spatial memory (Hung 
et al., 2008). Despite the availability of multiple mouse models, the regulation of Shank3 by 
post-translational modifications such as phosphorylation has not yet been explored.  
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 The proline-directed serine/threonine kinase cyclin-dependent kinase 5 (Cdk5) is a key 
mediator in various aspects of neuronal function including cortical layering, axon guidance, and 
neuropathic pain. Multiple studies have identified Cdk5 as a regulator of synapse formation (Li 
et al., 2001; Lin et al., 2005; Samuels et al., 2007), synaptic transmission (Guan et al., 2011; Li et 
al., 2001), and homeostatic plasticity (Mitra et al., 2012; Seeburg et al., 2008). At the presynaptic 
terminal, Cdk5 plays a role in vesicle endocytosis (Tomizawa et al., 2003) and vesicle recycling 
pool to modulate neurotransmitter release (Kim and Ryan, 2010). At the postsynaptic density, 
Cdk5 has previously been demonstrated to regulate PSD-95 and NMDA receptor surface levels 
(Morabito et al., 2004; Zhang et al., 2008). Cdk5 requires its regulatory subunit, p35, for 
function; upon dysregulation and neurotoxic insults, p35 is cleaved to p25 to promote Cdk5 
hyperactivity and subsequently disrupt cellular function and impair cognition (Cruz et al., 2003; 
Lee et al., 2000; Patrick et al., 1999). The collective studies underscore how Cdk5 is tightly 
regulated in the nervous system through its association with p35 and p25 under physiological and 
neurotoxic conditions. 
 In this study, we provide evidence that Shank3, a major postsynaptic scaffolding protein, 
is a Cdk5 substrate. Phosphorylation of Shank3 was mapped to a key residue at S985. 
Overexpression of the Shank3 S985A phosphorylation mutant in primary neurons resulted in a 
striking phenotype resembling acute knockdown of Shank3 that was partially reversed by 
overexpression of wild-type full-length Shank3. Synaptic plasticity experiments revealed a 
reduction in LTP after Shank3 knockdown, whereas overexpression of wild-type – and, 
unexpectedly, the S985A phosphorylation mutant – were able to restore LTP to control levels. 
Our collective results suggest that Shank3 phosphorylation by Cdk5 plays an important 
component in the maintenance of mature dendritic spines to ultimately affect synaptic plasticity. 
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Methods 
Constructs  
 The rat Shank3 cDNA corresponding to GenBank accession number NM_021676 was a 
kind gift from Dr. Morgan Sheng (Genentech, USA) and cloned into GST-Shank3 fusion 
constructs using the pGEX4T2 vector (Phusion, NEB). The GST fragments were subdivided into 
the ankyrin (aa 1-400), SH3 (aa 401-540), PDZ (aa 541-667), proline-rich region (five 
fragments: aa 660-860, 861-1000, 1001-1147, 1148-1300, 1301-1500, 1301-1680), and SAM (aa 
1600-1741) domains. Mutagenesis was conducted using QuickChange Lightning Kit 
(Stratagene) and verified by sequencing.  
 To generate GST fusion proteins, constructs were transformed into BL21 competent 
cells. After adding 0.2 mM IPTG to the growth medium to induce protein expression, cells were 
harvested by centrifugation, resuspended in TNT buffer (100 mM Tris-HCl [pH 8], 150 mM 
NaCl, 5 mM EDTA, 0.05% Tween-20), sonicated, and bound to Glutathione Sepharose 4B beads 
(Amersham Biosciences). The protein complex was loaded onto a chromatography column (Bio-
Rad), washed with TNT buffer, and eluted using glutathione buffer (200 mM Tris [pH 8], 0.1% 
Triton-X 100, 15 mM glutathione). Following de-salting and concentration of the eluate using 
high-speed centrifugation and cellulose filter units (Centricon, Millipore), the final protein 
concentration was assayed using the Bradford Protein Assay (Bio-Rad). Reagents were 
purchased from Sigma. 
 
Viral vectors 
 Full-length mouse Shank3 cDNA corresponding to GenBank accession number 
NM_021423 was a generous gift from Dr. Shigeo Uchino (Tokyo, Japan). Vectors containing 
Shank3 shRNAs were obtained for screening (Open Biosystems). Both Shank3 shRNA and the 
full-length, shRNA-resistant Shank3 construct were cloned into the herpes simplex virus vector 
p1006+ (a gift from Dr. Rachael L. Neve). Simultaneous knockdown of Shank3 was achieved by 
the HSV vector co-expressing a Shank3 shRNA under the CMV promoter and a full-length 
shRNA-resistant wild-type Shank3 or phosphorylation mutant S985A Shank3 under the I/E 4/5 
promoter. HSVs were packaged according to the standard protocol (Neve et al., 2005) and 
contained scrambled shRNA, Shank3 shRNA, Shank3 shRNA + wild-type shRNA-resistant 
Shank3 or Shank3 shRNA + S985A full-length shRNA-resistant phosphomutant Shank3.  
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In vitro kinase assay 
 Kinase assays were conducted by co-incubating Cdk5/p25 active kinase (Cell Signaling) 
with 10-20 µg of purified GST protein fused with various Shank3 fragments diluted in kinase 
buffer (30 mM HEPES [pH 7.2], 10 mM MgCl2, 5 mM MnCl2, 100 mM ATP, 5 mCi [32P] 
γATP (Perkin-Elmer, MA, USA), 1 mM DTT). The reaction was terminated by the addition of 
sample buffer (100 mM Tris [pH 6.8], 4% SDS (w/v), 0.2% Bromophenol blue (w/v), 20% 
glycerol (v/v), 200 mM DTT), separated by SDS-PAGE (Bio-Rad), stained with Coomassie blue 
(Invitrogen) and dried prior to autoradiography. GST alone was a negative control, and Histone 
H1, a Cdk5 substrate, was a positive control. 
 
Surgeries 
 All surgeries were performed according to the guidelines in the National Institute of 
Health Guide for the Care and Use of Laboratory. Adult (8-10 week old) male mice (Jackson 
Laboratory) were group housed in the small animal facility at MIT (Cambridge, MA). For 
anesthesia, ketamine/xylazine were administered intraperitoneally at a dosage of 100 mg/kg 
(ketamine) and 10 mg/kg (xylazine) followed by buprenorphine administration at a dosage of 
0.05 mg/kg. After exposing the skull, HSVs were delivered bilaterally using a computer-
controlled micropump injector with a thin glass capillary at coordinates relative to Bregma: –2.0 
mm posterior, +/– 1,6 medial/lateral, –1.2 ventral for hippocampal area CA1. The needle was left 
in place for 5 min after viral delivery for virus diffusion. Post-operative care consisted of 
buprenorphine administration every 12 hours and monitoring animals.  
 
Electrophysiology 
 To record field excitatory postsynaptic potentials, transverse hippocampal slices were 
prepared from 8-week old mice 2-3 days post-surgery. In brief, the brain was rapidly removed 
and transferred to ice-cold, oxygenated (95 % O2 and 5 % CO2) cutting solution containing (mM) 
211 sucrose, 3.3 KCl, 1.3 NaH2PO4, 0.5 CaCl2, 10 MgCl2, 26 NaHCO3 and 11 glucose. 
Hippocampal slices were cut with a Leica VT1000S vibratome (Leica) and transferred for 
recovery to a holding chamber containing oxygenated artificial cerebrospinal fluid (ACSF) 
consisted of (mM) 124 NaCl, 3.3 KCl, 1.3 NaH2PO4, 2.5 CaCl2, 1.5 MgCl2, 26 NaHCO3 and 11 
glucose at 28-30 °C for at least 1 h before recording. CA1 field potentials evoked by Schaffer 
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collateral stimulation were measured. After recording of stable baseline (at least 20 min of stable 
responses), LTP was induced by theta-burst stimulation (4x TBS, 10 s intervals). Recordings 
were performed using AM-1800 Microelectrode amplifier (A-M systems) and a Digidata 1440A 
A-D converter and analyzed by pClamp 10 software (Axon Instruments). All experiments were 
performed blind to the group of subjects. 
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Results 
Shank3 is a Cdk5 substrate 
 We previously conducted a proteomics screen on synaptosomal preparations from control 
and Cdk5 conditional knockout mice (Guan et al., 2011). In addition to alterations in synaptic 
protein composition, a separate phospho-proteomic study conducted using Cdk5 conditional 
knockout synaptosomal preparations suggested that Shank2 and Shank3 are potential Cdk5 
substrates (Table 1). Known substrates of Cdk5 that were detected in the phosphoproteomics 
screen include Dlg4, also known as PSD-95. Other notable phosphopeptides detected that are 
potential Cdk5 substrates included synapsin, piccolo, bassoon, and CaMKII, and other intriguing 
Cdk5 candidate substrates include the presynaptic protein Rims1 and the postsynaptic, 
multistructural-domain proteins Dlg1 (SAP97), and Dlg2 (PSD-93). 
 To confirm that Shank3 is a Cdk5 substrate, we cloned Shank3 into various fragments 
spanning the ankyrin repeats, the SH3, PDZ domain, proline-rich and SAM domains (Figure 
1A). In vitro kinase assays were then conducted using active Cdk5/p25 kinase co-incubated with 
purified Shank3 protein fragments (Figure 1B). We consistently observed that one of fragments 
containing the proline-rich region (aa 861-1000) was robustly phosphorylated by Cdk5. This 
purified protein fragment in the proline-rich region contains six potential Cdk5 phosphorylation 
sites (Figure 1C). Upon further examination using single and combinatorial point mutations, one 
key phosphorylation site was mapped to Serine 985 (Figure 1D).  
 
Dendritic spine regulation by Cdk5-mediated phosphorylation of Shank3 
 Having established Shank3 as a Cdk5 substrate, we next investigated whether Cdk5-
mediated phosphorylation of Shank3 is involved in dendritic spine formation and maintenance. 
To this end, we screened for a series of shRNA to mediate knockdown of Shank3 (Figure 2A) 
and generated a bi-cistronic herpes simplex virus (HSV)-based vector to simultaneously reduce 
endogenous levels of Shank3 while overexpressing either full-length wild-type (WT) or 
phosphorylation mutant (S985A) Shank3 (Figure 2B). Consistent with previous reports that 
Shank3 is required for dendritic spine formation, knockdown of endogenous Shank3 in DIV 17 
primary neurons resulted in a significant increase in immature, thin, filopodia-like spines (Figure 
3A, 3B). Strikingly, however, Shank3 knockdown while overexpressing S985A Shank3 revealed 
a dendritic spine phenotype that is reminiscent of Shank3 shRNA alone (Figure 3A, 3B).
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Table 1. Phospho-proteomics screen of synaptosomal proteins from Cdk5 conditional knockout 
mice suggest multiple Cdk5 substrates. 
A proteomics screen revealed potential Cdk5 phosphorylation sites within synapse-specific proteins, 
including bassoon, piccolo, multiple actin and microtubule-associated proteins, and Shank2 and Shank3, 
proteins whose dysfunction has been implicated in autism spectrum disorders. 
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Figure 1. Shank3 is a Cdk5 substrate. 
(A) Shank3 was cloned into GST expression vectors consisting of various regions: ankyrin, SH3, PDZ, 
the proline-rich, or the SAM domain. The purified protein fragments were incubated with active 
Cdk5/p25 kinase and subjected to in vitro kinase assays.  
(B) The proline-rich region (aa 861-1000) was consistently and robustly phosphorylated by Cdk5/p25 in 
vitro. GST alone served as a negative control, while Histone H1 was used as a positive control. 
(C) The potential Cdk5 phosphorylation sites were mapped to six residues using site-directed 
mutagenesis. Only the S986A phosphorylation mutant in rat Shank3 (S985A in mouse Shank3) 
completely eliminated Cdk5 phosphorylation. 
(D) A combination of single, double, and multi-site phosphorylation mutants revealed S986 as the critical 
Cdk5 phosphorylation site. Whereas single point mutations in the other sites failed to abolish 
phosphorylation, double and multiple point mutations containing S986A reduced the phosphorylation 
signal. The only combination in which S985A failed to abolish phosphorylation was in conjunction with 
S975. 
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Figure 2. Screening Shank3 shRNA and generation of bi-cistronic viral vectors. 
(A) Several shRNAs were screened against both mouse and rat Shank3 constructs. shRNA #4 and #6, 
targeted against the N-terminus ankyrin region of Shank3, reduced protein levels of both mouse and rat 
Shank3, and shRNA #6 was used for cloning into the viral vector for further studies. 
(B) The Shank3 shRNA was successful in reducing Shank3 protein in heterologous H293 cells 
overexpressing full-length mouse Shank3 cDNA. Furthermore, shRNA-resistant full-length mouse 
Shank3 constructs were generated by site-directed mutagenesis and tested in conjuction with Shank3 
shRNA. The R535W and R1118X mutants were generated due to its association with childhood 
schizophrenia but were not used for further experiments. 
(C) Schematic of the HSV bi-cistronic construct. Simultaneous knockdown of Shank3 was achieved 
under the CMV promoter expressing a fluorescent, GFP-tagged micro-RNA-based hairpin, while full-
length shRNA-resistant Shank3 was expressed under the IE 4/5 promoter. The S985A, 6X, R535W, and 
R1118X mutations were generated in the full-length mouse Shank3 construct, but only the WT and 
S985A Shank3 were used in this study. 
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Figure 3. Cdk5-mediated phosphorylation of Shank3 alters dendritic spine morphology. 
(A) Primary neurons were fixed at DIV19 following 48 hr transduction with HSV co-expressing Shank3 
shRNA and shRNA-resistant WT Shank3 (shRNA+WT) or S985A phosphorylation mutant Shank3 
(shRNA+S985A). Scrambled shRNA HSV served as a control.  
(B) Quantification of dendritic spine and filopodium protrusion following shRNA-mediated Shank3 
knockdown and replacement with the indicted WT or mutant Shank3. Whereas scrambled shRNA did not 
result in increased filopodia-like formation, both shRNA and shRNA+S985A induced greater filopodia-
like formation while decreasing the number of mature, study spines. Spine density was unaltered in 
shRNA+WT compared to scrambled shRNA alone but the filopodia density was also increased. 
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 Together, our data suggests that Cdk5-mediated phosphorylation of Shank3 is required 
for maintaining mature dendritic spine morphology. Although Shank3 association with other 
synaptic proteins such as Homer and Cortactin were unaltered by the S985A Shank3 in vitro 
(data not shown), it is possible that total levels of key postsynaptic proteins may be decreased in 
these filopodia-like spines. As it was previously shown that Shank3 knockout mice exhibit lower 
NMDA receptors, and Shank2 knockout mice display lower levels of NMDA and AMPA 
receptors, we also predict that synaptic NMDA or AMPA receptor levels might be 
downregulated. Downstream signaling cascades involving the actin remodeling complex are also 
likely to be disrupted.  
 
Synaptic plasticity is affected by Cdk5-mediated phosphorylation of Shank3 
 Synaptic plasticity as measured by long-term potentiation is a form of persistent 
transmission across synapses, and it is correlated with dendritic spine size and maturity as well as 
learning and memory (Bourne and Harris, 2008; Toni et al., 1999). Because of the striking 
observations that dendritic spines appear elongated and more filopodia-like in primary neurons 
expressing Shank3 shRNA or shRNA+S985A Shank3, we predicted that these alterations would 
in turn impact synaptic transmission and synaptic plasticity. We first examined acute 
hippocampal slices prepared from wild-type mice transduced with HSVs expressing scrambled 
shRNA, Shank3 shRNA alone, shRNA+WT Shank3 or shRNA+S985A Shank3. Measurements 
of basal synaptic transmission did not reveal any alterations compared to slices expressing 
control, scrambled shRNA (Figure 4A). Compared to slices expressing scrambled shRNA, 
paired-pulse facilitation ratios, a form of presynaptic plasticity, were not significantly affected 
(Figure 4B). We next induced LTP using a theta-burst stimulation protocol on acute 
hippocampal slices prepared from wild-type mice transduced with HSVs expressing scrambled 
control shRNA, Shank3 shRNA alone, shRNA+WT Shank3 or shRNA+S985A Shank3. 
Consistent with previous reports that Shank3 knockout mice exhibit impaired LTP and synaptic 
transmission (Wang et al., 2011), acute knockdown of Shank3 also significantly reduced LTP 
compared to control shRNA (Figure 4C, 4D). Slices expressing shRNA+WT Shank3 exhibited 
somewhat enhanced LTP but did not completely restore LTP to control levels. Unexpectedly, 
however, in slices expressing shRNA+S985A Shank3, LTP is dramatically enhanced relative to 
shRNA and is similar to the level of LTP in control, scrambled shRNA slices (Figure 4C, 4D).  
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Figure 4. Synaptic plasticity is impacted by Cdk5-mediated phosphorylation of Shank3. 
(A) Basal synaptic transmission and presynaptic plasticity are unaffected Cdk5-mediated phosphorylation 
of Shank3. HSVs expressing various Shank3 constructs were delivered to hippocampal area CA1, and 
acute hippocampal slices were prepared 2-3 days later. Basal synaptic transmission, as measured by the 
input-output curve where fEPSC slope is plotted against stimulation intensity, did not reveal any 
differences in synaptic transmission compared to slices expressing control, scrambled shRNA. 
(B) Presynaptic plasticity was measured by paired-pulse facilitation ratios at different intervals, and 
compared to control, scrambled shRNA, there were no differences in PPF ratios.  
(C) In slices expressing scrambled shRNA, LTP was reliably induced by three theta burst stimulations in 
the Schaffer collateral pathway. However, compared to scrambled shRNA, there was a deficit in LTP in 
slices expressing Shank3 shRNA. Slices expressing simultaneous knockdown and overexpression of 
wild-type Shank3 (shRNA+WT) exhibited LTP comparable to shRNA, whereas slices expressing 
simultaneous knockdown and overexpression of Cdk5-phosphorylation resistant Shank3 S985A 
(shRNA+S985A) showed elevated levels of LTP compared to shRNA.  
(D) Quantification of the last 10 min of LTP. Data shown are means ± SEM.	  Statistical significance was 
calculated using one-way ANOVA followed by Tukey’s multiple comparison test (p < 0.05; **p < 0.01; 
***p < 0.001). N=8 slices, 4-6 mice per group.
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Discussion 
 In our study, we identified Shank3, a gene associated with autism spectrum disorder and 
intellectual disabilities, as a Cdk5 substrate and demonstrate a role for the phosphorylation on 
S985 in the maintenance of dendritic spines and in mediating synaptic plasticity. Our results 
highlight a novel aspect of post-translational regulation of Shank3 and suggest that actin-
remodeling pathways may play a role in shaping dendritic spine formation and maturation. 
 
Shank3 and dendritic spine remodeling 
 As Shank3 is known to associate with cortactin and homer to affect the actin cytoskeleton 
to remodel dendritic spines (Hering and Sheng, 2003), it will be essential to determine whether 
the S985A Shank3 phosphorylation mutant impacts the interaction of Shank3 with cortacin and 
homer to affect actin polymerization. Preliminary observations suggest that in heterologous cells, 
expression of S985A Shank3 phosphorylation mutant does not affect its binding with either 
cortacin and Homer, but the possibility that Shank1 or Shank2 proteins may be involved cannot 
be excluded. Shank3 is strongly associated with autism spectrum disorders due to the 
identification of de novo mutations in patients that, while not causative of autism, are implicated 
as risk factors for autism (Durand et al., 2007). Intriguingly, the human Shank3 mutations affect 
spine development in an actin-dependent manner and also affect synaptic plasticity (Durand et 
al., 2012). Other studies have identified de novo mutations in the Shank2 gene in autism 
spectrum disorder patients (Berkel et al., 2010), and expressing these mutations in mouse 
systems reduces dendritic spine volume and altered synaptic transmission mediated by AMPA 
receptors (Berkel et al., 2012). 
 
Cdk5-mediated phosphorylation of Shank3 impacts synaptic plasticity 
 Notably, our results are somewhat unexpected due to the observation that slices 
expressing S985A Shank3 phosphorylation mutant demonstrate enhanced hippocampal LTP 
compared to slices expressing shRNA and do not differ from slices expressing control scrambled 
shRNA. However, previous studies have reported dendritic spine maturation with LTP induction 
(Engert and Bonhoeffer, 1999; Kopec et al., 2006; Maletic-Savatic et al., 1999). It is possible 
that LTP induction produced activity-dependent changes in the dendritic spines of synapses 
expressing S985A Shank3 phosphorylation mutant that enabled rapid spine maturation 
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throughout the LTP measurement period compared to the slices expressing Shank3 shRNA. It 
will be of great interest in future studies to determine how the S985A Shank3 phosphorylation 
mutant affects dendritic spine formation during LTP, and how it affects activity-dependent actin 
remodeling and surface expression of glutamate receptors. A potential future approaches 
includes generating transgenic mouse models. such as a knock-in mouse model, to gain better 
insight into how phosphorylation of Shank3 by Cdk5 may also impact synaptogenesis and 
synaptic plasticity. 
 
Future directions of autism research 
 Recent advances in genome-wide association studies have revealed that copy number 
variations are associated with autism spectrum disorders and intellectual disabilities (Glessner et 
al., 2009; Sebat et al., 2007). Other studies using deep sequencing of affected and unaffected 
controls have identified de novo mutations in protein-coding exons of several key genes 
implicated in synaptic function to be strongly associated with autism spectrum disorders (Neale 
et al., 2012; O'Roak et al., 2012; Sanders et al., 2012). Shank3 is particularly interesting due to 
its association with Phelan-McDermid Syndrome, a disorder that affects deletion of Shank3 and 
other chromosomal regions on 22q13.3 (Phelan and Rogers, 1993). Patients diagnosed Phelan-
McDermid Syndrome exhibit global developmental delays, speech delay, and hypotonia and in 
over half of the cases, the patients also show autism-like behavior. While the cause of the 
disorder is unknown, it is hypothesized that Shank3 haploinsufficiency may affect development 
of various organs as well as synaptic structures. Future studies on the biology underlying Phelan-
McDermid Syndrome should also enhance our understanding of how Shank3 is involved in 
organization of synapses and proper development.  
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Chapter 5 
 
 
Forebrain-specific deletion of Cdk5 in pyramidal neurons results in hyperactivity, synaptic 
 plasticity deficits, and cognitive impairment  
 
 
 
Summary 
 Cyclin-dependent kinase 5 (Cdk5) is associated with synaptic plasticity and cognitive 
function. Although previous reports have described Cdk5 conditional knockout mouse models 
exhibiting enhanced learning and memory, others have shown that Cdk5 is necessary for 
memory formation. Despite the literature on various mouse models of Cdk5 ablation, its role in 
exact cell types are still unclear. Here we have generated and characterized a forebrain-specific 
Cdk5 conditional knockout mouse model using the αCaMKII-Cre driver line. When Cdk5 is 
reduced in excitatory pyramidal neurons of the forebrain, the number of dendritic spines is 
decreased. Additionally, we observed strong behavioral alterations including hyperactivitiy and 
reduced behavioral despair. The Cdk5 conditional knockout mice also exhibit impaired spatial 
learning in the watermaze and cognitive impairment in fear conditioning memory, along with 
deficits in synaptic plasticity. The hyperactivity can be restored to control levels by the 
administration of lithium chloride, an inhibitor of GSK3β signaling. Our data suggests that Cdk5 
ablation from forebrain excitatory neurons have a deleterious effect on synaptic plasticity, 
emotional and cognitive behavior, and may alter the GSK3β signaling pathway. 
 
 
 
 
 
 
 
 
______________________ 
I prepared samples for electron microscopy processing and acquired the images for analysis, conducted 
light/dark test, open field, forced swim test, pre-pulse inhibition test, contextual and tone fear 
conditioning tests and analyzed the data, and conducted biochemical experiments and analyzed the data.
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Introduction 
 The neuronal kinase cyclin-dependent kinase 5 (Cdk5) is a multi-faceted kinase that plays 
an important role in synaptic plasticity and learning and memory (Guan et al., 2011; Hawasli et 
al., 2007). In addition to targeting NMDA receptors and postsynaptic scaffolding proteins such 
as PSD-95 (Li et al., 2001; Morabito et al., 2004), Cdk5 activity is involved in the formation of 
long-term potentiation (LTP) at hippocampal synapses (Fischer et al., 2005; Li et al., 2001). 
Recent studies have examined how Cdk5 regulates activity and modifies synaptic transmission to 
fine-tune homeostatic plasticity (Kim and Ryan, 2010; Mitra et al., 2011; Seeburg et al., 2008). 
Despite the wealth of evidence regarding Cdk5 and its influence on synaptic plasticity, recent 
studies on behavioral outcomes of Cdk5 loss-of-function is still unclear. One study reports an 
increase in learning and memory in a Cdk5 conditional knockout mouse line (Hawasli et al., 
2007). Other mouse models in which p35, the regulatory subunit of Cdk5, has been deleted show 
hyperactivity and alterations in the dopaminergic and cholinergic system (Drerup et al., 2010; 
Krapacher et al., 2010). Yet other studies have indicated that loss of Cdk5 or inhibiting Cdk5 
activity is detrimental to memory acquisition and synaptic plasticity (Guan et al., 2011; Li et al., 
2001).  
 In this study, we examine a conditional knockout mouse model in which Cdk5 is 
selectively ablated in forebrain excitatory neurons. Through a series of behavioral tasks, we 
assessed the outcome of Cdk5 reduction in motor activity, cognitive function, and synaptic 
plasticity. We show that Cdk5 loss-of-function in αCaMKII-positive excitatory neurons results 
in hyperactivity, impaired cognitive function and deficits in synaptic plasticity. Upon closer 
examination, treatment of the Cdk5 conditional knockout mice with lithium chloride restores 
their locomoter activity. Further evaluation of the molecular mechanisms underlying the 
behavioral phenotype in this line of Cdk5 conditional knockout mice will be useful to better 
understand how Cdk5 may regulate synaptic function. 
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Methods 
Animals 
 Cdk5 conditional knockout mice were generated by crossing the αCaMKII-Cre (CW2) 
line (generous gift from Dr. Susumu Tonegawa) with the Cdk5 floxed/floxed (Cdk5f/f) line to 
generate αCaMKII-Cre;Cdk5fl/fl mice, also referred to as Cdk5 conditional knockout 
(Cdk5f/f/CW2) mice. Mice were generated and maintained in a C57Bl/6J background and group-
housed in a 12 hr light-dark cycle, with food and water ad libitum. Mice were handled according 
to the National Institutes of Health Care and Use of Laboratory Animals. All behavior studies 
were conducted using adult, 3-5 month old male mice. 
 
Behavior   
Light dark test 
 Mice were placed into a light-dark chamber apparatus and allowed to explore the arenas 
for 10 min. A video recorded the latency to enter the light for the first time, duration spent in the 
light chamber and the number of crossings from the dark to the light chamber. Statistical 
significance was calculated for the control (Cdk5f/f) and Cdk5 conditional knockout 
(Cdk5f/f/CW2) groups using unpaired Student’s t-test. 
 
Open Field Test 
 Mice were placed into 40 cm x 40 cm arenas with orthogonal lasers to track position and 
locomotor activity for 60 min (VersaMax). Data was collected and analyzed (Graphpad). Each 
activity was calculated as the mean with standard error and compared across control (Cdk5f/f) 
and Cdk5f/f/CW2 groups with unpaired Student’s t-test. For LiCl treatment, LiCl was injected 
intraperitoneally 40 min before beginning the task at a dosage of 85 mg/kg. 
 
Forced swim test 
 Animals were placed in a 4000 ml Pyrex cylindrical container at 24C and various 
parameters such as velocity, mobile duration and time, immobile duration and time, were 
automatically recorded for 6 min (VersaMax). Immobility was measured during the last 4 min of 
the test.  
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Morris water maze task 
 Spatial memory was performed using a circular tank (1.2 m in diameter) filled with 
opaque water at 22C. The walls contained spatial reference cues, and inside the tank was a fixed 
platform (10 cm in diameter) in a target quadrant. During pre-training (Day 1), mice were placed 
in the water, guided to the platform, and allowed to stay in the platform for 15 s. In the following 
days, mice were placed into the maze randomly and allowed to search for the platform for 60 s. 
Two trials a day were conducted with a 2 min interval. Mouse behavior was recorded and 
analyzed, and escape latency was scored (TSE Systems). On day 9, the platform was removed 
and a probe trial was conducted to assess spatial learning.  
 
In vivo recordings 
 Mice were placed under isofluorane and placed into a custom stereotaxic stage. A small 
craniotomy was made over the somatosensory cortex, and spontaneous local field potentials 
(LFPs) were recorded using a glass electrode from layers II-IV of the somatosensory cortex. 
Relative power was calculated by measuring the ratio of power within the band of interest to 
total power (1-100 Hz) in the power spectrum of the unfiltered LTP. 
 
Fear conditioning  
 Both contextual and cued fear conditioning was conducted over the course of 3 days. On 
day 1, mice were placed in a fear conditioning apparatus chamber for 3 min and then presented 
with a 2 s foot shock delivery at 0.8 mA preceded by a 30 s, 75 dB tone (TSE Systems). After the 
animals were placed in their homecage for 24 hr, they were assessed for contextual learning by 
recording the freezing behavior for 3 min in the training context. On day 3, the animals were 
presented with a different context but levels of freezing were assessed after exposure to the same 
tone. Prior to each trial, each context was cleaned with 70% ethanol except for on day 3, where it 
was cleaned with acetic acid. 
 
Electrophysiology 
 To record field excitatory postsynaptic potentials, transverse hippocampal slices were 
prepared from 8-12 week old adult mice. In brief, the brain was rapidly removed and transferred 
to ice-cold, oxygenated (95 % O2 and 5 % CO2) cutting solution containing (mM) 211 sucrose, 
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3.3 KCl, 1.3 NaH2PO4, 0.5 CaCl2, 10 MgCl2, 26 NaHCO3 and 11 glucose. Hippocampal slices 
were cut with a Leica VT1000S vibratome (Leica) and transferred for recovery to a holding 
chamber containing oxygenated artificial cerebrospinal fluid (ACSF) consisted of (mM) 124 
NaCl, 3.3 KCl, 1.3 NaH2PO4, 2.5 CaCl2, 1.5 MgCl2, 26 NaHCO3 and 11 glucose at 28-30 °C for 
at least 1 h before recording. CA1 field potentials evoked by Schaffer collateral stimulation were 
measured. Recordings were performed using a MultiClamp 700B amplifier and a Digidata 
1440A A-D converter and analyzed by pClamp 10 software (Axon Instruments). Experiments 
were performed blind to the genotype. 
 For miniature recordings, whole-cell recordings were performed in CA1 pyramidal 
neurons for mEPSC and mIPSC measurements. Cells were held at -70 mV and data were 
acquired using a MultiClamp 700B amplifier and a Digidata 1440A A-D converter (Axon 
Instruments). The internal solution contained (mM) 145 CsCl, 5 NaCl, 10 HEPES-CsOH, 10 
EGTA, 4 MgATP and 0.3 Na2GTP. TTX (1 µM), D-APV (50 µM) and either picrotoxin (50 µM) 
or CNQX (10 µM) were added to ACSF for mEPSC or mIPSC, respectively.  
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Results 
Conditional knockout of Cdk5 results in decreased number of synapses 
 Cdk5 conditional knockout mice (Cdk5f/f/CW2) were generated as previously described 
in which Cdk5 is ablated specifically in excitatory pyramidal neurons of the forebrain by 
crossing floxed Cdk5 mice to CW-2 Cre line driven by the αCaMKII (Guan et al., 2011; Zeng et 
al., 2001). The Cdk5f/f/CW2 mice do not exhibit gross developmental abnormalities and survive 
until 5-6 months of age, when they begin to suffer seizures. Using electron microscopy studies to 
obtain a higher resolution of the synapse, we observed a small but significant reduction in 
postsynaptic density (PSD) thickness and density in hippocampal CA1 (Figure 1A, 1B).  
 
Reduced anxiety and hyperactivity in Cdk5f/f/CW2 mice  
 We next utilized a set of behavioral assays to examine how loss of Cdk5 affects anxiety 
and cognition. A well-characterized behavioral assay for anxiety, the light-dark test, revealed 
significantly and consistently decreased anxiety in the Cdk5f/f/CW2 mice compared to control 
(Cdk5f/f) mice due to a faster entry to the light, more time spent in the light and increased 
number of crossings between the two chambers (Figure 2A-C). Interestingly, Cdk5f/f/CW2 
mice were hyperactive in the open field test as measured by the total distance traveled (Figure 
3A). This hyperactivity corresponded to Cdk5f/f/CW2 spending increased time and distance in 
the center of the open field arena (Figure 3B, 3C) as well as increased distance, but not time, in 
the margin area (Figure 3D, 3E). Furthermore, compared to control Cdk5f/f mice, Cdk5f/f/CW2 
exhibited a significant enhancement of rearing activity (Figure 3F), increased horizontal and 
vertical movements (Figure 3G, 3H) but no changes stereotypic movements (Figure 3I), 
consistent with reduced anxiety. The hyperactivity is specific and may have affected their 
behavior in the forced swim test for learned helplessness, in which Cdk5f/f/CW2 mice show 
reduced behavioral despair by their overall increased distance and velocity and decreased 
immobility compared to control Cdk5f/f mice (Figure 4A-D). In a well-characterized test for 
sensorimotor gating, Cdk5f/f/CW2 exhibited increased startle to the training tones compared to 
control Cdk5f/f mice (Figure 5A), but did not exhibit any alterations in pre-pulse inhibition 
(Figure 5B).  
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Figure 1. PSD thickness and overall density is reduced in Cdk5f/f/CW2 mice.  
(A) Electron microscopy images acquired from hippocampal area CA1 synapses revealed a reduction in 
PSD thickness of Cdk5f/f/CW2 synapses compared to control Cdk5f/f synapses. 
(B) The PSD density is also reduced in the Cdk5f/f/CW2 synapses compared to control Cdk5f/f synapses, 
consistent with a reduction in the total number of synapses. Data shown are means ± SEM.	   Statistical 
significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
 
 
 
 
 
Figure 2. Cdk5f/f/CW2 exhibit reduced anxiety in the light/dark test. 
(A) The light/dark test was used to assess anxiety in Cdk5f/f and Cdk5f/f/CW2 mice. While control 
Cdk5f/f animals were more anxious of the light region, Cdk5f/f/CW2 mice crossed over into the bright 
region faster than their control littermates.  
(B) Compared to their control Cdk5f/f littermates, Cdk5f/f/CW2 mice spent more time overall in the light. 
(C) Compared to their control Cdk5f/f littermates, Cdk5f/f/CW2 mice also crossed over into the light 
region with more frequency. N=8 for Cdk5f/f, N=9 for Cdk5f/f/CW2. Data shown are means ± SEM.	  
Statistical significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Figure 3. Cdk5f/f/CW2 are hyperactive as measured by the open field test. 
(A) Compared to Cdk5f/f control littermates, Cdk5f/f/CW2 mice were consistently and significantly more 
active overall and traveled a greater distance in the open field arena over a period of 60 min. 
(B) Cdk5f/f/CW2 traveled a greater distance in the center of the open field, indicating reduced anxiety. 
(C) Upon further examination, Cdk5f/f/CW2 mice spent more time in the center of the open field arena, 
indicative of a reduction in anxiety that is consistent with observations from the light/dark test. 
(D) Cdk5f/f/CW2 traveled a greater distance in the margin of the open field test, reflecting a generalized 
hyperactivity. 
(E) There were no significant differences in time spent in the margin of the open field arena between 
control Cdk5f/f and Cdk5f/f/CW2 mice. 
(F) Rearing activity, another way of measuring anxiety, indicated that Cdk5f/f/CW2 mice exhibited 
increased rearing and provided further evidence that Cdk5f/f/CW2 mice demonstrated a reduction in 
anxiety.  
(G) Consistent with the observation that Cdk5f/f/CW2 display increased overall activity, their horizontal 
activity was also increased. 
(H) Also consistent with the rearing activity, the number of infrared beam breaks detecting vertical 
movement was significantly higher in the Cdk5f/f/CW2 mice compared to Cdk5f/f control mice. 
(I) Neither group of mice exhibited any alterations in stereotypy behaviors. N=9 animals for both Cdk5f/f 
and Cdk5f/f/CW2 genotypes. Data shown are means ± SEM.	  Statistical significance was calculated using 
Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Figure 4. Forced swim test did not reveal any differences in learned helplessness behavior. 
(A) Compared to Cdk5f/f control littermates, Cdk5f/f/CW2 mice were more active overall in the water 
during the forced swim test.   
(B) Cdk5f/f/CW2 were more active in the forced swim test and also exhibited a greater velocity in their 
swimming movements.   
(C) The mobile durations between Cdk5f/f and Cdk5f/f/CW2 mice were not significantly different.   
(D) In the immobile duration, Cdk5f/f/CW2 mice spent less time immobile compared to control Cdk5f/f 
mice, indicating a reduction in behavior despair. N=8 animals for both Cdk5f/f and Cdk5f/f/CW2 
genotypes. Data shown are means ± SEM.	   Statistical significance was calculated using Student’s t-test 
(*p < 0.05; **p < 0.01; ***p < 0.001). 
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Figure 5. Cdk5f/f/CW2 mice did not reveal any deficits in pre-pulse inhibition. 
(A) Compared to control Cdk5f/f mice, Cdk5f/f/CW2 mice exhibited greater startle in the pre-pulse 
inhibition test.   
(B) The percent of pre-pulse inhibition, a measurement of sensorimotor gating, did not significantly differ 
between Cdk5f/f and Cdk5f/f/CW2 mice. N=9 animals for both Cdk5f/f and Cdk5f/f/CW2 genotypes. 
Data shown are means ± SEM.	  Statistical significance was calculated using Student’s t-test (*p < 0.05; 
**p < 0.01; ***p < 0.001).	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Cdk5f/f/CW2 mice are impaired in cognitive behavioral tasks 
 To further examine the cognitive abilities of the Cdk5f/f/CW2 animals, we performed the 
Morris water maze task to test for hippocampus-dependent spatial learning. Contrary to several 
reports (Hawasli et al., 2007), but consistent with others (Guan et al., 2011), Cdk5f/f/CW2 mice 
displayed a severe impairment in memory acquisition and retention during training (Figure 6A). 
Moreover, while control Cdk5f/f mice spent more time in the target quadrant during the probe 
test, Cdk5f/f/CW2 mice performed at chance, suggesting that Cdk5f/f/CW2 mice was unable to 
form a spatial memory (Figure 6B). In contextual fear conditioning, animals were placed in a 
conditioning chamber and presented with an unconditioned stimulus (footshock). Both Cdk5f/f 
and Cdk5f/f/CW2 mice displayed similar distance traveled, velocity, and response to footshock 
during the training period (Figure 7A-C). Upon testing for fear memory in the same chamber 1 
hr and 24 hr later, however, Cdk5f/f/CW2 animals exhibited a dramatic reduction in freezing 
levels compared to control Cdk5f/f animals, indicating a severe impairment of cognitive function 
(Figure 7D, 7E). Tone-dependent fear conditioning, however, was not significantly impaired 
(Figure 7F).  
 
Cdk5f/f/CW2 mice exhibit impairments in synaptic plasticity 
 Because Cdk5 loss-of-function in excitatory neurons may elicit a compensatory response 
in the inhibitory interneurons, we next examined if cortical oscillations, which have been 
implicated in cognition and are attributed to interneuron activity, were altered (Cardin et al., 
2009). However, we did not detect any changes in cortical oscillations in the theta and gamma 
bands between control Cdk5f/f and Cdk5f/f/CW2 animals (Figure 8A, 8B). We next examined 
synaptic plasticity by preparing acute hippocampal slices from control Cdk5f/f and Cdk5f/f/CW2 
animals and stimulating the Schaffer collateral pathway. Consistent with a reduction in the total 
number of synapses in hippocampal area CA1, basal synaptic transmission was severely reduced 
in slices prepared from Cdk5f/f/CW2 animals (Figure 9A). Paired-pulse facilitation ratios, a 
measurement of presynaptic transmitter release, did not significantly differ between control 
Cdk5f/f and Cdk5f/f/CW2 (Figure 9B). Moreover, the frequency (Figure 9C), but not amplitude 
(Figure 9D), of miniature excitatory postsynaptic current (mEPSCs) was reduced in the 
Cdk5f/f/CW2, supporting the notion of reduced synapse numbers.   
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Figure 6. Cdk5f/f/CW2 exhibit spatial learning impairments in the Morris water maze. 
(A) While control Cdk5f/f mice learned the spatial memory task during the 8 day training session, 
Cdk5f/f/CW2 mice were consistently impaired in acquisition of the spatial memory. 
(B) During the probe trial on day 9, Cdk5f/f/CW2 mice spent significantly less time in the target quadrant 
(p=0.0035) and instead spent more time in the opposite quadrant (p=0.0204) compared to control Cdk5f/f 
littermates. N=8 for Cdk5f/f; N=5 for Cdk5f/f/CW2. Data shown are means ± SEM.	   Statistical 
significance was calculated using One-way ANOVA followed by Tukey’s multiple comparison test (*p < 
0.05; **p < 0.01; ***p < 0.001). 
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Figure 7. Cdk5f/f/CW2 are impired in contextual, but not tone, fear conditioning task. 
(A) The distance traveled in the fear conditioning chamber did not significant differ between control 
Cdk5f/f and Cdk5f/f/CW2 mice in the 3 min exploration time before the footshock. 
(B) The average velocity did not significantly differ between control Cdk5f/f and Cdk5f/f/CW2 mice in 
the 3 min exploration time before the footshock. 
(C) Both Cdk5f/f and Cdk5f/f/CW2 groups responded to the footshock as shown by their increase in 
mean velocity before (left) and after (right) the shock. 
(D) Whereas control Cdk5f/f mice displayed robust freezing levels upon testing 1 hr after the footshock, 
Cdk5f/f/CW2 were significantly impaired in fear memory. 
(E) Whereas control Cdk5f/f mice displayed robust freezing levels upon testing 24 hr after the footshock, 
Cdk5f/f/CW2 were significantly impaired in fear memory. 
(F) Tone-dependent fear conditioning is not significantly impacted in Cdk5f/f/CW2 mice compared to 
control Cdk5f/f mice. N=9 for Cdk5f/f; N=7 for Cdk5f/f/CW2. Data shown are means ± SEM.	  Statistical 
significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Figure 8. No alterations in cortical oscillations were observed in the Cdk5f/f/CW2 mice 
(A) There were no differences in the relative power at the 4-12 Hz band of theta oscillations in the 
somatosensory cortex of anesthetized animals between control Cdk5f/f and Cdk5f/f/CW2 mice.  
(B) There were no differences in the relative power at the 30-60 Hz band of gamma oscillations in the 
somatosensory cortex of anesthetized animals between control Cdk5f/f and Cdk5f/f/CW2 mice. N=3 
animals for both Cdk5f/f and Cdk5f/f/CW2 genotypes.  
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Figure 9. Basal synaptic transmission and spontaneous transmission is impaired in Cdk5f/f/CW2 
mice.  
(A) Basal synaptic transmission in the Schaffer collateral pathway is severely impaired in acute 
hippocampal slices prepared from Cdk5f/f/CW2 animals compared to control Cdk5f/f animals.  
(B) Compared to control Cdk5f/f animals, the paired-pulse facilitation ratios at various interstimulus 
intervals are not significantly different from Cdk5f/f/CW2 animals. 
(C) Compared to slices prepared from control Cdk5f/f animals, the frequency of spontaneous mEPSC is 
significantly decreased in slices prepared from Cdk5f/f/CW2. 
(D) The mEPSC amplitude did not significantly differ between the control Cdk5f/f and Cdk5f/f/CW2 
groups. N=3 animals, 9-14 slices, for both Cdk5f/f and Cdk5f/f/CW2 genotypes. Data shown are means ± 
SEM.	  Statistical significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Rescue of hyperactivity in Cdk5f/f/CW2 mice by lithium administration 
 Since our data suggests that Cdk5f/f/CW2 mice exhibit mania-like hyperactivity and 
reduced anxiety, we sought to address whether pharmacological administration may alleviate 
some of these symptoms. A previous mouse model exhibiting manic-like behavior including 
reduced anxiety, hyperactivity, and reduced depressive-like symptoms has been reported in a 
kainate receptor (GluR6) knockout, and successful amelioration of the symptoms was achieved 
by lithium administration (Shaltiel et al., 2008). Therefore, we asked whether lithium could 
improve some of the behavioral deficits that were observed in the open field test in the 
Cdk5f/f/CW2 animals. To test this possibility, lithium was administered to animals prior to the 
open field test. Remarkably, acute lithium administration was able to restore the hyperactivity of 
Cdk5f/f/CW2 to control levels as determined by overall activity, time spent in center versus 
margin, horizontal and vertical activity (Figure 10A-F). However, consistent with our 
observations that stereotypy was not initially affected in Cdk5f/f/CW2 mice, lithium treatment 
had no further effect (Figure 10G).  
 
Cdk5f/f/CW2 display increased phosphorylation of GSK3αβ  
 As lithium is a well-known inhibitor of GSK3β, we examined protein levels of GSKβ as 
a potential molecular mechanism underlying the hyperactivity in Cdk5f/f/CW2 mice. 
Surprisingly, while total levels of GSK3β remained unchanged in the Cdk5f/f/CW2 mice, 
phospho-GSK3α/β (S21/9) levels were significantly increased in the Cdk5f/f/CW2 forebrain 
lysates. Other molecules in the GSK3β signaling pathway, including total levels of β-catenin, 
were unaltered (Figure 11A-C). Thus, Cdk5f/f/CW2 mice exhibit mania-like behavior that can 
be rescued by lithium treatment, and biochemical data hint at alterations in GSK3β activity as a 
potential mechanism underlying these behaviors. 
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Figure 10. LiCl treatment rescues open field deficits. 
(A) Lithium chloride administration prior to the open field test is able to restore the total distance traveled 
by the Cdk5f/f/CW2 to control Cdk5f/f levels, whereas lithium failed to further dampen the activity of 
Cdk5f/f mice.  
(B) While the Cdk5f/f/CW2 mice spent more time in the center of the open field arena before treatment, 
lithium administration decreased the amount of time Cdk5f/f/CW2 spent in the center back to control 
Cdk5f/f levels. 
(C) Conversely, while Cdk5f/f/CW2 mice initially sent less time in the margin of the open field arena 
before treatment, lithium administration ameliorated this effect and restored time spent in the margin to 
control Cdk5f/f levels. 
(D) Horizontal activity was decreased to control Cdk5f/f levels after Cdk5f/f/CW2 were treated with 
lithium chloride. 
(E) Similar to horizontal activity, vertical activity was decreased to control Cdk5f/f levels after 
Cdk5f/f/CW2 were treated with lithium chloride. 
(F) Rearing movement number, a measurement of anxiety, was initially higher in Cdk5f/f/CW2 mice, 
consistent with earlier observations that these Cdk5f/f/CW2 mice have reduced anxiety. However, after 
treatment with lithium chloride, Cdk5f/f/CW2 mice exhibited similar rearing movements as control 
Cdk5f/f mice.  
(G) As stereotypy was initially unaffected, lithium treatment on Cdk5f/f/CW2 mice had no further effect. 
Lithium had no significant effect on the Cdk5f/f control mice in all behavioral measurements. N=11 for 
Cdk5f/f; N=9 for Cdk5f/f/CW2. Data shown are means ± SEM.	   Statistical significance was calculated 
using One-way ANOVA (Tukey’s multiple comparison test) (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Figure 11. Increased GSK3α /β  phosphorylation in Cdk5f/f/CW2 lysates. 
(A) Levels of phospho-GSK3α/β (S21/9) are increased in Cdk5f/f/CW2 forebrain lysates compared to 
control Cdk5f/f lysates, where total GSK3α/β levels remain unaltered. 
(B) Compared to control Cdk5f/f lysates, total levels of β-catenin were unchanged in the Cdk5f/f/CW2 
lysates. Cdk5 levels are significantly reduced in the Cdk5f/f/CW2 mice. 
(C) Quantification of the phospho-GSK3α/β (S21/9) protein levels, total β-catenin levels and Cdk5 
levels. N=3 animals for Cdk5f/f and Cdk5f/f/CW2 genotypes. Data shown are means ± SEM.	  Statistical 
significance was calculated using Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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Discussion 
 Here we have described a mouse model in which Cdk5 deletion from αCaMKII-positive 
excitatory neurons of the forebrain results in a distinct hyperactivity phenotype, disrupted 
cognitive performance, and impaired synaptic plasticity as measured by basal synaptic 
transmission and spontaneous neurotransmitter release. Mechanistically, hints that the GSK3β 
signaling pathway may be impaired arise from the observation that treatment of the 
Cdk5f/f/CW2 mice with lithium can ameliorate the hyperactive movements. Intriguingly, we 
observed that phospho-GSK3β is increased in the forebrain lysates of Cdk5f/f/CW2. Taken 
together, our mouse model can serve as a useful tool to examine signaling cascades underlying 
mouse models exhibiting manic-like hyperactivity. 
 
Cdk5 and homeostatic plasticity 
 Increasing number of studies have identified Cdk5 as a critical regulator of synaptic 
transmission and homeostatic plasticity by downregulating activity in response to heightened 
activity (Seeburg et al., 2008), affecting vesicle pool size during neurotransmitter release (Kim 
and Ryan, 2010), and silencing recurrent networks during prolonged inactivity (Mitra et al., 
2011). While Cdk5 activity is important as a mediator of homeostatic plasticity, precisely how 
chronic Cdk5 loss-of-function impacts synaptic plasticity is still unclear. Earlier studies from p35 
knockout mice and found that loss of one copy of p35 leads to pre-pulse inhibition deficits in 
female mice and impaired reverse learning in the water maze task (Engmann et al., 2011). 
However, the authors found that only male mice exhibited cognitive deficits in a spatial memory 
task, along with impaired social interaction. In these mice, treatment with a chromatin modifying 
enzyme inhibitor restored the behavioral deficits.  
 Our results differ from previous reports that Cdk5 conditional knockout mice exhibit 
enhanced learning and memory in the water maze task and fear conditioning, and increased 
NR2B surface expression levels due to a reduction in calpain-mediated cleavage and reduction of 
NR2B (Hawasli et al., 2007). One notable difference was the use of a prion promoter Cre mouse 
line, which provided temporal deletion of Cdk5 but targeted Cdk5 in a wider range of different 
cell types and brain regions including the retina, olfactory bulb, and cerebellum (Weber et al., 
2001). In a separate study, the Cdk5 conditional knockout mice generated by the prion promoter 
Cre line exhibited enhanced hippocampal theta oscillations, which is in stark contrast to our mice 
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generated by the αCaMKII-Cre promoter (Hawasli et al., 2009). However, both Cdk5 mutant 
mouse models exhibit seizure phenotypes. Hawasli et al. proposed that an acute increase in p25 
levels in their mouse model during seizure activity is a compensatory mechanism, and long-term 
loss of Cdk5 also results in a reduction in p25. While we have not yet examined the relationship 
of p35 to p25 levels in our Cdk5f/f/CW2 mice, we would predict normal expression of p35 and 
cleavage of p35 to p25 under neurotoxic conditions. Future experiments also include LTP and 
LTD studies, and based on the deficits in cognitive functions, we would also expect to observe a 
decrease in LTP in Cdk5f/f/CW2 mice. If we do observe a deficit in LTP, this would again 
contrast the findings from Hawasli et al. who determined that αCaMKII-restricted Cdk5 
knockout results in an enhancement of LTP. 
 Our behavioral rescue of hyperactivity using lithium treatment prompted us to examine 
levels of GSK3β in Cdk5f/f/CW2 mice, as lithium is a well-known inhibitor of GSK3β. 
Surprisingly, our results differ from the prediction that because young p25 transgenic animals 
expressing hyperactive Cdk5 have increased GSK3αβ phosphorylation (S21/9), loss of Cdk5 
would decrease levels of phospho-GSK3αβ (S21/9). (Plattner et al., 2006). Instead we found that 
loss of Cdk5 increased levels of phospho-GSK3αβ (S21/9). However, in older p25 transgenic 
animals, phospho-GSK3β (S21/9) levels do not differ from control animals and GSK3β activity 
is increased. Although seemingly contradictory, our mouse model could reflect a compensation 
mechanism in which loss of Cdk5 results in increased inhibition of GSK3β that is due to a 
reduction in phosphatase 2A (PP2A), which is known to interact with both Cdk5 and GSK3β. 
We also cannot exclude the possibility that other phosphatases targeting phospho-GSK3β 
(S21/9) are impaired in these Cdk5f/f/CW2 mice, in which steady loss of Cdk5 throughout the 
mouse lifespan may result in long-term compensatory changes. It will therefore be interesting to 
examine levels of GSK3β, PP2A, and p25 after lithium treatment in our Cdk5f/f/CW2 mice. 
Moreover, it will also be essential to examine the activation site of GSK3β on Tyr279/216, as we 
only evaluated the phosphorylation sites which result in GSK3β inhibition. Finally, it will be of 
great interest to measure how other components of the GSK3β signaling pathway, including Akt 
and ERK phosphorylation, are impacted by chronic loss of Cdk5 to address whether the GSK3β 
pathway is directly affected by lithium in our study.  
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Chapter 6 
 
 
Conclusions 
 The central goal of the thesis was to further our understanding of how a prolific neuronal 
serine/threonine kinase such as Cdk5 contributes to various aspects of synaptic function, synaptic 
plasticity, and learning and memory. I began in Chapter 1 with an introduction to the diversity of 
Cdk5 substrates in the nervous system, followed by an overview of how dysregulation of Cdk5 is 
implicated in various neurodegenerative disorders. In Chapter 2, I described a specific signaling 
pathway that is affected in a hippocampus-specific knockout of Cdk5 that impairs learning and 
memory, which can be restored by phosphodiesterase inhibitors. In Chapter 3, I presented 
evidence for Cdk5-mediated phosphorylation of a presynaptic voltage-gated N-type calcium 
channel. The phosphorylation event enhances calcium influx and promotes vesicle docking and 
interaction with the active zone protein RIM1 to enhance synaptic transmission. I then provided 
data in Chapter 4 that Cdk5-mediated phosphorylation of a postsynaptic density protein, Shank3, 
is involved in dendritic spine maturation and synaptic plasticity. Finally, I extended our initial 
proteomic characterizations of our forebrain-specific Cdk5 deletion mouse model from Chapter 2 
by investigating whether these mice display impairments in learning and memory. The animals 
were subjected to various behavior tasks, and the findings are summarized in Chapter 5.  
 
 These collective studies raise a more general question of how the activity of Cdk5 itself is 
regulated. To address this topic, recent studies examined upstream, post-translational 
modifications of Cdk5 itself and noted that S-nitrosylation of Cdk5 at Cysteine 83 plays an 
important role in dendrite outgrowth (Zhang et al., 2010) and amyloid beta-induced spine loss, 
although how S-nitrosylation impacts Cdk5 activity remains unclear and may differ under 
pathological conditions (Qu et al., 2011). Furthermore, phosphorylation of Cdk5 itself at 
Tyrosine 15 (Y15) in response to ephrinA-1 ligand heightens its activity (Fu et al., 2007). A 
different future approach might be to limit the generation of p25, the Cdk5 subunit implicated in 
neurodegeneration (Patrick et al., 1999). Under physiological conditions p35 is associated with 
Cdk5 to the cytoplasm with a half life of approiximately 20-30 min (Patrick et al., 1998). 
Furthermore, p35 undergoes ubiquitin-mediated proteolysis as a mechanism for rapid regulation 
of Cdk5 kinase activity. However, when neurons are subjected to neurotoxic insults including 
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excitotoxicity, oxidative stress, or amyloid peptides, the calcium-dependent protease calpain 
cleaves p35 to liberate the p25 fragment (Kusakawa et al., 2000; Lee et al., 2000). This p25 
fragment, when bound to Cdk5, displays a longer half-life of approximately 60 min and can 
shuttle to the nucleus where it mediates cell death (O'Hare et al., 2005). These results raise the 
possibility of using genetic mouse models or pharmacological tools during excitotoxicity to 
prevent the generation of p25 or shorten its half-life. Moreover, one could potentially reduce the 
activity of calpain or increase levels of calpastatin, a calpain inhibitor. To test whether calpain 
directly contributes to p25 generation, transgenic mouse models of calpastatin were previously 
generated. In a mouse model overexpressing calpastatin, p25 is not produced, and p35 was 
subjected to calcium-dependent proteosomal degradation (Sato et al., 2011). Conversely, 
calpastatin knockout mice produced greater p25 levels. Interestingly, in brain tissue of 
Alzheimer’s disease patients, downregulation of calpastatin is observed, suggesting a 
dysregulation of calpain activity. Future research into calpain and calpastatin activity may reveal 
how Cdk5 is preferentially associated with p35 or p25 in disease states.  
 
 Recent literature suggests that Cdk5 is one of the few candidates known to be involved in 
the regulation of synaptic homeostasis (Kim and Ryan, 2010; Mitra et al., 2012; Seeburg et al., 
2008). Additional experiments using imaging, biophysical, and biochemical techniques to more 
precisely determine how Cdk5 controls the dynamics of neurotransmitter release will be 
informative. In particular, because Cdk5 loss of function studies presented in Chapters 2 and 5 
focused primarily on excitatory neurons, it will also be compelling to address the activity of 
Cdk5 in inhibitory neurons. Due to its ubiquitous presence in both the presynaptic and 
postsynaptic terminals, silencing Cdk5 activity in a subset of neurons as well as in distinct spatial 
compartments using either mouse models or a combination of genetic and pharmacological 
manipulations will allow us to further probe how Cdk5 gates neurotransmission. Whether Cdk5 
is upstream or acts in concert with other well-known synaptic homeostatic scaling candidate 
proteins including Arc (Beique et al., 2011), PSD-93 and PSD-95 (Sun and Turrigiano, 2011), 
MeCP2 (Qiu et al., 2012) remains to be determined, but nonetheless the importance of Cdk5 in 
fine-tuning synaptic transmission is quickly becoming one of the research highlights in the field 
of synaptic transmission and synaptic plasticity. 
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 Although we focused mainly on the synaptic functions of Cdk5, further investigation of 
how aberrant Cdk5 activity contributes to neurological disorders is of great interest, as it may 
play a direct role in the neuropathological mechanisms underlying major neurodegenerative 
disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic 
lateral sclerosis, and Niemann-Pick Type C. To date, there have been no mutations identified in 
Cdk5 itself shown to be directly associated with neurodegeneration or psychiatric disorders. 
However, Cdk5 is implicated in almost every neuronal signaling pathway examined thus far, and 
its activity is essential during cell death of an autosomal dominant disease model in fruit flies 
(Kang et al., 2012). Moreover, there are also important non-neuronal functions involving Cdk5 
involving adipose tissue and diabetes signaling pathway in mice (Choi et al., 2010; Choi et al., 
2011) as well as the cancer signaling pathway in human cell lines (Ajay et al., 2010). Therefore, 
we hypothesize that deregulation of Cdk5 activity mediated by p35 and p25 levels is a key factor 
in contributing to the disease state (Chang et al., 2012). This prediction encompasses a complex 
interplay of kinases and phosphatases, including calcineurin, a calmodulin-dependent 
serine/threonine protein phosphatase which opposes Cdk5 activity and is also essential for 
learning and memory (Miyakawa et al., 2003; Zeng et al., 2001). Indeed, the protein phosphatase 
2A (PP2A) is the phosphatase opposing Cdk5 phosphorylation of the neurofilament heavy chain 
(Veeranna et al., 1995), and knockout mouse models of PP2A exhibit dysregulated Cdk5 activity 
and increased tau phosphorylation (Louis et al., 2011). Furthermore, protein phosphatase 1 (PP1) 
is directly associated with Cdk5/p25 (Agarwal-Mawal and Paudel, 2001; Bibb et al., 2001), 
suggesting that phosphatases are also tightly regulated by Cdk5 activity. Intriguingly, 
phosphorylation of phosphatase inhibitor-1 by Cdk5 does not inhibit phosphatases directly, but 
instead modulates the activity of cAMP signaling pathways in striatal tissue, adding yet another 
element of complexity (Bibb et al., 2001). Future studies using a well-characterized Cdk5 
substrate, DARPP-32, which can function as either a kinase or phosphatase (Bibb et al., 1999), 
will be helpful in mapping out the consequences of imbalanced activity of either Cdk5 or the 
phosphatases. 
 
 We did not explore other forms of post-translational modifications in our studies; 
however, it is notable that Cdk5 has also been implicated in the epigenetic regulation of histone-
modifying enzymes (Graff et al., 2011). Recent work highlights the function of Cdk5-mediated 
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phosphorylation and PP2A-dephosphorylation on a histone deacetylase enzyme, HDAC5, in 
shuttling in and out of the nucleus during cocaine reward (Taniguchi et al., 2012). Strong 
evidence of an association between Cdk5 and epigenetic modification components was further 
provided by a study examining the how Cdk5-mediated phosphorylation of mSds3, a component 
of the HDAC co-repressor complex, regulates transcriptional repression and neuronal survival 
through histone acetylation (Fu et al., 2012; Li et al., 2004). Yet another study highlights how 
Cdk5/p25 deregulates the activity of HDAC1 during DNA damage and cell death processes 
(Kim et al., 2008). As the field of neuroepigenetics expands to include the examination of 
various kinases in conjunction with other post-translational modifications of acetylation, 
methylation, nitrosylation, ubiquitination, it will be of great interest to investigate the role of 
Cdk5 in regulating the transcriptional landscape of the mammalian genome and examine how 
this landscape is altered during neurodegeneration.  
  
 Future directions from work presented here include the pursuit of targeting Cdk5 activity 
as a potential therapeutic strategy in synaptic dysfunctions and in neurodegeneration. 
Specifically limiting Cdk5 activity by targeting the generation of p25 or by inhibiting Cdk5/p25 
activity may ameliorate cognitive decline and attenuate neurodegeneration. Several molecules 
have been implicated in Alzheimer’s Disease including Cdk5/p25, β-secretase (BACE1), and γ-
secretase which cleaves the amyloid precursor protein (APP) into the pathogenic amyloid beta 
(Su and Tsai, 2011). In an intriguing study, mice overexpressing Cdk5/p25 exhibited increased 
BACE1 levels and enhanced APP processing due to the activity of Cdk5-responsive site in 
STAT3, a transcriptional activator in the BACE1 promoter region (Wen et al., 2008). As Cdk5 
inhibitors are non-specific with potential side-effects, an ideal approach would consist of 
systematically targeting Cdk5 activity in a spatial and temporal manner. One such study that 
inhibited Cdk5 using RNA-mediated knockdown resulted in decreased neurofibrillary tangles in 
mouse models of Alzheimer’s disease (Piedrahita et al., 2010). We predict that restricting 
Cdk5/p25 activity during a critical time frame during the early initiating events preceding 
neurodegeneration would be most beneficial for therapeutic intervention. By studying a Cdk5 in 
the dynamic context of synaptic function, synaptic plasticity, and learning and memory, we 
ultimately seek to address how neurons maintain their proper synaptic connectivity and functions 
in the brain. 
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